The 2014 International Society of Urological Pathology (ISUP) Gleason Grading of Prostatic Carcinoma

Citation Report

#	ARTICLE	IF	CITATIONS
2	A new contemporary prostate cancer grading system. Annales De Pathologie, 2015, 35, 474-476.	0.1	17
3	Glutamate Decarboxylase 1 Overexpression as a Poor Prognostic Factor in Patients with Nasopharyngeal Carcinoma. Journal of Cancer, 2016, 7, 1716-1723.	1.2	16
4	Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, e235-e245.	1.8	26
5	Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e235-e245.	1.8	16
6	Diagnostic Accuracy of Robot-Guided, Software Based Transperineal MRI/TRUS Fusion Biopsy of the Prostate in a High Risk Population of Previously Biopsy Negative Men. BioMed Research International, 2016, 2016, 1-6.	0.9	19
7	One is the new six: The International Society of Urological Pathology (ISUP) patient-focused approach to Gleason grading. Canadian Urological Association Journal, 2016, 10, 339.	0.3	14
8	Spatial Genome Organization and Its Emerging Role as a Potential Diagnosis Tool. Frontiers in Genetics, 2016, 7, 134.	1.1	50
9	Carbonic anhydrase IX is a marker of hypoxia and correlates with higher Gleason scores and ISUP grading in prostate cancer. Diagnostic Pathology, 2016, 11, 45.	0.9	54
10	Mutation Profiling Indicates High Grade Prostatic Intraepithelial Neoplasia as Distant Precursors of Adjacent Invasive Prostatic Adenocarcinoma. Prostate, 2016, 76, 1227-1236.	1.2	11
12	Prostate cancer glands with cribriform architecture and with glomeruloid features should be considered as Gleason pattern 4 and not pattern 3. Future Oncology, 2016, 12, 1431-1433.	1.1	5
13	The impact of the 2005 International Society of Urological Pathology consensus guidelines on Gleason grading â€" a matchedâ€pair analysis. BJU International, 2016, 117, 883-889.	1.3	19
14	Changes in prostate cancer grading: Including a new patientâ€centric grading system. Prostate, 2016, 76, 427-433.	1.2	36
15	Spectrum of Cystic Epithelial Tumors of the Prostate. American Journal of Surgical Pathology, 2016, 40, 886-895.	2.1	23
16	International Society of Urological Pathology (ISUP) Grading of Prostate Cancer: Author's Reply. American Journal of Surgical Pathology, 2016, 40, 862-864.	2.1	9
17	Re: Clinical significance of prospectively assigned gleason tertiary pattern 4 in contemporary Gleason score 3â€‰+â€‰3â€‰=â€‰6 prostate cancer. Prostate, 2016, 76, 1130-1131.	1.2	5
18	Perinatal and childhood factors and risk of prostate cancer in adulthood: MCC-Spain case-control study. Cancer Epidemiology, 2016, 43, 49-55.	0.8	8
19	Can atorvastatin with metformin change the natural history of prostate cancer as characterized by molecular, metabolomic, imaging and pathological variables? A randomized controlled trial protocol. Contemporary Clinical Trials, 2016, 50, 16-20.	0.8	5
20	International Society of Urological Pathology (<scp>ISUP</scp>) grading of prostate cancer â€" An <scp>ISUP</scp> consensus on contemporary grading. Apmis, 2016, 124, 433-435.	0.9	152

#	ARTICLE	IF	CITATIONS
21	Gleason and Fuhrman no longer make the grade. Histopathology, 2016, 69, 340-341.	1.6	3
22	A retrospective analysis of Victorian and South Australian clinical registries for prostate cancer: trends in clinical presentation and management of the disease. BMC Cancer, 2016, 16, 607.	1.1	21
23	Intraductal carcinoma of prostate reporting practice: a survey of expert European uropathologists. Journal of Clinical Pathology, 2016, 69, 852-857.	1.0	29
24	Novel concepts for risk stratification in prostate cancer. Journal of Clinical Urology, 2016, 9, 18-23.	0.1	11
25	Analysis of Zinc-Exporters Expression in Prostate Cancer. Scientific Reports, 2016, 6, 36772.	1.6	32
26	Histologic Grading of Prostatic Adenocarcinoma Can Be Further Optimized. American Journal of Surgical Pathology, 2016, 40, 1439-1456.	2.1	107
27	In Regard to Zietman et al. International Journal of Radiation Oncology Biology Physics, 2016, 96, 1126-1127.	0.4	3
29	What is new in Genitourinary Pathology? Recent developments and highlights of the new 2016 World Health Organization classification of tumors of the urinary system and male genital organs. Applied Cancer Research, 2016, 36, .	1.0	8
30	Clinical impact of prostate biopsy undergrading in an academic and community setting. World Journal of Urology, 2016, 34, 1481-1490.	1.2	6
31	Editorial Comment. Urology, 2016, 91, 148.	0.5	0
32	Intra-individual comparison of 68Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1400-1406.	3.3	101
33	New Gleason grading system: Statement from the Editors of six journals. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 253.	0.8	9
34	Stage Grouping. Journal of Urology, 2016, 195, 1723-1723.	0.2	9
35	Independent validation of the prognostic capacity of the ISUP prostate cancer grade grouping system for radiation treated patients with long-term follow-up. Prostate Cancer and Prostatic Diseases, 2016, 19, 292-297.	2.0	38
36	Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy. Modern Pathology, 2016, 29, 630-636.	2.9	174
37	Ten- and 15-yr Prostate Cancer-specific Mortality in Patients with Nonmetastatic Locally Advanced or Aggressive Intermediate Prostate Cancer, Randomized to Lifelong Endocrine Treatment Alone or Combined with Radiotherapy: Final Results of The Scandinavian Prostate Cancer Group-7. European Urology, 2016, 70, 684-691.	0.9	71
38	Validation of a contemporary prostate cancer grading system using prostate cancer death as outcome. British Journal of Cancer, 2016, 114, 1078-1083.	2.9	105
39	Can 68GA-PSMA or radiolabeled choline PET/CT guide salvage lymph node dissection in recurrent prostate cancer?. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1407-1409.	3.3	4

#	ARTICLE	IF	CITATIONS
40	Impact of Gleason pattern 5 including tertiary pattern 5 on outcomes of salvage treatment for biochemical recurrence in pT2-3N0M0 prostate cancer. International Journal of Clinical Oncology, 2016, 21, 975-980.	1.0	13
41	Association of ring box-1 protein overexpression with clinicopathologic prognostic parameters in prostate carcinoma. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 336.e7-336.e12.	0.8	2
42	New prostate cancer grade group system correlates with prostate cancer death in addition to biochemical recurrence. British Journal of Cancer, 2016, 114, 1069-1070.	2.9	6
43	Prostate cancer outcomes of men with biopsy Gleason score 6 and 7 without cribriform or intraductal carcinoma. European Journal of Cancer, 2016, 66, 26-33.	1.3	66
44	Three‐dimensional microscopic analysis of clinical prostate specimens. Histopathology, 2016, 69, 985-992.	1.6	71
45	Promoter methylation of the immune checkpoint receptor *PD-1* (*PDCD1*) is an independent prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy. OncoImmunology, 2016, 5, e1221555.	2.1	43
47	Author Reply. Urology, 2016, 96, 154-155.	0.5	0
48	*CDO1* promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients. Epigenetics, 2016, 11, 871-880.	1.3	37
49	Do Black NonHispanic Men Produce Less Prostate Specific Antigen in Benign Prostate Tissue or Cancer Compared to White NonHispanic Men with Gleason Score 6 (Grade Group 1) Prostate Cancer?. Journal of Urology, 2016, 196, 1659-1663.	0.2	9
50	New Gleason grading system: Statement from the editors of 6 journals. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 479-480.	0.8	0
51	Newly Proposed Prognostic Grade Group System for Prostate Cancer: Genesis, Utility and its Implications in Clinical Practice. Current Urology Reports, 2016, 17, 80.	1.0	3
52	Current concepts in the diagnosis and pathobiology of intraepithelial neoplasia: A review by organ system. Ca-A Cancer Journal for Clinicians, 2016, 66, 408-436.	157.7	33
53	The role of androgen deprivation therapy plus radiation therapy in patients with non-metastatic prostate cancer. Expert Review of Anticancer Therapy, 2016, 16, 929-942.	1.1	5
54	Validation of the novel International Society of Urological Pathology 2014 five‐tier Gleason grade grouping: biochemical recurrence rates for 3+5 disease may be overestimated. BJU International, 2016, 118, 502-505.	1.3	17
55	Prostate cancer grading: recent developments and future directions. BJU International, 2016, 117, 7-8.	1.3	19
56	Recent advances in prostate cancer pathology: Gleason grading and beyond. Pathology International, 2016, 66, 260-272.	0.6	28
57	Loss of PTEN expression in ERG-negative prostate cancer predicts secondary therapies and leads to shorter disease-specific survival time after radical prostatectomy. Modern Pathology, 2016, 29, 1565-1574.	2.9	43
58	High Testosterone Preoperative Plasma Levels Independently Predict Biopsy Gleason Score Upgrading in Men with Prostate Cancer Undergoing Radical Prostatectomy. Urologia Internationalis, 2016, 96, 470-478.	0.6	24

#	ARTICLE	IF	CITATIONS
59	Consensus guidelines for reporting prostate cancer Gleason Grade. BJU International, 2016, 117, 849-849.	1.3	11
60	Prognostic implications of 2005 Gleason grade modification. Population‐based study of biochemical recurrence following radical prostatectomy. Journal of Surgical Oncology, 2016, 114, 664-670.	0.8	8
61	Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy. Journal of Clinical Oncology, 2016, 34, 3648-3654.	0.8	296
62	Consensus guidelines for reporting prostate cancer Gleason Grade. BJU International, 2016, 118, E1-2.	1.3	10
63	Mean diffusivity discriminates between prostate cancer with grade group 1&2 and grade groups equal to or greater than 3. European Journal of Radiology, 2016, 85, 1794-1801.	1.2	14
64	Reply by the Authors. Urology, 2016, 96, 179-180.	0.5	0
65	Androgen deprivation modulates gene expression profile along prostate cancer progression. Human Pathology, 2016, 56, 81-88.	1.1	20
66	Re: Consensus Guidelines for Reporting Prostate Cancer Gleason Grade. Journal of Urology, 2016, 196, 1321-1323.	0.2	0
67	From Gleason to International Society of Urological Pathology (ISUP) grading of prostate cancer. Scandinavian Journal of Urology, 2016, 50, 325-329.	0.6	31
68	Editorial Comment. Urology, 2016, 96, 154.	0.5	1
69	Active surveillance appropriateness criteria â€" a way forward. Nature Reviews Urology, 2016, 13, 633-634.	1.9	0
70	Interobserver Reproducibility of Percent Gleason Pattern 4 in Prostatic Adenocarcinoma on Prostate Biopsies. American Journal of Surgical Pathology, 2016, 40, 1686-1692.	2.1	37
71	Contemporary Gleason grading and novel Grade Groups in clinical practice. Current Opinion in Urology, 2016, 26, 488-492.	0.9	32
72	Prognostic Significance of Percentage and Architectural Types of Contemporary Gleason Pattern 4 Prostate Cancer in Radical Prostatectomy. American Journal of Surgical Pathology, 2016, 40, 1400-1406.	2.1	117
73	Gleason grade 4 prostate adenocarcinoma patterns: an interobserver agreement study among genitourinary pathologists. Histopathology, 2016, 69, 441-449.	1.6	82
74	Outcome of Gleason 3 + 5 = 8 Prostate Cancer Diagnosed on Needle Biopsy: Prognostic Comparison with Gleason 4 + 4 = 8. Journal of Urology, 2016, 196, 1076-1081.	0.2	60
75	Formation of intracellular lumina in human prostate carcinoma (DU145) cells, maturation into signet cells, and the cribriform morphology of tumors. Ultrastructural Pathology, 2016, 40, 189-199.	0.4	2
76	Perspectives of Prostate Cancer Patients on Gleason Scores and the New Grade Groups: Initial Qualitative Study. European Urology, 2016, 70, 1083-1085.	0.9	16

#	ARTICLE	IF	CITATIONS
77	Urology journals recommend new prostate cancer grade groups. Nature Reviews Urology, 2016, 13, 374-375.	1.9	5
78	Total intraglandular and index tumor volumes predict biochemical recurrence in prostate cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 469, 305-312.	1.4	8
79	A Case of Prostate Cancer in Lynch Syndrome. Urology, 2016, 95, 25-28.	0.5	0
80	Grading of prostatic adenocarcinoma: current state and prognostic implications. Diagnostic Pathology, 2016, 11, 25.	0.9	201
81	Prostate cancer volume associates with preoperative plasma levels of testosterone that independently predicts high grade tumours which show low densities (quotient testosterone/tumour) Tj ETQq0 0 0 rgBT /Overlock 10 Tf		
82	Author Reply. Urology, 2016, 91, 148-149.	0.5	1
83	Editorial Statement on Gleason Scoring for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1092.	0.4	2
84	Definition of Insignificant Tumor Volume of Gleason Score 3 + 3 = 6 (Grade Group 1) Prostate Cancer at Radical Prostatectomyâ€"Is it Time to Increase the Threshold?. Journal of Urology, 2016, 196, 1664-1669.	0.2	23
85	International Society of Urological Pathology (ISUP) Grading of Prostate Cancer. American Journal of Surgical Pathology, 2016, 40, 858-861.	2.1	37
86	Radical Prostatectomy Findings in White Hispanic/Latino Men With NCCN Very Low-risk Prostate Cancer Detected by Template Biopsy. American Journal of Surgical Pathology, 2016, 40, 1125-1132.	2.1	15
87	Reply: Gleason and Fuhrman no longer make the grade. Histopathology, 2016, 69, 341-342.	1.6	0
88	Prostate Cancer Grading: A Decade After the 2005 Modified Gleason Grading System. Archives of Pathology and Laboratory Medicine, 2016, 140, 1140-1152.	1.2	74
89	The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organsâ€"Part B: Prostate and Bladder Tumours. European Urology, 2016, 70, 106-119.	0.9	1,323
90	Pathology and Genetics: Tumours of the Urinary System and Male Genital System. European Urology, 2016, 70, 120-123.	0.9	65
91	Gleason Misclassification Rate Is Independent of Number of Biopsy Cores in Systematic Biopsy. Urology, 2016, 91, 143-149.	0.5	23
92	Consensus Guidelines for Reporting Prostate Cancer Gleason Grade. Urology, 2016, 93, 1.	0.5	9
93	Describing the Grade of Prostate Cancer: Consistent Use of Contemporary Terminology Is Now Required. European Urology, 2016, 70, 1.	0.9	16
97	Grading of Prostate Cancer: Past, Present, and Future. Current Urology Reports, 2016, 17, 25.	1.0	32

#	ARTICLE	IF	CITATIONS
98	Utility of Reporting the Percentage of High-grade Prostate Cancer. European Urology, 2016, 69, 599-600.	0.9	14
99	Prognostic Value of Percent Gleason Grade 4 at Prostate Biopsy in Predicting Prostatectomy Pathology and Recurrence. Journal of Urology, 2016, 196, 405-411.	0.2	89
100	The molecular and cellular origin of human prostate cancer. Biochimica Et Biophysica Acta - Molecular Cell Research, 2016, 1863, 1238-1260.	1.9	92
101	More Favorable Pathological Outcomes in Men with Low Risk Prostate Cancer Diagnosed on Repeat versus Initial Transrectal Ultrasound Guided Prostate Biopsy. Journal of Urology, 2016, 195, 1767-1772.	0.2	13
102	A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. European Urology, 2016, 69, 428-435.	0.9	1,039
103	La resonancia magnética en el nuevo paradigma del diagnóstico del cáncer de próstata. Radiologia, 2017, 59, 94-99.	0.3	5
104	Implementation of Dynamically Updated Prediction Models at the Point of Care at a Major Cancer Center: Making Nomograms More Like Netflix. Urology, 2017, 102, 1-3.	0.5	9
105	Prostate Health Index density improves detection of clinically significant prostate cancer. BJU International, 2017, 120, 793-798.	1.3	69
106	Prognostic value of prostate biopsy grade: forever a product of sampling. BJU International, 2017, 119, 5-7.	1.3	2
107	Variant Histology and Clinicopathological Features of Prostate Cancer in Men Younger than 50 Years Treated with Radical Prostatectomy. Journal of Urology, 2017, 198, 79-85.	0.2	16
108	SOCS3 Immunohistochemical Expression Seems to Support the 2005 and 2014 International Society of Urological Pathology (ISUP) Modified Gleason Grading System. Prostate, 2017, 77, 597-603.	1.2	4
109	Oncological Outcomes After Radical Prostatectomy for High‐Risk Prostate Cancer Based on New Gleason Grouping System: A Validation Study From University of Southern California With 3,755 Cases. Prostate, 2017, 77, 743-748.	1.2	10
110	Global Gleason grade groups in prostate cancer: concordance of biopsy and radical prostatectomy grades and predictors of upgrade and downgrade. Histopathology, 2017, 70, 1098-1106.	1.6	42
111	Prostate Cancer Grading: A Decade After the 2005 Modified Gleason Grading System. Archives of Pathology and Laboratory Medicine, 2017, 141, 182-183.	1.2	4
112	Population-Based Validation of the 2014 ISUP Gleason Grade Groups in Patients Treated With Radical Prostatectomy, Brachytherapy, External Beam Radiation, or no Local Treatment. Prostate, 2017, 77, 686-693.	1.2	33
113	Impact of Gleason Subtype on Prostate Cancer Detection Using Multiparametric Magnetic Resonance Imaging: Correlation with Final Histopathology. Journal of Urology, 2017, 198, 316-321.	0.2	74
114	Prognostic value of the new Grade Groups in Prostate Cancer: a multi-institutional European validation study. Prostate Cancer and Prostatic Diseases, 2017, 20, 197-202.	2.0	35
115	DCE‐MRI of the prostate using shutter‐speed vs. Tofts model for tumor characterization and assessment of aggressiveness. Journal of Magnetic Resonance Imaging, 2017, 46, 837-849.	1.9	10

#	Article	IF	Citations
116	Dishevelled segment polarity protein 3 (DVL3): a novel and easily applicable recurrence predictor in localised prostate adenocarcinoma. BJU International, 2017, 120, 343-350.	1.3	7
117	Use of the Prostate Health Index for detection of prostate cancer: results from a large academic practice. Prostate Cancer and Prostatic Diseases, 2017, 20, 228-233.	2.0	61
118	Prostate cancer â€" major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. Ca-A Cancer Journal for Clinicians, 2017, 67, 245-253.	157.7	245
119	Novel Definitions of Low-risk and High-risk Prostate Cancer: Implications for the European Randomized Study of Screening for Prostate Cancer Risk Assessment Tool. European Urology, 2017, 72, 52-53.	0.9	1
120	Biopsy undergrading in men with Gleason scoreÂ6 and fatal prostate cancer in the European Randomized study of Screening for Prostate Cancer Rotterdam. International Journal of Urology, 2017, 24, 281-286.	0.5	4
121	Riskâ€stratification based on magnetic resonance imaging and prostateâ€specific antigen density may reduce unnecessary followâ€up biopsy procedures in men on active surveillance for lowâ€risk prostate cancer. BJU International, 2017, 120, 511-519.	1.3	67
122	Resonancia magnÃ©tica multiparamÃ©trica y cÃ¡ncer de prÃ³stata: Â¿quÃ© hay de nuevo?. Radiologia, 2017, 59, 196-208.	0.3	5
123	PI-RADSv2: How we do it. Journal of Magnetic Resonance Imaging, 2017, 46, 11-23.	1.9	13
124	Pathological Findings in Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion-guided Biopsy: Relation to Prostate Cancer Focal Therapy. Urology, 2017, 105, 18-23.	0.5	11
125	<scp>UICC</scp> drops the ball in the 8th edition <scp>TNM</scp> staging of urological cancers. Histopathology, 2017, 71, 5-11.	1.6	37
126	Intraductal Carcinoma of the Prostate on Diagnostic Needle Biopsy Predicts Prostate Cancer Mortality: A Populationâ€Based Study. Prostate, 2017, 77, 859-865.	1.2	32
127	Accuracy of Grading Gleason Score 7 Prostatic Adenocarcinoma on Needle Biopsy: Influence of Percent Pattern 4 and Other Histological Factors. Prostate, 2017, 77, 681-685.	1.2	17
128	Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator for Initial Prostate Biopsy by Incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth. European Urology, 2017, 72, 45-51.	0.9	63
129	Clinical significance of miRNA host gene promoter methylation in prostate cancer. Human Molecular Genetics, 2017, 26, 2451-2461.	1.4	43
130	Improving the evaluation and diagnosis of clinically significant prostate cancer. Current Opinion in Urology, 2017, 27, 191-197.	0.9	11
131	Total and beverage-specific alcohol intake and the risk of aggressive prostate cancer: a caseâ€"control study. Prostate Cancer and Prostatic Diseases, 2017, 20, 305-310.	2.0	10
132	Editorial Comment to Biopsy undergrading in men with Gleason score 6 and fatal prostate cancer in the European Randomized study of Screening for Prostate Cancer Rotterdam. International Journal of Urology, 2017, 24, 286-287.	0.5	0
133	Smoking increased the risk of prostate cancer with grade groupâ€‰â‰¥â€‰4 and intraductal carcinoma in a prospective biopsy cohort. Prostate, 2017, 77, 984-989.	1.2	9

#	Article	IF	Citations
134	Nuclear morphometry in histological specimens of canine prostate cancer: Correlation with histological subtypes, Gleason score, methods of collection and survival time. Research in Veterinary Science, 2017, 114, 212-217.	0.9	5
135	Prostate zonal anatomy correlates with the detection of prostate cancer on multiparametric magnetic resonance imaging/ultrasound fusionâ€"targeted biopsy in patients with a solitary PI-RADS v2â€"scored lesion. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 542.e19-542.e24.	0.8	10
136	Clinical significance of endothelial cell marker CD34 and mast cell marker CD117 in prostate adenocarcinoma. Pathology Research and Practice, 2017, 213, 612-618.	1.0	29
137	HOXB13 a useful marker in pleomorphic giant cell adenocarcinoma of the prostate: a case report and review of the literature. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 133-136.	1.4	12
138	PTEN loss and p27 loss differ among morphologic patterns of prostate cancer, including cribriform. Human Pathology, 2017, 65, 85-91.	1.1	36
139	Body mass index as a classifier to predict biochemical recurrence after radical prostatectomy in patients with lower prostate-specific antigen levels. Molecular and Clinical Oncology, 2017, 6, 748-752.	0.4	3
140	Evaluation of ERG and PTEN protein expression in cribriform architecture prostate carcinomas. Pathology Research and Practice, 2017, 213, 34-38.	1.0	12
141	Clinical and molecular rationale to retain the cancer descriptor for Gleason score 6 disease. Nature Reviews Urology, 2017, 14, 59-64.	1.9	3
142	The present and future of prostate cancer histopathology. Current Opinion in Urology, 2017, 27, 464-468.	0.9	4
143	Tumour heterogeneity poses a significant challenge to cancer biomarker research. British Journal of Cancer, 2017, 117, 367-375.	2.9	110
144	Evaluation of the changing landscape of prostate cancer diagnosis and management from 2005 to 2016. Prostate International, 2017, 5, 130-134.	1.2	12
145	Presence of invasive cribriform or intraductal growth at biopsy outperforms percentage grade 4 in predicting outcome of Gleason score 3+4=7 prostate cancer. Modern Pathology, 2017, 30, 1126-1132.	2.9	82
146	Multiparametric magnetic resonance imaging and prostate cancer: What's new?. Radiologia, 2017, 59, 196-208.	0.3	2
147	Genetic ancestry and prostate cancer susceptibility SNPs in Puerto Rican and African American men. Prostate, 2017, 77, 1118-1127.	1.2	18
148	Prostate cancer in Jordanian-Arab population: ERG status and relationship with clinicopathologic characteristics. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 753-759.	1.4	8
149	The Impact of Prostate Cancer Zonal Origin on Pathological Parameters at Radical Prostatectomy and Subsequent Biochemical Failure. Journal of Urology, 2017, 198, 1316-1323.	0.2	20
150	Pathology and molecular updates in tumors of the prostate: towards a personalized approach. Expert Review of Molecular Diagnostics, 2017, 17, 781-789.	1.5	9
151	Blinded review of archival radical prostatectomy specimens supports that contemporary Gleason score 6 prostate cancer lacks metastatic potential. Prostate, 2017, 77, 1076-1081.	1.2	6

#	ARTICLE	IF	CITATIONS
152	Grade Group Underestimation in Prostate Biopsy: Predictive Factors and Outcomes in Candidates for Active Surveillance. Clinical Genitourinary Cancer, 2017, 15, e907-e913.	0.9	11
153	Effect of pathologic revision and Ki67 and ERG immunohistochemistry on predicting radical prostatectomy outcome in men initially on active surveillance. Prostate, 2017, 77, 1137-1143.	1.2	5
154	Prostate Cancer Antigen 3 Score Does Not Predict for Adverse Pathologic Features at Radical Prostatectomy or for Progression-free Survival in Clinically Localized, Intermediate- and High-risk Prostate Cancer. Urology, 2017, 107, 171-177.	0.5	3
155	Trends in Diagnosis of Gleason Score 2 Through 4 Prostate Cancer in the National Cancer Database, 1990â€"2013. Archives of Pathology and Laboratory Medicine, 2017, 141, 1686-1696.	1.2	9
156	Mucinous adenocarcinoma of prostate and prostatic adenocarcinoma with mucinous components: a clinicopathological analysis of 143 cases. Histopathology, 2017, 71, 641-647.	1.6	19
157	Contemporary Gleason Grading of Prostatic Carcinoma. American Journal of Surgical Pathology, 2017, 41, e1-e7.	2.1	233
158	Adherence to nutritionâ€based cancer prevention guidelines and breast, prostate and colorectal cancer risk in the <scp>MCC</scp>â€<scp>S</scp>pain caseâ€"control study. International Journal of Cancer, 2017, 141, 83-93.	2.3	48
159	Gleason sum upgrading between biopsy and radical prostatectomy in Chinese population: Updated nomograms. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2017, 41, 162-171.	0.2	2
160	External Beam Radiation Therapy With a Brachytherapy Boost Versus Radical Prostatectomy in Gleason Pattern 5 Prostate Cancer: A Population-Based Cohort Study. International Journal of Radiation Oncology Biology Physics, 2017, 98, 1045-1052.	0.4	12
161	Extracellular vesicles for liquid biopsy in prostate cancer: where are we and where are we headed?. Prostate Cancer and Prostatic Diseases, 2017, 20, 251-258.	2.0	82
162	Predictive value of the 2014 International Society of Urological Pathology grading system for prostate cancer in patients undergoing radical prostatectomy with longâ€term followâ€up. BJU International, 2017, 120, 651-658.	1.3	30
163	Spontaneous tumor lysis syndrome in a patient with metastatic prostate cancer. Molecular and Clinical Oncology, 2017, 6, 589-592.	0.4	14
164	Ejaculatory frequency and the risk of aggressive prostate cancer: Findings from a case-control study. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 530.e7-530.e13.	0.8	13
165	Histopathology of Prostate Cancer. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a030411.	2.9	96
166	Convolutional neural networks for an automatic classification of prostate tissue slides with high-grade Gleason score. Proceedings of SPIE, 2017, , .	0.8	19
167	Comparison of semi-automated and manual methods to measure the volume of prostate cancer on magnetic resonance imaging. Diagnostic and Interventional Imaging, 2017, 98, 423-428.	1.8	17
169	Establishing the pathways and indications for performing isotope bone scans in newly diagnosed intermediateâ€risk localised prostate cancer â€" results from a large contemporaneous cohort. BJU International, 2017, 120, E59-E63.	1.3	8
170	Low-risk Prostate Cancer: Identification, Management, and Outcomes. European Urology, 2017, 72, 238-249.	0.9	55

#	ARTICLE	IF	CITATIONS
171	Gleason grade grouping of prostate cancer is of prognostic value in Asian men. Journal of Clinical Pathology, 2017, 70, 745-753.	1.0	12
172	Transperineal biopsies of MRI-detected aggressive index lesions in low- and intermediate-risk prostate cancer patients: Implications for treatment decision. Brachytherapy, 2017, 16, 201-206.	0.2	3
173	The Gleason Grading System: The Approach that Changed Prostate Cancer Assessment. Journal of Urology, 2017, 197, S140-S141.	0.2	0
174	Implementation of a Precision Pathology Program Focused on Oncology-Based Prognostic and Predictive Outcomes. Molecular Diagnosis and Therapy, 2017, 21, 115-123.	1.6	8
175	Application of a Prognostic Gleason Grade Grouping System to Assess Distant Prostate Cancer Outcomes. European Urology, 2017, 71, 750-759.	0.9	40
176	PITX2 DNA Methylation as Biomarker for Individualized Risk Assessment of Prostate Cancer in Core Biopsies. Journal of Molecular Diagnostics, 2017, 19, 107-114.	1.2	41
177	Magnetic Resonance Imaging Provides Added Value to the Prostate Cancer Prevention Trial Risk Calculator for Patients With Estimated Risk of High-grade Prostate Cancer Less Than or Equal to 10%. Urology, 2017, 102, 183-189.	0.5	16
178	Unscreened older men diagnosed with prostate cancer are at increased risk of aggressive disease. Prostate Cancer and Prostatic Diseases, 2017, 20, 193-196.	2.0	6
179	Extraprostatic Extension Is Extremely Rare for Contemporary Gleason Score 6 Prostate Cancer. European Urology, 2017, 72, 455-460.	0.9	28
180	The effect of limited (tertiary) Gleason pattern 5 on the new prostate cancer grade groups. Human Pathology, 2017, 63, 27-32.	1.1	28
181	Latest Novelties on the World Health Organization Morphological Classifications of Genitourinary Cancers. European Urology Supplements, 2017, 16, 199-209.	0.1	5
182	SFRP4 gene expression is increased in aggressive prostate cancer. Scientific Reports, 2017, 7, 14276.	1.6	23
183	Whom to Treat. Urologic Clinics of North America, 2017, 44, 547-555.	0.8	5
185	Re: Validation of the 2015 Prostate Cancer Grade Groups for Predicting Long-term Oncologic Outcomes in a Shared Equal-access Health System. European Urology, 2017, 72, 1023-1024.	0.9	0
187	A Prospective Comparison of Selective Multiparametric Magnetic Resonance Imaging Fusion-Targeted and Systematic Transrectal Ultrasound-Guided Biopsies for Detecting Prostate Cancer in Men Undergoing Repeated Biopsies. Urologia Internationalis, 2017, 99, 384-391.	0.6	24
188	Ten-year Mortality in Men With Nonmetastatic Prostate Cancer in Norway. Urology, 2017, 110, 140-147.	0.5	8
189	The updated grading system of prostate carcinoma: an interâ€observer agreement study among general pathologists in an academic practice. Apmis, 2017, 125, 957-961.	0.9	5
190	Population-based study of the incidence and survival for intraductal carcinoma of the prostate. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 673.e9-673.e14.	0.8	25

#	ARTICLE	IF	CITATIONS
191	The role of 68Ga-PSMA-I&T PET/CT in the pretreatment staging of primary prostate cancer. Nuclear Medicine Communications, 2017, 38, 956-963.	0.5	29
192	Expression of PD-L1 in Hormone-naÃ¯ve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide. Clinical Cancer Research, 2017, 23, 6812-6822.	3.2	77
193	An improved model for prostate diffusion incorporating the results of Monte Carlo simulations of diffusion in the cellular compartment. NMR in Biomedicine, 2017, 30, e3782.	1.6	10
194	Impact of fiveâ€tiered Gleason grade groups on prognostic prediction in clinical stage T3 prostate cancer undergoing highâ€doseâ€rate brachytherapy. Prostate, 2017, 77, 1520-1527.	1.2	6
195	Prostate-specific Antigen Parameters and Prostate Health Index Enhance Prostate Cancer Prediction With the In-bore 3-T Magnetic Resonance Imaging-guided Transrectal Targeted Prostate Biopsy After Negative 12-Core Biopsy. Urology, 2017, 110, 148-153.	0.5	22
196	Outcomes of treatment in men with prostate cancer at the cancer centre Bahamas. Cancer Causes and Control, 2017, 28, 1285-1293.	0.8	3
197	Prostascore: A Simplified Tool for Predicting Outcomes among Patients with Treatment-naive Advanced Prostate Cancer. Clinical Oncology, 2017, 29, 732-738.	0.6	7
198	Retzius-Sparing Robotic-Assisted Laparoscopic Radical Prostatectomy: A Safe Surgical Technique with Superior Continence Outcomes. Journal of Endourology, 2017, 31, 1244-1250.	1.1	69
199	Nuclear mTOR acts as a transcriptional integrator of the androgen signaling pathway in prostate cancer. Genes and Development, 2017, 31, 1228-1242.	2.7	103
201	Dynamic Contrast Enhanced Magnetic Resonance Imaging Improves Classification of Prostate Lesions: A Study of Pathological Outcomes on Targeted Prostate Biopsy. Journal of Urology, 2017, 198, 1301-1308.	0.2	22
202	Perineural invasion by prostate cancer on MR/US fusion targeted biopsy is associated with extraprostatic extension and early biochemical recurrence after radical prostatectomy. Human Pathology, 2017, 66, 206-211.	1.1	27
204	Evidencedâ€based clinical practice guideline for prostate cancer (summary: Japanese Urological) Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.5	111
205	The impact of multifocal perineural invasion on biochemical recurrence and timing of adjuvant androgenâ€deprivation therapy in highâ€risk prostate cancer following radical prostatectomy. Prostate, 2017, 77, 1279-1287.	1.2	16
206	Gleason Grading, Biochemical Failure, and Prostate Cancerâ€"Specific Death. American Journal of Clinical Pathology, 2017, 147, 273-277.	0.4	4
207	Urinary-exosomal miR-2909: A novel pathognomonic trait of prostate cancer severity. Journal of Biotechnology, 2017, 259, 135-139.	1.9	59
208	Higher Prostate Cancer Grade Groups Are Detected in Patients Undergoing Multiparametric MRI-targeted Biopsy Compared With Standard Biopsy. American Journal of Surgical Pathology, 2017, 41, 101-105.	2.1	45
209	Histopathological Evaluation in Prostate Cancer. , 2017, , 169-189.		0
210	High miR-205 expression in normal epithelium is associated with biochemical failure - an argument for epithelial crosstalk in prostate cancer?. Scientific Reports, 2017, 7, 16308.	1.6	15

#	Article	IF	Citations
211	In Reply. Archives of Pathology and Laboratory Medicine, 2017, 141, 183-184.	1.2	3
212	Impact of Pathology Review for Decision Therapy in Localized Prostate Cancer. Clinical Medicine Insights Pathology, 2017, 10, 117955571774013.	0.6	5
213	The Diagnosis and Treatment of Prostate Cancer. JAMA - Journal of the American Medical Association, 2017, 317, 2532.	3.8	959
214	Multiparametric dynamic contrast-enhanced ultrasound imaging of prostate cancer. European Radiology, 2017, 27, 3226-3234.	2.3	38
217	Proliferation index of different Gleason pattern 4 histomorphologies and associated pattern 3 adenocarcinoma of the prostate. Human Pathology, 2017, 70, 1-5.	1.1	6
218	Expression of SOCS1 and the downstream targets of its putative tumor suppressor functions in prostate cancer. BMC Cancer, 2017, 17, 157.	1.1	17
219	^{68}Ga-PSMA PET/CT and Volumetric Morphology of PET-Positive Lymph Nodes Stratified by Tumor Differentiation of Prostate Cancer. Journal of Nuclear Medicine, 2017, 58, 1949-1955.	2.8	27
220	Validation of the 2015 prostate cancer grade groups for predicting longâ€term oncologic outcomes in a shared equalâ€access health system. Cancer, 2017, 123, 4122-4129.	2.0	15
221	Distinguishing pediatric and adolescent renal cell carcinoma from other renal malignancies. Pediatric Blood and Cancer, 2017, 64, e26315.	0.8	14
222	Active surveillance for intermediate-risk prostate cancer. Prostate Cancer and Prostatic Diseases, 2017, 20, 1-6.	2.0	90
223	Detection of High Grade Prostate Cancer among PLCO Participants Using a Prespecified 4-Kallikrein Marker Panel. Journal of Urology, 2017, 197, 1041-1047.	0.2	23
224	The Impact of Downgrading from Biopsy Gleason 7 to Prostatectomy Gleason 6 on Biochemical Recurrence and Prostate Cancer Specific Mortality. Journal of Urology, 2017, 197, 1060-1067.	0.2	10
225	Significance of Gleason Score 7 With Tertiary Pattern 5 at Radical Prostatectomy. Urology, 2017, 100, 175-179.	0.5	13
226	The prognostic role of tertiary Gleason pattern 5 in a contemporary grading system for prostate cancer. Prostate Cancer and Prostatic Diseases, 2017, 20, 93-98.	2.0	19
227	New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8â€"10 Prostate Cancer. European Urology, 2017, 71, 907-912.	0.9	44
228	The New Prostate Cancer Grading System Does Not Improve Prediction of Clinical Recurrence After Radical Prostatectomy: Results of a Large, Twoâ€Center Validation Study. Prostate, 2017, 77, 263-273.	1.2	22
229	Reply to â€˜Comment on â€œValidation of a contemporary prostate cancer grading system using prostate cancer death as outcomeâ€â€™. British Journal of Cancer, 2017, 116, e4-e4.	2.9	0
230	Metastatic potential to regional lymph nodes with Gleason score â‰¥7, including tertiary pattern 5, at radical prostatectomy. BJU International, 2017, 119, 872-878.	1.3	11

#	Article	IF	Citations
231	Clinical Outcomes for Patients with Gleason Score 9â€"10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. European Urology, 2017, 71, 766-773.	0.9	83
232	Second harmonic generation (SHG) imaging of cancer heterogeneity in ultrasound guided biopsies of prostate in men suspected with prostate cancer. Journal of Biophotonics, 2017, 10, 911-918.	1.1	31
233	EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. European Urology, 2017, 71, 618-629.	0.9	2,497
234	Limitations in Predicting Organ Confined Prostate Cancer in Patients with Gleason Pattern 4 on Biopsy: Implications for Active Surveillance. Journal of Urology, 2017, 197, 75-83.	0.2	39
235	Re: Anthony Zietman, Joseph Smith, Eric Klein, Michael Droller, Prokar Dasgupta, James Catto. Describing the Grade of Prostate Cancer: Consistent Use of Contemporary Terminology Is Now Required. Eur Urol 2016;70:1. European Urology, 2017, 71, e52-e53.	0.9	0
236	Magnetic Resonance Imagingâ€"Ultrasound Fusion Biopsy During Prostate Cancer Active Surveillance. European Urology, 2017, 72, 275-281.	0.9	88
237	Pathology and Molecular Pathology of Prostate Cancer. , 2017, , 127-149.		1
238	Reporting intraductal carcinoma of the prostate: a plea for greater standardization. Histopathology, 2017, 70, 504-507.	1.6	22
239	Prognostic Utility of a New mRNA Expression Signature of Gleason Score. Clinical Cancer Research, 2017, 23, 81-87.	3.2	58
240	Small cell-like glandular proliferation of prostate: a rare lesion not related to small cell prostate cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 47-54.	1.4	7
241	InfragradaciÃ³n de la biopsia de prÃ³stata respecto a la pieza de prostatectomÃa la poblaciÃ³n china: nomogramas actualizados. Actas UrolÃ³gicas EspaÃ±olas, 2017, 41, 162-171.	0.3	3
242	PTEN Loss in Gleason Score 3 + 4 = 7 Prostate Biopsies is Associated with Nonorgan Confined Disease at Radical Prostatectomy. Journal of Urology, 2017, 197, 1054-1059.	0.2	32
243	Upgrading and upstaging at radical prostatectomy in the postâ€"prostate-specific antigen screening era: an effect of delayed diagnosis or a shift in patient selection?. Human Pathology, 2017, 59, 87-93.	1.1	6
244	The Emerging Role of MRI in Prostate Cancer Active Surveillance and Ongoing Challenges. American Journal of Roentgenology, 2017, 208, 131-139.	1.0	66
245	Prediction of pathological stage based on clinical stage, serum prostateâ€"specific antigen, and biopsy Gleason score: Partin Tables in the contemporary era. BJU International, 2017, 119, 676-683.	1.3	86
246	A model describing diffusion in prostate cancer. Magnetic Resonance in Medicine, 2017, 78, 316-326.	1.9	25
247	Should Hypoechoic Lesions on Transrectal Ultrasound Be Sampled During Magnetic Resonance Imaging-targeted Prostate Biopsy?. Urology, 2017, 105, 113-117.	0.5	12
248	Multicentre evaluation of targeted and systematic biopsies using magnetic resonance and ultrasound imageâ€"fusion guided transperineal prostate biopsy in patients with a previous negative biopsy. BJU International, 2017, 120, 631-638.	1.3	104

#	Article	IF	Citations
249	Management of prostate cancer patients with locally adverse pathologic features after radical prostatectomy: feasibility of active surveillance for cases with Gleason grade 3Â+Â4Â=Â7. Journal of Cancer Research and Clinical Oncology, 2017, 143, 123-129.	1.2	5
250	Correlation between Chromosome 9p21 Locus Deletion and Prognosis in Clinically Localized Prostate Cancer. International Journal of Biological Markers, 2017, 32, 248-254.	0.7	7
251	Favorable Gleason 3Â+ 4 Prostate Cancer Shows Comparable Outcomes With Gleason 3Â+ 3 Prostate Cancer: Implications for the Expansion of Selection Criteria for Active Surveillance. Clinical Genitourinary Cancer, 2017, 15, e1117-e1122.	0.9	9
252	Second harmonic generation microscopy as a cancer diagnosis tool. , 2017, , .		0
253	Isolated prostate cancer soft tissue recurrence 10 years after radical prostatectomy. BMJ Case Reports, 2017, 2017, bcr-2017-220140.	0.2	0
254	PSA screening for prostate cancer. Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira, 2017, 63, 722-725.	0.3	8
255	Androgen receptor splice variants and prostate cancer: From bench to bedside. Oncotarget, 2017, 8, 18550-18576.	0.8	100
256	A Unique Cellular and Molecular Microenvironment Is Present in Tertiary Lymphoid Organs of Patients with Spontaneous Prostate Cancer Regression. Frontiers in Immunology, 2017, 8, 563.	2.2	51
257	Prognostic Value of the New Prostate Cancer International Society of Urological Pathology Grade Groups. Frontiers in Medicine, 2017, 4, 157.	1.2	21
258	The Importance of Histology and Pathology in Mass Spectrometry Imaging. Advances in Cancer Research, 2017, 134, 1-26.	1.9	19
259	Are the Pathological Characteristics of Prostate Cancer More Aggressive or More Indolent Depending upon the Patient Age?. BioMed Research International, 2017, 2017, 1-6.	0.9	14
260	Lack of evidence of HPV etiology of prostate cancer following radical surgery and higher frequency of the Arg/Pro genotype in turkish men with prostate cancer. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2017, 43, 36-46.	0.7	10
261	Evaluation of the major changes in eighth edition of the American Joint Committee on Cancer pathological staging for prostate cancer treated with prostatectomy. PLoS ONE, 2017, 12, e0187887.	1.1	5
262	Markers of epithelial-to-mesenchymal transition reflect tumor biology according to patient age and Gleason score in prostate cancer. PLoS ONE, 2017, 12, e0188842.	1.1	36
264	Oncological outcomes in an Australian cohort according to the new prostate cancer grading groupings. BMC Cancer, 2017, 17, 537.	1.1	3
265	Analysis of Fascin-1 in Relation to Gleason Risk Classification and Nuclear ETS-Related Gene Status of Human Prostate Carcinomas: An Immunohistochemical Study of Clinically Annotated Tumours From the Wales Cancer Bank. Biomarkers in Cancer, 2017, 9, 1179299X1771094.	3.6	9
266	Preoperative Plasma Levels of Total Testosterone Associated with High Grade Pathology-Detected Prostate Cancer: Preliminary Results of a Prospective Study in a Contemporary Cohort of Patients. Current Urology, 2017, 10, 72-80.	0.4	6
267	The impact of the 2005 International Society of Urological Pathology Gleason grading consensus on active surveillance for prostate cancer. Central European Journal of Urology, 2017, 70, 344-348.	0.2	2

#	ARTICLE	IF	CITATIONS
268	The Modulating Effects of Benign Prostate Enlargement Medications on Upgrading Predictors in Patients with Gleason 6 at Biopsy. Current Urology, 2017, 10, 97-104.	0.4	2
269	Diagnostic performance of 68Gallium-PSMA-11 PET/CT to detect significant prostate cancer and comparison with 18FEC PET/CT. Oncotarget, 2017, 8, 111073-111083.	0.8	39
270	Clinical implications of PTEN loss in prostate cancer. Nature Reviews Urology, 2018, 15, 222-234.	1.9	408
272	Prostate Cancer Risk Reduced by Physical Activity Even Among Men With Prolonged Sitting Time: A Study From Vietnam. Asia-Pacific Journal of Public Health, 2018, 30, 227-234.	0.4	3
273	Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer. JAMA - Journal of the American Medical Association, 2018, 319, 896.	3.8	252
274	Pathology of Prostate Cancer. Molecular Pathology Library, 2018, , 37-56.	0.1	1
275	A Magnetic Resonance Imaging–Based Prediction Model for Prostate Biopsy Risk Stratification. JAMA Oncology, 2018, 4, 678.	3.4	141
276	C–C motif ligand 5 promotes migration of prostate cancer cells in the prostate cancer bone metastasis microenvironment. Cancer Science, 2018, 109, 724-731.	1.7	29
277	Predictors for the detection of prostate cancer and clinically significant prostate cancer using TRUS-guided biopsy in patients with negative initial biopsy results. World Journal of Urology, 2018, 36, 1047-1053.	1.2	1
278	Prostate Cancer Molecular Prognosis. Molecular Pathology Library, 2018, , 503-522.	0.1	2
279	Methodology for tissue sample collection within a translational sub-study of the CHHiP trial (CRUK/06/016), a large randomised phase III trial in localised prostate cancer. Clinical and Translational Radiation Oncology, 2018, 10, 1-6.	0.9	1
280	3 + 4 = 6? Implications of the stratification of localized Gleason 7 prostate cancer by number and percentage of positive biopsy cores in selecting patients for active surveillance. Actas Urológicas Españolas (English Edition), 2018, 42, 103-113.	0.2	2
281	The impact of intraductal carcinoma of the prostate on the site and timing of recurrence and cancer–specific survival. Prostate, 2018, 78, 697-706.	1.2	25
282	Digital versus light microscopy assessment of surgical margin status after radical prostatectomy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 472, 451-460.	1.4	9
283	Validation of American Joint Committee on Cancer eighth staging system among prostate cancer patients treated with radical prostatectomy. Therapeutic Advances in Urology, 2018, 10, 35-42.	0.9	10
284	High expression of NPRL2 is linked to poor prognosis in patients with prostate cancer. Human Pathology, 2018, 76, 141-148.	1.1	9
285	In-bore 3.0-T Magnetic Resonance Imaging-guided Transrectal Targeted Prostate Biopsy in a Repeat Biopsy Population: Diagnostic Performance, Complications, and Learning Curve. Urology, 2018, 114, 139-146.	0.5	11
286	The Heterogeneity of Prostate Cancer: A Practical Approach. Pathobiology, 2018, 85, 108-116.	1.9	93

#	Article	IF	Citations
287	Multiparametric (mp) MRI of prostate cancer. Progress in Nuclear Magnetic Resonance Spectroscopy, 2018, 105, 23-40.	3.9	29
288	Diagnostic accuracy of biparametric vs multiparametric MRI in clinically significant prostate cancer: Comparison between readers with different experience. European Journal of Radiology, 2018, 101, 17-23.	1.2	69
289	Histogram analysis of stretchedâ€exponential and monoexponential diffusionâ€weighted imaging models for distinguishing low and intermediate/high gleason scores in prostate carcinoma. Journal of Magnetic Resonance Imaging, 2018, 48, 491-498.	1.9	14
290	New prostate cancer grade grouping system predicts survival after radical prostatectomy. Human Pathology, 2018, 75, 159-166.	1.1	17
291	Role of Magnetic Resonance Imaging Targeted Biopsy in Detection of Prostate Cancer Harboring Adverse Pathological Features of Intraductal Carcinoma and Invasive Cribriform Carcinoma. Journal of Urology, 2018, 200, 104-113.	0.2	41
292	Evaluation of clinical staging of the American Joint Committee on Cancer (eighth edition) for prostate cancer. World Journal of Urology, 2018, 36, 769-774.	1.2	5
293	Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer: Comparing definitions of CHAARTED and LATITUDE trial. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 158.e13-158.e20.	0.8	27
294	Concordance of Gleason grading with three-dimensional ultrasound systematic biopsy and biopsy core pre-embedding. World Journal of Urology, 2018, 36, 863-869.	1.2	3
295	Efficacy of docetaxel in castration-resistant prostate cancer patients with intraductal carcinoma of the prostate. International Journal of Clinical Oncology, 2018, 23, 584-590.	1.0	15
296	3-D Quantitative Dynamic Contrast Ultrasound for Prostate Cancer Localization. Ultrasound in Medicine and Biology, 2018, 44, 807-814.	0.7	11
297	Molecular Imaging of Prostate Cancer: Radiopharmaceuticals for Positron Emission Tomography (PET) and Single-Photon Emission Computed Tomography (SPECT). Molecular Pathology Library, 2018, , 475-501.	0.1	2
298	Utility of Pathology Imagebase for standardisation of prostate cancer grading. Histopathology, 2018, 73, 8-18.	1.6	36
299	External validation of the prostascore model in patients with metastatic hormoneâ€sensitive prostate cancer recruited to the CHAARTED study. BJU International, 2018, 122, 394-400.	1.3	1
300	The Gleason pattern 4 in radical prostatectomy specimens in current practice - Quantification, morphology and concordance with biopsy. Annals of Diagnostic Pathology, 2018, 34, 13-17.	0.6	5
301	Prostatic adenocarcinoma in the setting of persistent mÃ¼llerian duct syndrome: a case report. Human Pathology, 2018, 75, 125-131.	1.1	2
302	Incidence of Extraprostatic Extension at Radical Prostatectomy with Pure Gleason Score 3 + 3 = 6 (Grade Group 1) Cancer: Implications for Whether Gleason Score 6 Prostate Cancer Should be Renamed "Not Cancer" and for Selection Criteria for Active Surveillance. Journal of Urology, 2018, 199, 1482-1487.	0.2	27
303	Development of a Nationally Representative Coordinated Registry Network for Prostate Ablation Technologies. Journal of Urology, 2018, 199, 1488-1493.	0.2	18
304	Prostate Cancer and the Evolving Role of Biomarkers in Screening and Diagnosis. Radiologic Clinics of North America, 2018, 56, 187-196.	0.9	13

#	ARTICLE	IF	CITATIONS
305	Future Perspectives and Challenges of Prostate MR Imaging. Radiologic Clinics of North America, 2018, 56, 327-337.	0.9	11
306	A direct comparison of contrast-enhanced ultrasound and dynamic contrast-enhanced magnetic resonance imaging for prostate cancer detection and prediction of aggressiveness. European Radiology, 2018, 28, 1949-1960.	2.3	16
307	Prostate Cancer Death After Radiotherapy or Radical Prostatectomy: A Nationwide Population-based Observational Study. European Urology, 2018, 73, 502-511.	0.9	37
308	Changes of Tumour–Node–Metastasis Staging in 2017: Concepts and Evolutions in the European and American Continents. European Urology, 2018, 73, 570-571.	0.9	4
309	Stochastic Modeling of Temporal Enhanced Ultrasound: Impact of Temporal Properties on Prostate Cancer Characterization. IEEE Transactions on Biomedical Engineering, 2018, 65, 1798-1809.	2.5	4
310	Updates in the Eighth Edition of the Tumor-Node-Metastasis Staging Classification for Urologic Cancers. European Urology, 2018, 73, 560-569.	0.9	401
311	Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls. Radiographics, 2018, 38, 200-217.	1.4	262
312	Mucinous and secondary tumors of the prostate. Modern Pathology, 2018, 31, 80-95.	2.9	37
313	Prostate cancer grading: a decade after the 2005 modified system. Modern Pathology, 2018, 31, 47-63.	2.9	83
314	Benign mimics of prostatic adenocarcinoma. Modern Pathology, 2018, 31, 22-46.	2.9	15
315	High-grade prostatic intraepithelial neoplasia, PIN-like carcinoma, ductal carcinoma, and intraductal carcinoma of the prostate. Modern Pathology, 2018, 31, 71-79.	2.9	73
317	Second harmonic generation imaging of the collagen architecture in prostate cancer tissue. Biomedical Physics and Engineering Express, 2018, 4, 025026.	0.6	16
318	The Cambridge Prognostic Groups for improved prediction of disease mortality at diagnosis in primary non-metastatic prostate cancer: a validation study. BMC Medicine, 2018, 16, 31.	2.3	36
319	ESTRO ACROP consensus guideline on CT- and MRI-based target volume delineation for primary radiation therapy of localized prostate cancer. Radiotherapy and Oncology, 2018, 127, 49-61.	0.3	157
320	Historical and contemporary perspectives on cribriform morphology in prostate cancer. Nature Reviews Urology, 2018, 15, 475-482.	1.9	28
321	Metabolomic Prediction of Human Prostate Cancer Aggressiveness: Magnetic Resonance Spectroscopy of Histologically Benign Tissue. Scientific Reports, 2018, 8, 4997.	1.6	39
322	Prostate cancer with cribriform morphology: diagnosis, aggressiveness, molecular pathology and possible relationships with intraductal carcinoma. Expert Review of Anticancer Therapy, 2018, 18, 685-693.	1.1	19
323	MAGI2 is an independent predictor of biochemical recurrence in prostate cancer. Prostate, 2018, 78, 616-622.	1.2	13

#	ARTICLE	IF	CITATIONS
324	Risk of Prostate Cancer in Men Treated With 5Î±-Reductase Inhibitorsâ€"A Large Population-Based Prospective Study. Journal of the National Cancer Institute, 2018, 110, 1216-1221.	3.0	27
325	Defining the optimal method for reporting prostate cancer grade and tumor extent on magnetic resonance/ultrasound fusionâ€"targeted biopsies. Human Pathology, 2018, 76, 68-75.	1.1	22
326	Ki67 Is an Independent Predictor of Recurrence in the Largest Randomized Trial of 3 Radiation Fractionation Schedules in Localized Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 101, 309-315.	0.4	19
327	Molecular correlates of intermediate- and high-risk localized prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 368-374.	0.8	5
328	Mesoscopic characterization of prostate cancer using Raman spectroscopy: potential for diagnostics and therapeutics. BJU International, 2018, 122, 326-336.	1.3	49
329	PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis. Scientific Reports, 2018, 8, 4254.	1.6	128
330	Integrating Tertiary Gleason 5 Patterns into Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens. European Urology, 2018, 73, 674-683.	0.9	40
331	From Gleason Grading System and High-grade Tertiary Patterns to Grade Groups and Integrated Quantitative Gleason Score. European Urology, 2018, 73, 684-686.	0.9	5
332	Characteristics of Prostate Cancer Found at Fifth Screening in the European Randomized Study of Screening for Prostate Cancer Rotterdam: Can We Selectively Detect High-grade Prostate Cancer with Upfront Multivariable Risk Stratification and Magnetic Resonance Imaging?. European Urology, 2018, 73, 343-350.	0.9	19
333	A Comprehensive Analysis of Cribriform Morphology on Magnetic Resonance Imaging/Ultrasound Fusion Biopsy Correlated with Radical Prostatectomy Specimens. Journal of Urology, 2018, 199, 106-113.	0.2	70
334	Characteristics and outcome of prostate cancer patients with overall biopsy Gleason score 3Â+Â4Â=Â7 and highest Gleason score 3Â+Â4Â=Â7 or >3Â+Â4Â=Â7. Histopathology, 2018, 72, 760-765.	1.6	14
335	Prognostic parameter for high risk prostate cancer patients at initial presentation. Prostate, 2018, 78, 11-16.	1.2	24
336	ISUP Group 4 â€" a Homogenous Group of Prostate Cancers?. Pathology and Oncology Research, 2018, 24, 921-925.	0.9	8
337	The Transcriptional Landscape of Radiation-Treated Human Prostate Cancer: Analysis of a Prospective Tissue Cohort. International Journal of Radiation Oncology Biology Physics, 2018, 100, 188-198.	0.4	24
338	Mediterranean Dietary Pattern is Associated with Low Risk of Aggressive Prostate Cancer: MCC-Spain Study. Journal of Urology, 2018, 199, 430-437.	0.2	89
339	Risk Stratification of Equivocal Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate. Journal of Urology, 2018, 199, 691-698.	0.2	38
340	Impact of Lesion Visibility on Transrectal Ultrasound on the Prediction of Clinically Significant Prostate Cancer (Gleason Score 3 + 4 or Greater) with Transrectal Ultrasound-Magnetic Resonance Imaging Fusion Biopsy. Journal of Urology, 2018, 199, 699-705.	0.2	16
341	Genomic Scores are Independent of Disease Volume in Men with Favorable Risk Prostate Cancer: Implications for Choosing Men for Active Surveillance. Journal of Urology, 2018, 199, 438-444.	0.2	11

#	Article	IF	Citations
342	Multiâ€institutional nomogram predicting benign prostate pathology on magnetic resonance/ultrasound fusion biopsy in men with a prior negative 12â€core systematic biopsy. Cancer, 2018, 124, 278-285.	2.0	41
343	Evaluation of tumor morphologies and association with biochemical recurrence after radical prostatectomy in grade group 5 prostate cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 472, 205-212.	1.4	22
344	Optimising preoperative risk stratification tools for prostate cancer using mpMRI. European Radiology, 2018, 28, 1016-1026.	2.3	18
345	Analysis of histological findings obtained combining US/mp-MRI fusion-guided biopsies with systematic US biopsies: mp-MRI role in prostate cancer detection and false negative. Radiologia Medica, 2018, 123, 143-152.	4.7	7
346	A novel biopsy-related parameter derived from location and relationship of positive cores on standard 12-core trans-rectal ultrasound-guided prostate biopsy: a useful parameter for predicting tumor volume compared to number of positive cores. Journal of Cancer Research and Clinical Oncology, 2018, 144, 135-143.	1.2	2
347	Â¿3 + 4Â= 6? Implicaciones de la estratificaciÃ³n del cÃ¡ncer de prÃ³stata localizado Gleason 7 por nÃºmero y porcentaje de cilindros positivos de biopsia en la selecciÃ³n de pacientes para vigilancia activa. Actas UrolÃ³gicas EspaÃ±olas, 2018, 42, 103-113.	0.3	2
348	Comparison of 11 Active Surveillance Protocols in Contemporary European Men Treated With Radical Prostatectomy. Clinical Genitourinary Cancer, 2018, 16, e141-e149.	0.9	10
349	Managing high-grade prostatic intraepithelial neoplasia (HGPIN) and atypical glands on prostate biopsy. Nature Reviews Urology, 2018, 15, 55-66.	1.9	18
350	Most Gleason 8 Biopsies are Downgraded at Prostatectomyâ€"Does 4 + 4 = 7?. Journal of Urology, 2018, 199, 706-712.	0.2	19
351	Removing the urinary catheter on post-operative day 2 after robot-assisted laparoscopic radical prostatectomy: a feasibility study from a single high-volume referral centre. Journal of Robotic Surgery, 2018, 12, 467-473.	1.0	5
352	Tumor necrosis in radical prostatectomies with high-grade prostate cancer is associated with multiple poor prognostic features and a high prevalence of residual disease. Human Pathology, 2018, 75, 1-9.	1.1	14
353	Contemporary prognostic indicators for prostate cancer incorporating International Society of Urological Pathology recommendations. Pathology, 2018, 50, 60-73.	0.3	29
354	Combining Prostate Health Index density, magnetic resonance imaging and prior negative biopsy status to improve the detection of clinically significant prostate cancer. BJU International, 2018, 121, 619-626.	1.3	70
355	Prostate cancer diagnosis and characterization with mass spectrometry imaging. Prostate Cancer and Prostatic Diseases, 2018, 21, 297-305.	2.0	19
356	Metabolic syndrome and low high-density lipoprotein cholesterol are associated with adverse pathological features in patients with prostate cancer treated by radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 80.e17-80.e24.	0.8	10
357	Atypical small acinar proliferation at index prostate biopsy: rethinking the re-biopsy paradigm. International Urology and Nephrology, 2018, 50, 1-6.	0.6	8
358	Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer. European Urology, 2018, 74, 99-106.	0.9	28
359	Genomic Gain of 16p13.3 in Prostate Cancer Predicts Poor Clinical Outcome after Surgical Intervention. Molecular Cancer Research, 2018, 16, 115-123.	1.5	12

#	ARTICLE	IF	CITATIONS
360	Altered mitochondrial genome content signals worse pathology and prognosis in prostate cancer. Prostate, 2018, 78, 25-31.	1.2	19
361	Prostate cancer detection among readers with different degree of experience using ultra-high b-value diffusion-weighted Imaging: Is a non-contrast protocol sufficient to detect significant cancer?. European Radiology, 2018, 28, 869-876.	2.3	20
362	The Immunohistochemical Analysis of SOCS3 Protein Identifies a Subgroup of Prostatic Cancer Biopsies With Aggressive Behavior. Applied Immunohistochemistry and Molecular Morphology, 2018, 26, 324-329.	0.6	4
363	Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in <i>BRCA2</i>-Associated Prostate Cancer Resulting From Biallelic <i>BRCA2</i> Reversion Mutations Restores Both Germline and Somatic Loss-of-Function Mutations. JCO Precision Oncology, 2018, 2, 1-8.	1.5	32
364	Being on active surveillance: the patient perspective. Translational Andrology and Urology, 2018, 7, 182-187.	0.6	2
365	Oncological Outcomes of Open Radical Retropubic Prostatectomy in Ireland: A Single Surgeon's 5-Year Experience. The Surgery Journal, 2018, 04, e226-e234.	0.3	1
366	On cribriform prostate cancer. Translational Andrology and Urology, 2018, 7, 145-154.	0.6	25
367	Beyond the Gleason score: the prognostic significance of prostate cancer subtypes. Translational Andrology and Urology, 2018, 7, S260-S261.	0.6	0
368	Clinical significance of subtypes of Gleason pattern 4 prostate cancer. Translational Andrology and Urology, 2018, 7, S477-S483.	0.6	15
369	Detection of extraprostatic disease and seminal vesicle invasion in patients undergoing magnetic resonance imaging-targeted prostate biopsies. Translational Andrology and Urology, 2018, 7, S392-S396.	0.6	9
370	Percent Gleason pattern 4 in stratifying the prognosis of patients with intermediate-risk prostate cancer. Translational Andrology and Urology, 2018, 7, S484-S489.	0.6	14
371	Radical prostatectomy performed via robotic, transperitoneal and extraperitoneoscopic approaches: functional and early oncological outcomes. Central European Journal of Urology, 2018, 71, 378-385.	0.2	3
372	Pattern of care of prostate cancer patients across the Martinique: results of a population-based study in the Caribbean. BMC Cancer, 2018, 18, 1130.	1.1	9
373	Prostatic cancers: understanding their molecular pathology and the 2016 WHO classification. Oncotarget, 2018, 9, 14723-14737.	0.8	39
374	Concordance of â€œCase Levelâ€•Global, Highest, and Largest Volume Cancer Grade Group on Needle Biopsy Versus Grade Group on Radical Prostatectomy. American Journal of Surgical Pathology, 2018, 42, 1522-1529.	2.1	23
376	Deep Learning for Natural Language Processing in Urology: State-of-the-Art Automated Extraction of Detailed Pathologic Prostate Cancer Data From Narratively Written Electronic Health Records. JCO Clinical Cancer Informatics, 2018, 2, 1-9.	1.0	150
377	A prospective study determining and comparing the diagnostic accuracy of fluoride-PET/CT, choline-PET/CT, whole-body bone SPECT/CT and whole-body MRI for the detection of bone metastases in patients with prostate cancer. European Journal of Hybrid Imaging, 2018, 2, .	0.6	3
378	Current topics on prostate and bladder pathology. Surgical and Experimental Pathology, 2018, 1, .	0.2	1

#	Article	IF	Citations
379	Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy. European Urology Oncology, 2018, 1, 109-117.	2.6	37
380	Updates on Grading and Staging of Prostate Cancer. Surgical Pathology Clinics, 2018, 11, 759-774.	0.7	19
381	Comparison of Gleason upgrading rates in transrectal ultrasound systematic random biopsies versus US-MRI fusion biopsies for prostate cancer. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2018, 44, 1106-1113.	0.7	19
383	Extraperitoneal robot-assisted radical prostatectomy: a high-volume surgical center experience. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2018, 70, 479-485.	3.9	10
384	SERS-Based Quantification of PSMA in Tissue Microarrays Allows Effective Stratification of Patients with Prostate Cancer. ACS Omega, 2018, 3, 16784-16794.	1.6	13
385	Prognostic indicators of outcome for patients with skeletal metastases from carcinoma of the prostate. Bone and Joint Journal, 2018, 100-B, 1647-1654.	1.9	4
386	Predicting Gleason Score of Prostate Cancer Patients Using Radiomic Analysis. Frontiers in Oncology, 2018, 8, 630.	1.3	72
387	National Comprehensive Cancer Network (NCCN) risk classification in predicting biochemical recurrence after radical prostatectomy: a retrospective cohort study in Chinese prostate cancer patients. Asian Journal of Andrology, 2018, 20, 551.	0.8	9
388	Una mirada global y actualizada del cáncer de próstata. Revista Facultad De Medicina, 2018, 66, 429-437.	0.0	2
389	"Mix-to-Go" Silver Colloidal Strategy for Prostate Cancer Molecular Profiling and Risk Prediction. Analytical Chemistry, 2018, 90, 12698-12705.	3.2	13
390	Contrast-enhanced ultrasound tractography for 3D vascular imaging of the prostate. Scientific Reports, 2018, 8, 14640.	1.6	8
391	Automatic grading of prostate cancer in digitized histopathology images: Learning from multiple experts. Medical Image Analysis, 2018, 50, 167-180.	7.0	114
392	Multiparametric Magnetic Resonance Imaging Features Identify Aggressive Prostate Cancer at the Phenotypic and Transcriptomic Level. Journal of Urology, 2018, 200, 1241-1249.	0.2	23
393	Updates in Urologic Pathology: Emerging Areas, Staging, Grading, Unexpected Entities, and Clinical Significance. Surgical Pathology Clinics, 2018, 11, ix-x.	0.7	0
395	Development and Internal Validation of Novel Nomograms Based on Benign Prostatic Obstruction-Related Parameters to Predict the Risk of Prostate Cancer at First Prostate Biopsy. Frontiers in Oncology, 2018, 8, 438.	1.3	29
396	Evaluation of Dispersion MRI for Improved Prostate Cancer Diagnosis in a Multicenter Study. American Journal of Roentgenology, 2018, 211, W242-W251.	1.0	7
397	Risk of upgrading from prostate biopsy to radical prostatectomy pathology: Is magnetic resonance imaging-guided biopsy more accurate?. Journal of Cancer, 2018, 9, 3634-3639.	1.2	22
398	Role of Prostate MRI in the Setting of Active Surveillance for Prostate Cancer. Advances in Experimental Medicine and Biology, 2018, 1096, 49-67.	0.8	1

#	Article	IF	Citations
399	Sarcomatoid Variant of Bladder Carcinoma: A Case Report. Case Reports in Oncology, 2018, 11, 633-637.	0.3	1
400	Evaluation of Prostate Needle Biopsies. Advances in Experimental Medicine and Biology, 2018, 1096, 69-86.	0.8	1
401	Serum thymidine kinase 1 is associated with Gleason score of patients with prostate carcinoma. Oncology Letters, 2018, 16, 6171-6180.	0.8	2
402	Large-Gland Proliferations of the Prostate. Surgical Pathology Clinics, 2018, 11, 687-712.	0.7	1
403	Genitourinary Pathology Reporting Parameters Most Relevant to the Medical Oncologist. Surgical Pathology Clinics, 2018, 11, 877-891.	0.7	0
404	Association of doublecortin-like kinase 1 with tumor aggressiveness and poor biochemical recurrence-free survival in prostate cancer. OncoTargets and Therapy, 2018, Volume 11, 1077-1086.	1.0	10
405	Are localized prostate cancer biomarkers useful in the clinical practice?. Tumor Biology, 2018, 40, 101042831879925.	0.8	15
406	Comparison of prostatic adenocarcinoma Gleason 5 and intraductal carcinoma of the prostate with tumor necrosis. A morphometric study. Pathology Research and Practice, 2018, 214, 1681-1685.	1.0	6
407	Reduction of MRI-targeted biopsies in men with low-risk prostate cancer on active surveillance by stratifying to PI-RADS and PSA-density, with different thresholds for significant disease. Translational Andrology and Urology, 2018, 7, 132-144.	0.6	43
408	Changes in Clinical Characteristics of Patients with an Initial Diagnosis of Prostate Cancer in Korea: 10-Year Trends Reported by a Tertiary Center. Journal of Korean Medical Science, 2018, 33, e42.	1.1	5
409	Genetics and biology of prostate cancer. Genes and Development, 2018, 32, 1105-1140.	2.7	434
410	Multi-region proteome analysis quantifies spatial heterogeneity of prostate tissue biomarkers. Life Science Alliance, 2018, 1, e201800042.	1.3	51
412	In reply to Egevad <i>et al</i>.: â€˜Utility of Pathology Imagebase for standardisation of prostate cancer gradingâ€™. Histopathology, 2018, 73, 360-361.	1.6	1
413	Protocols for Tissue Microarrays in Prostate Cancer Studies. Methods in Molecular Biology, 2018, 1786, 103-116.	0.4	1
414	Dissecting the heterogeneity of localized prostate cancer risk groups through integration of percent of positive cores. Future Oncology, 2018, 14, 1469-1476.	1.1	0
415	A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts. European Urology, 2018, 74, 197-203.	0.9	93
416	The p21-activated kinase 4-Slug transcription factor axis promotes epithelialâˆ'mesenchymal transition and worsens prognosis in prostate cancer. Oncogene, 2018, 37, 5147-5159.	2.6	41
417	High expression of QSOX1 is associated with tumor invasiveness and high grades groups in prostate cancer. Pathology Research and Practice, 2018, 214, 964-967.	1.0	19

#	ARTICLE	IF	CITATIONS
418	Serum procalcitonin levels in prostate cancer: A new biomarker?. Urologia, 2018, 85, 46-50.	0.3	6
419	PSA-density does not improve bi-parametric prostate MR detection of prostate cancer in a biopsy naÃ¯ve patient population. European Journal of Radiology, 2018, 104, 64-70.	1.2	36
421	Clinical Utility of Multiparametric Magnetic Resonance Imaging as the First-line Tool for Men with High Clinical Suspicion of Prostate Cancer. European Urology Oncology, 2018, 1, 208-214.	2.6	24
422	The Impact of Pathologic Upgrading of Gleason Score 7 Prostate Cancer on the Risk of the Biochemical Recurrence after Radical Prostatectomy. BioMed Research International, 2018, 2018, 1-6.	0.9	7
423	Prostate cancer grading in 2018: limitations, implementations, cribriform morphology, and biological markers. International Journal of Biological Markers, 2018, 33, 331-334.	0.7	10
424	Cribriform morphology in prostate pathology. Diagnostic Histopathology, 2018, 24, 215-219.	0.2	1
425	Association between pathologic factors and ERG expression in prostate cancer: finding pivotal networking. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1665-1683.	1.2	8
426	Radio-pathomic Maps of Epithelium and Lumen Density Predict the Location of High-Grade Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 101, 1179-1187.	0.4	49
427	Landmarks in prostate cancer. Nature Reviews Urology, 2018, 15, 627-642.	1.9	78
428	The clinical usefulness of natural killer cell activity in patients with suspected or diagnosed prostate cancer: an observational cross-sectional study. OncoTargets and Therapy, 2018, Volume 11, 3883-3889.	1.0	4
429	Progesterone Receptors in Prostate Cancer: Progesterone receptor B is the isoform associated with disease progression. Scientific Reports, 2018, 8, 11358.	1.6	34
430	Prostate Cancer: Overview, Detection, Treatment. , 2018, , 474-478.		0
431	Spectrum of Cribriform Proliferations of the Prostate: From Benign to Malignant. Archives of Pathology and Laboratory Medicine, 2018, 142, 938-946.	1.2	17
432	Overview on Clinical Relevance of Intra-Tumor Heterogeneity. Frontiers in Medicine, 2018, 5, 85.	1.2	182
433	Gaâ€68â€PSMA PET/CT in treatmentâ€naÃ¯ve patients with prostate cancer: Which clinical parameters and risk stratification systems best predict PSMAâ€positive metastases?. Prostate, 2018, 78, 1103-1110.	1.2	15
434	Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging. European Urology, 2018, 74, 722-728.	0.9	70
435	Natural History of High-Risk Prostate Cancer. , 2018, , 3-9.		0
436	ADC Metrics From Multiparametric MRI: Histologic Downgrading of Gleason Score 9 or 10 Prostate Cancers Diagnosed at Nontargeted Transrectal Ultrasoundâ€"Guided Biopsy. American Journal of Roentgenology, 2018, 211, W158-W165.	1.0	7

#	Article	IF	Citations
437	Should reporting of peri-neural invasion and extra prostatic extension be mandatory in prostate cancer biopsies? correlation with outcome in biopsy cases treated conservatively. Oncotarget, 2018, 9, 20555-20562.	0.8	14
438	Continuous versus discontinuous tumor involvement: A dilemma in prostate biopsy quantitation. Prostate, 2018, 78, 1166-1171.	1.2	4
439	The Ability of Prostate Health Index (PHI) to Predict Gleason Score in Patients With Prostate Cancer and Discriminate Patients Between Gleason Score 6 and Gleason Score Higher Than 6â€"A Study on 320 Patients After Radical Prostatectomy. Technology in Cancer Research and Treatment, 2018, 17, 153303381878737.	0.8	15
440	Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations. BMC Cancer, 2018, 18, 8.	1.1	93
441	Possible association between androgenic alopecia and risk of prostate cancer and testicular germ cell tumor: a systematic review and meta-analysis. BMC Cancer, 2018, 18, 279.	1.1	8
442	Unfavorable Pathology, Tissue Biomarkers and Genomic Tests With Clinical Implications in Prostate Cancer Management. Advances in Anatomic Pathology, 2018, 25, 293-303.	2.4	11
443	Clinical Significance of Complex Glandular Patterns in Lung Adenocarcinoma. American Journal of Clinical Pathology, 2018, 150, 65-73.	0.4	31
444	Can Apparent Diffusion Coefficient Values Assist PI-RADS Version 2 DWI Scoring? A Correlation Study Using the PI-RADSv2 and International Society of Urological Pathology Systems. American Journal of Roentgenology, 2018, 211, W33-W41.	1.0	26
445	Predictors of adverse pathologic features after radical prostatectomy in low-risk prostate cancer. BMC Cancer, 2018, 18, 545.	1.1	11
446	A prospective randomized multicentre study of the impact of galliumâ€68 prostateâ€specific membrane antigen (PSMA) PET/CT imaging for staging highâ€risk prostate cancer prior to curativeâ€intent surgery or radiotherapy (proPSMA study): clinical trial protocol. BJU International, 2018, 122, 783-793.	1.3	96
447	Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer. Clinical Epigenetics, 2018, 10, 105.	1.8	36
448	Temporal Trend in Incidental Prostate Cancer Detection at Surgery for Benign Prostatic Hyperplasia. Urology, 2018, 122, 152-157.	0.5	36
449	Computer-aided classification of prostate cancer grade groups from MRI images using texture features and stacked sparse autoencoder. Computerized Medical Imaging and Graphics, 2018, 69, 60-68.	3.5	62
450	Tissue-based multigene expression tests for pretreatment prostate cancer risk assessment: current status and future perspectives. Future Oncology, 2018, 14, 3073-3083.	1.1	4
452	Increased Paxillin expression in prostate cancer is associated with advanced pathological features, lymph node metastases and biochemical recurrence. Journal of Cancer, 2018, 9, 959-967.	1.2	11
453	Development and validation of a novel automated Gleason grade and molecular profile that define a highly predictive prostate cancer progression algorithm-based test. Prostate Cancer and Prostatic Diseases, 2018, 21, 594-603.	2.0	22
454	Photoacoustic tomography of intact human prostates and vascular texture analysis identify prostate cancer biopsy targets. Photoacoustics, 2018, 11, 46-55.	4.4	22
455	External validation of the novel International Society of Urological Pathology (ISUP) Gleason grading groups in a large contemporary Canadian cohort. Canadian Urological Association Journal, 2018, 12, .	0.3	2

#	Article	IF	Citations
456	Human HLA‑F adjacent transcript 10 promotes the formation of cancer initiating cells and cisplatin resistance in bladder cancer. Molecular Medicine Reports, 2018, 18, 308-314.	1.1	6
457	Evolution in Prostate Cancer Staging: Pathology Updates From AJCC 8th Edition and Opportunities That Remain. Advances in Anatomic Pathology, 2018, 25, 327-332.	2.4	9
458	Comedonecrosis Revisited. American Journal of Surgical Pathology, 2018, 42, 1036-1041.	2.1	44
459	Assessment of the Diagnostic Accuracy of Biparametric Magnetic Resonance Imaging for Prostate Cancer in Biopsy-Naive Men. JAMA Network Open, 2018, 1, e180219.	2.8	135
461	Features and Prognostic Significance of Intraductal Carcinoma of the Prostate. European Urology Oncology, 2018, 1, 21-28.	2.6	27
462	Gleason score assignment is the sole responsibility of the pathologist. Histopathology, 2018, 73, 5-7.	1.6	12
463	Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations. Cancer Research, 2018, 78, 4716-4730.	0.4	56
464	Predictive role of PI-RADSv2 and ADC parameters in differentiating Gleason pattern 3‰+‰4 and 4‰+‰3 prostate cancer. Abdominal Radiology, 2019, 44, 279-285.	1.0	24
465	Standard vs delayed ligature of the dorsal vascular complex during robot-assisted radical prostatectomy: results from a randomized controlled trial. Journal of Robotic Surgery, 2019, 13, 253-260.	1.0	11
466	How Are Gleason Scores Categorized in the Current Literature: An Analysis and Comparison of Articles Published in 2016–2017. European Urology, 2019, 75, 25-31.	0.9	8
467	Prostate Cancers Detected by Magnetic Resonance Imaging–Targeted Biopsies Have a Higher Percentage of Gleason Pattern 4 Component and Are Less Likely to Be Upgraded in Radical Prostatectomies. Archives of Pathology and Laboratory Medicine, 2019, 143, 86-91.	1.2	12
468	The relationship between body-mass index, physical activity, and pathologic and clinical outcomes after radical prostatectomy for prostate cancer. World Journal of Urology, 2019, 37, 789-798.	1.2	7
469	Optimization of the 2014 Gleason grade grouping in a Canadian cohort of patients with localized prostate cancer. BJU International, 2019, 123, 624-631.	1.3	16
470	Prostate Cancer Grading: Are We Heading Towards Grade Grouping Version 2?. European Urology, 2019, 75, 32-34.	0.9	3
471	Molecular Pathology of High-Grade Prostatic Intraepithelial Neoplasia: Challenges and Opportunities. Cold Spring Harbor Perspectives in Medicine, 2019, 9, a030403.	2.9	25
472	Importance of metastatic volume in prognostic models to predict survival in newly diagnosed metastatic prostate cancer. World Journal of Urology, 2019, 37, 2565-2571.	1.2	10
473	Prostate volume index and prostatic chronic inflammation have an effect on tumor load at baseline random biopsies in patients with normal DRE and PSA values less than 10‰ng/ml: results of 564 consecutive cases. Therapeutic Advances in Urology, 2019, 11, 175628721986860.	0.9	5
475	High efficacy of hypofractionated proton therapy with 4 fractions of 5‾Gy as a boost to 50‾Gy photon therapy for localized prostate cancer. Radiotherapy and Oncology, 2019, 141, 164-173.	0.3	6

#	ARTICLE	IF	CITATIONS
476	Urinary DNA methylation biomarkers for prediction of prostate cancer upgrading and upstaging. Clinical Epigenetics, 2019, 11, 115.	1.8	24
477	Nomograms Predict Survival Advantages of Gleason Score 3+4 Over 4+3 for Prostate Cancer: A SEER-Based Study. Frontiers in Oncology, 2019, 9, 646.	1.3	28
478	Comparison of bi- and multiparametric magnetic resonance imaging to select men for active surveillance. Acta Radiologica Open, 2019, 8, 205846011986635.	0.3	6
479	Extent and predictors of grade upgrading and downgrading in an Australian cohort according to the new prostate cancer grade groupings. Asian Journal of Urology, 2019, 6, 321-329.	0.5	7
480	Association Between Tumor Multifocality on Multi-parametric MRI and Detection of Clinically-Significant Prostate Cancer in Lesions with Prostate Imaging Reporting and Data System (PI-RADS) Score 4. Urology, 2019, 134, 173-180.	0.5	3
481	Grade groups at diagnosis in African Caribbean men with prostate cancer: Results of a comparative study. Prostate, 2019, 79, 1640-1646.	1.2	4
482	Improving ultrasound-based prostate volume estimation. BMC Urology, 2019, 19, 68.	0.6	18
483	The Calculus of Serum PSA. American Journal of Clinical Pathology, 2019, 152, 365-368.	0.4	0
484	Does ductal adenocarcinoma of the prostate (DA) have any prognostic impact on patients with de novo metastatic prostate cancer?. Prostate, 2019, 79, 1673-1682.	1.2	7
485	Predicting biochemical recurrence after radical prostatectomy: the role of prognostic grade group and index tumor nodule. Human Pathology, 2019, 93, 6-15.	1.1	3
486	ERG expression in prostate cancer biopsies with and without high-grade prostatic intraepithelial neoplasia: a study in Jordanian Arab patients . Research and Reports in Urology, 2019, Volume 11, 149-155.	0.6	0
487	Omega-3 Fatty Acids Survey in Men under Active Surveillance for Prostate Cancer: from Intake to Prostate Tissue Level. Nutrients, 2019, 11, 1616.	1.7	13
488	AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration–resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first–line therapy. Prostate, 2019, 79, 1553-1562.	1.2	22
490	Contemporary Approach to Gleason Grading of Prostate Cancer. , 2019, , 45-67.		0
491	Intraductal Carcinoma of the Prostate (IDC-P) and Atypical Intraductal Proliferation (AIP). , 2019, , 127-132.		0
492	State–of–the–Art Report: Visual Computing in Radiation Therapy Planning. Computer Graphics Forum, 2019, 38, 753-779.	1.8	9
493	Fluorine-18-Labeled Fluciclovine PET/CT in Clinical Practice: Factors Affecting the Rate of Detection of Recurrent Prostate Cancer. American Journal of Roentgenology, 2019, 213, 851-858.	1.0	24
494	PI-RADS version 2: optimal time range for determining positivity of dynamic contrast-enhanced MRI in peripheral zone prostate cancer. Clinical Radiology, 2019, 74, 895.e27-895.e34.	0.5	4

#	ARTICLE	IF	CITATIONS
495	Clinical outcomes of external beam radiotherapy in patients with localized prostate cancer: Does dose escalation matter?. Asia-Pacific Journal of Clinical Oncology, 2019, 15, 323-330.	0.7	2
496	Low Expression of miR-424-3p is Highly Correlated with Clinical Failure in Prostate Cancer. Scientific Reports, 2019, 9, 10662.	1.6	32
497	<p>The validation of the 2014 International Society of Urological Pathology (ISUP) grading system for patients with high-risk prostate cancer: a single-center retrospective study</p>. Cancer Management and Research, 2019, Volume 11, 6521-6529.	0.9	3
498	Gleason grading of prostate cancer: a pragmatic approach. Diagnostic Histopathology, 2019, 25, 371-378.	0.2	11
499	Evaluation of neurotensin receptor 1 as potential biomarker for prostate cancer theranostic use. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2199-2207.	3.3	11
500	The pathological upgrading after radical prostatectomy in low‐risk prostate cancer patients who are eligible for active surveillance: How safe is it to depend on bioptic pathology?. Prostate, 2019, 79, 1523-1529.	1.2	21
501	Controversial issues in Gleason and International Society of Urological Pathology (ISUP) prostate cancer grading: proposed recommendations for international implementation. Pathology, 2019, 51, 463-473.	0.3	47
502	Pathological upgrading in prostate cancer treated with surgery in the United Kingdom: trends and risk factors from the British Association of Urological Surgeons Radical Prostatectomy Registry. BMC Urology, 2019, 19, 94.	0.6	25
503	Long noncoding RNA HOTTIP overexpression: A potential prognostic biomarker in prostate cancer. Pathology Research and Practice, 2019, 215, 152649.	1.0	13
504	Tissue Proteome Signatures Associated with Five Grades of Prostate Cancer and Benign Prostatic Hyperplasia. Proteomics, 2019, 19, e1900174.	1.3	27
505	MRI-Fusion Targeted vs. Systematic Prostate Biopsy—How Does the Biopsy Technique Affect Gleason Grade Concordance and Upgrading After Radical Prostatectomy?. Frontiers in Surgery, 2019, 6, 55.	0.6	19
506	Automated grading of prostate cancer using convolutional neural network and ordinal class classifier. Informatics in Medicine Unlocked, 2019, 17, 100256.	1.9	36
507	Prognostic significance of the presence of tertiary Gleason grade 5 in robot-assisted radical prostatectomy specimens in Japanese patients with clinically localized prostate cancer. Japanese Journal of Clinical Oncology, 2019, 49, 276-280.	0.6	0
508	Impact of GAS5 genetic polymorphism on prostate cancer susceptibility and clinicopathologic characteristics. International Journal of Medical Sciences, 2019, 16, 1424-1429.	1.1	23
509	Comparison of PI-RADS version 2 and PI-RADS version 2.1 for the detection of transition zone prostate cancer. European Journal of Radiology, 2019, 121, 108704.	1.2	70
510	Proportion of cores with the highest Gleason grade group among positive cores on prostate biopsy: does this affect the probability of upgrading or downgrading?. Scandinavian Journal of Urology, 2019, 53, 372-377.	0.6	5
511	In Vivo Evidence for Voltage-Gated Sodium Channel Expression in Carcinomas and Potentiation of Metastasis. Cancers, 2019, 11, 1675.	1.7	86
512	Adjuvant versus early salvage radiotherapy: outcome of patients with prostate cancer treated with postoperative radiotherapy after radical prostatectomy. Radiation Oncology, 2019, 14, 198.	1.2	6

#	Article	IF	Citations
513	Translational AI and Deep Learning in Diagnostic Pathology. Frontiers in Medicine, 2019, 6, 185.	1.2	165
514	p53 nuclear accumulation as an early indicator of lethal prostate cancer. British Journal of Cancer, 2019, 121, 578-583.	2.9	10
515	Total testosterone density predicts high tumor load and disease reclassification of prostate cancer: results in 144 low-risk patients who underwent radical prostatectomy. International Urology and Nephrology, 2019, 51, 2169-2180.	0.6	9
516	Correlation between 18F-1-amino-3-fluorocyclobutane-1-carboxylic acid (18F-fluciclovine) uptake and expression of alanine-serine-cysteine-transporter 2 (ASCT2) and L-type amino acid transporter 1 (LAT1) in primary prostate cancer. EJNMMI Research, 2019, 9, 50.	1.1	14
517	Artificial intelligenceâ€¢based versus manual assessment of prostate cancer in the prostate gland: a method comparison study. Clinical Physiology and Functional Imaging, 2019, 39, 399-406.	0.5	30
518	Developing a National Center of Excellence for Prostate Imaging. Current Urology Reports, 2019, 20, 59.	1.0	2
519	Is possible to rule out clinically significant prostate cancer using PI-RADS v2 for the assessment of prostate MRI?. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2019, 45, 724-731.	0.7	5
520	Biofluid quantification of TWEAK/Fn14 axis in combination with a selected biomarker panel improves assessment of prostate cancer aggressiveness. Journal of Translational Medicine, 2019, 17, 307.	1.8	8
521	Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. European Urology, 2019, 76, 831-842.	0.9	148
522	Diagnosis: From classification to prediction. Social Science and Medicine, 2019, 237, 112444.	1.8	9
523	Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer.. Cancers, 2019, 11, 1355.	1.7	54
524	Semen miRNAs Contained in Exosomes as Non-Invasive Biomarkers for Prostate Cancer Diagnosis. Scientific Reports, 2019, 9, 13772.	1.6	92
525	Gleason pattern 5 is associated with an increased risk for metastasis following androgen deprivation therapy and radiation: An analysis of RTOG 9202 and 9902. Radiotherapy and Oncology, 2019, 141, 137-143.	0.3	8
526	High surgeon volume and positive surgical margins can predict the risk of biochemical recurrence after robot-assisted radical prostatectomy. Therapeutic Advances in Urology, 2019, 11, 175628721987828.	0.9	8
527	Digital versus light microscopy assessment of extraprostatic extension in radical prostatectomy samples. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 475, 735-744.	1.4	3
528	Pathological Characteristics of Prostate Cancer Occurring in Younger Men: A Retrospective Study of Prostatectomy Patients. Urology, 2019, 134, 163-167.	0.5	3
529	Consensus statements on the management of clinically localized prostate cancer from the Hong Kong Urological Association and the Hong Kong Society of Uroâ€¢Oncology. BJU International, 2019, 124, 221-241.	1.3	4
530	Optical Coherence Tomography in Urologic Oncology: a Comprehensive Review. SN Comprehensive Clinical Medicine, 2019, 1, 67-84.	0.3	15

#	Article	IF	Citations
531	A Grading System for the Assessment of Risk of Extraprostatic Extension of Prostate Cancer at Multiparametric MRI. Radiology, 2019, 290, 709-719.	3.6	140
532	Computer-aided grading of prostate cancer from MRI images using Convolutional Neural Networks. Journal of Intelligent and Fuzzy Systems, 2019, 36, 2015-2024.	0.8	18
533	MicroRNA 141 is associated to outcome and aggressive tumor characteristics in prostate cancer. Scientific Reports, 2019, 9, 386.	1.6	43
534	Value of Increasing Biopsy Cores per Target with Cognitive MRI-targeted Transrectal US Prostate Biopsy. Radiology, 2019, 291, 83-89.	3.6	43
535	Combined-modality 125J-seed-brachytherapy, external beam radiation and androgen deprivation therapy of unfavorable-risk prostate cancer: report of outcomes and side-effects. World Journal of Urology, 2019, 37, 2355-2363.	1.2	4
536	Low-molecular-weight Protein Tyrosine Phosphatase Is a Possible Biomarker for Predicting Postoperative Biochemical Recurrence in Prostate Cancer With Negative Surgical Margins. Anticancer Research, 2019, 39, 957-964.	0.5	5
537	Interleukinâ€"35 is associated with the tumorigenesis and progression of prostate cancer. Oncology Letters, 2019, 17, 5094-5102.	0.8	10
538	Dynamic Contrast-Enhanced MRIâ€"Upgraded Prostate Imaging Reporting and Data System Version 2 Category 3 Peripheral Zone Observations Stratified by a Size Threshold of 15 mm. American Journal of Roentgenology, 2019, 213, 836-843.	1.0	4
539	PTEN and ERG detection in multiparametric magnetic resonance imaging/ultrasound fusion targeted prostate biopsy compared to systematic biopsy. Human Pathology, 2019, 90, 20-26.	1.1	7
540	Fluorescence Detection of Prostate Cancer by an Activatable Fluorescence Probe for PSMA Carboxypeptidase Activity. Journal of the American Chemical Society, 2019, 141, 10409-10416.	6.6	69
541	Validation of IMPROD biparametric MRI in men with clinically suspected prostate cancer: A prospective multi-institutional trial. PLoS Medicine, 2019, 16, e1002813.	3.9	43
542	Development and validation of a deep learning algorithm for improving Gleason scoring of prostate cancer. Npj Digital Medicine, 2019, 2, 48.	5.7	244
543	Gleason grade patterns in nodal metastasis and corresponding prostatectomy specimens: impact on patient outcome. Histopathology, 2019, 75, 715-722.	1.6	18
544	Prostate-Specific Antigen After Neoadjuvant Androgen Suppression in Prostate Cancer Patients Receiving Short-Term Androgen Suppression and External Beam Radiation Therapy: Pooled Analysis of Four NRG Oncology Radiation Therapy Oncology Group Randomized Clinical Trials. International Journal of Radiation Oncology Biology Physics, 2019, 104, 1057-1065.	0.4	9
545	Histological differences in cancer cells, stroma, and luminal spaces strongly correlate with in vivo MRI-detectability of prostate cancer. Modern Pathology, 2019, 32, 1536-1543.	2.9	21
546	Comparison of PI-RADS v1 and v2 for multiparametric MRI detection of prostate cancer with whole-mount histological workup as reference standard. European Journal of Radiology, 2019, 116, 180-185.	1.2	10
547	Prostate cancer: On the road of progress. Asian Journal of Urology, 2019, 6, 123-124.	0.5	3
548	Treatment outcomes of prostate cancer patients with Gleason scoreÂ8â€"10 treated with definitive radiotherapy. Strahlentherapie Und Onkologie, 2019, 195, 882-893.	1.0	6

#	ARTICLE	IF	CITATIONS
549	Prostate cancer aggressive prediction: preponderant diagnostic performances of intravoxel incoherent motion (IVIM) imaging and diffusion kurtosis imaging (DKI) beyond ADC at 3.0 T scanner with gleason score at final pathology. Abdominal Radiology, 2019, 44, 3441-3452.	1.0	20
550	The TNM 8th edition: Validation of the proposal for organ - confined (pT2) prostate cancer. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2019, 45, 229-236.	0.7	2
551	High Diagnostic Performance of Short Magnetic Resonance Imaging Protocols for Prostate Cancer Detection in Biopsy-naïve Men: The Next Step in Magnetic Resonance Imaging Accessibility. European Urology, 2019, 76, 574-581.	0.9	114
552	Genetic polymorphism and carbonic anhydrase 9 expression can predict nodal metastatic prostate cancer risk in patients with prostate-specific antigen levels �≠0 ng/ml at initial biopsy. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 814.e9-814.e16.	0.8	9
553	PI-RADS Steering Committee: The PI-RADS Multiparametric MRI and MRI-directed Biopsy Pathway. Radiology, 2019, 292, 464-474.	3.6	162
554	Reliable identification of prostate cancer using mass spectrometry metabolomic imaging in needle core biopsies. Laboratory Investigation, 2019, 99, 1561-1571.	1.7	35
555	68Ga-PSMA PET/CT: Does it predict adverse pathology findings at radical prostatectomy?. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 574.e19-574.e24.	0.8	11
556	Are Prostate Specific-Antigen (PSA) and age associated with the risk of ISUP Grade 1 prostate cancer? Results from 72 996 individual biopsy cores in 6 083 men from the Stockholm3 study. PLoS ONE, 2019, 14, e0218280.	1.1	7
557	[68]Gallium-labelled PSMA-PET/CT as a diagnostic and clinical decision-making tool in Asian prostate cancer patients following prostatectomy. Cancer Biology and Medicine, 2019, 16, 157.	1.4	12
558	PTEN loss in prostatic adenocarcinoma correlates with specific adverse histologic features (intraductal carcinoma, cribriform Gleason pattern 4 and stromogenic carcinoma). Prostate, 2019, 79, 1267-1273.	1.2	34
559	Syntaphilin Is a Novel Biphasic Biomarker of Aggressive Prostate Cancer and a Metastasis Predictor. American Journal of Pathology, 2019, 189, 1180-1189.	1.9	4
560	Grading (and Classification) Systems Quick Reference: Solid Tumors. , 2019, , 93-111.		0
561	Multiparametric MRI prior to radical prostatectomy identifies intraductal and cribriform growth patterns in prostate cancer. BJU International, 2019, 124, 992-998.	1.3	25
562	TMPRSS2–ERG fusions linked to prostate cancer racial health disparities: A focus on Africa. Prostate, 2019, 79, 1191-1196.	1.2	28
563	Lymph Nodes Invasion of Marcille's Fossa Associates with High Metastatic Load in Prostate Cancer Patients Undergoing Extended Pelvic Lymph Node Dissection: The Role of "Marcillectomy". Urologia Internationalis, 2019, 103, 25-32.	0.6	28
564	Artificial intelligence at the intersection of pathology and radiology in prostate cancer. Diagnostic and Interventional Radiology, 2019, 25, 183-188.	0.7	62
565	Dataset for the reporting of prostate carcinoma in radical prostatectomy specimens: updated recommendations from the International Collaboration on Cancer Reporting. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 475, 263-277.	1.4	19
566	Co‐expression of TLR‐9 and MMP‐13 is associated with the degree of tumour differentiation in prostate cancer. International Journal of Experimental Pathology, 2019, 100, 123-132.	0.6	19

#	ARTICLE	IF	CITATIONS
567	Comparison of preoperative locoregional Ga–68 PSMA–11 PET–CT and mp–MRI results with postoperative histopathology of prostate cancer. Prostate, 2019, 79, 1007-1017.	1.2	32
568	Eukaryotic translation initiation factor 5A2 is highly expressed in prostate cancer and predicts poor prognosis. Experimental and Therapeutic Medicine, 2019, 17, 3741-3747.	0.8	13
569	Emerging Role of Fluciclovine and Other Next Generation PET Imaging Agents in Prostate Cancer Management. Current Radiology Reports, 2019, 7, 1.	0.4	0
570	Influence of African American race on the association between preoperative biopsy grade group and adverse histopathologic features of radical prostatectomy. Cancer, 2019, 125, 3025-3032.	2.0	3
571	Concordance of cribriform architecture in matched prostate cancer biopsy and radical prostatectomy specimens. Histopathology, 2019, 75, 338-345.	1.6	22
572	Impact of Magnetic Resonance Imaging on Prostate Cancer Staging and European Association of Urology Risk Classification. Urology, 2019, 130, 113-119.	0.5	19
573	The percentage of high–grade prostatic adenocarcinoma in prostate biopsies significantly improves on Grade Groups in the prediction of prostate cancer death. Histopathology, 2019, 75, 589-597.	1.6	11
574	A predictive model based on biparametric magnetic resonance imaging and clinical parameters for improved risk assessment and selection of biopsy-naïve men for prostate biopsies. Prostate Cancer and Prostatic Diseases, 2019, 22, 609-616.	2.0	20
575	Development of a glycoproteomic strategy to detect more aggressive prostate cancer using lectin-immunoassays for serum fucosylated PSA. Clinical Proteomics, 2019, 16, 13.	1.1	18
576	Three-dimensional greyscale transrectal ultrasound-guidance and biopsy core preembedding for detection of prostate cancer: Dutch clinical cohort study. BMC Urology, 2019, 19, 23.	0.6	6
577	Clinical Significance of Multiparametric Magnetic Resonance Imaging as a Preoperative Predictor of Oncologic Outcome in Very Low–Risk Prostate Cancer. Journal of Clinical Medicine, 2019, 8, 542.	1.0	3
578	The influence of the presence of intraductal carcinoma of the prostate on the grade group system's prognostic performance. Prostate, 2019, 79, 1065-1070.	1.2	27
579	Diagnostic performance of 68Ga-PSMA PET/CT for identification of aggressive cribriform morphology in prostate cancer with whole-mount sections. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1531-1541.	3.3	25
580	MRI ultrasound fusion biopsy in prostate cancer detection: Are randomized clinical trials reproducible in everyday clinical practice?. Urologia, 2019, 86, 9-16.	0.3	6
581	Anti-metastatic effect of ranolazine in an in vivo rat model of prostate cancer, and expression of voltage-gated sodium channel protein in human prostate. Prostate Cancer and Prostatic Diseases, 2019, 22, 569-579.	2.0	31
582	A five–microRNA model (<i>pCaP</i>) for predicting prostate cancer aggressiveness using cell–free urine. International Journal of Cancer, 2019, 145, 2558-2567.	2.3	36
583	Cell division cycle 20 (CDC20) drives prostate cancer progression via stabilization of Î²-catenin in cancer stem-like cells. EBioMedicine, 2019, 42, 397-407.	2.7	63
584	Intratumoral Sterol-27-Hydroxylase (<i>CYP27A1</i>) Expression in Relation to Cholesterol Synthesis and Vitamin D Signaling and Its Association with Lethal Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1052-1058.	1.1	14

#	ARTICLE	IF	CITATIONS
585	The effect of time from biopsy to radical prostatectomy on adverse pathologic outcomes . Research and Reports in Urology, 2019, Volume 11, 53-60.	0.6	11
586	MRI for prostate cancer: can computed high b-value DWI replace native acquisitions?. European Radiology, 2019, 29, 5197-5204.	2.3	34
587	Characterizing the learning curve of MRI-US fusion prostate biopsies. Prostate Cancer and Prostatic Diseases, 2019, 22, 546-551.	2.0	37
588	Persistent Homology for the Quantitative Evaluation of Architectural Features in Prostate Cancer Histology. Scientific Reports, 2019, 9, 1139.	1.6	47
589	Intraductal carcinoma of the prostate: a critical re-appraisal. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 525-534.	1.4	40
590	A transcriptomic signature of tertiary Gleason 5 predicts worse clinicopathological outcome. BJU International, 2019, 124, 155-162.	1.3	7
591	The role of prostate-specific antigen density in men with low-risk prostate cancer suitable for active surveillance: results of a prospective observational study. Prostate International, 2019, 7, 139-142.	1.2	4
592	Joint Prostate Cancer Detection and Gleason Score Prediction in mp-MRI via FocalNet. IEEE Transactions on Medical Imaging, 2019, 38, 2496-2506.	5.4	133
593	IMPROD biparametric MRI in men with a clinical suspicion of prostate cancer (IMPROD Trial): Sensitivity for prostate cancer detection in correlation with wholeâ€mount prostatectomy sections and implications for focal therapy. Journal of Magnetic Resonance Imaging, 2019, 50, 1641-1650.	1.9	16
595	<i>Ex vivo</i> fluorescence confocal microscopy: the first application for realâ€time pathological examination of prostatic tissue. BJU International, 2019, 124, 469-476.	1.3	59
596	Open-Top Light-Sheet Microscopy Image Atlas of Prostate Core Needle Biopsies. Archives of Pathology and Laboratory Medicine, 2019, 143, 1069-1075.	1.2	44
597	The updated points of TNM classification of urological cancers in the 8th edition of AJCC and UICC. Japanese Journal of Clinical Oncology, 2019, 49, 421-425.	0.6	13
598	The Association of Invasive Cribriform Lesions With Adverse Prostatic Adenocarcinoma Outcomes: An Institutional Experience, Systematic Review, and Meta-analysis. Archives of Pathology and Laboratory Medicine, 2019, 143, 1012-1021.	1.2	4
599	Moving Beyond Gleason Scoring. Archives of Pathology and Laboratory Medicine, 2019, 143, 565-570.	1.2	14
600	Essential Updates in Grading, Morphotyping, Reporting, and Staging of Prostate Carcinoma for General Surgical Pathologists. Archives of Pathology and Laboratory Medicine, 2019, 143, 550-564.	1.2	15
601	Headâ€toâ€head comparison between multiparametric MRI, the partin tables, memorial sloan kettering cancer center nomogram, and CAPRA score in predicting extraprostatic cancer in patients undergoing radical prostatectomy. Journal of Magnetic Resonance Imaging, 2019, 50, 1604-1613.	1.9	21
602	Three-dimensional Elastic Augmented-reality Robot-assisted Radical Prostatectomy Using Hyperaccuracy Three-dimensional Reconstruction Technology: A Step Further in the Identification of Capsular Involvement. European Urology, 2019, 76, 505-514.	0.9	82
603	Diagnostic Accuracy of a MR Protocol Acquired with and without Endorectal Coil for Detection of Prostate Cancer: A Multicenter Study. Current Urology, 2019, 12, 88-96.	0.4	15

#	ARTICLE	IF	CITATIONS
604	Predictive Factors and Oncologic Outcome of Downgrade to Pathologic Gleason Score 6â€"7 after Radical Prostatectomy in Patients with Biopsy Gleason Score 8â€"10. Journal of Clinical Medicine, 2019, 8, 438.	1.0	6
605	Estimation of Relative and Absolute Risks in a Competing-Risks Setting Using a Nested Case-Control Study Design: Example From the ProMort Study. American Journal of Epidemiology, 2019, 188, 1165-1173.	1.6	4
606	Ki-67 is an independent predictor of prostate cancer death in routine needle biopsy samples: proving utility for routine assessments. Modern Pathology, 2019, 32, 1303-1309.	2.9	25
607	The Utility of Prostate Specific Antigen Density, Prostate Health Index, and Prostate Health Index Density in Predicting Positive Prostate Biopsy Outcome is Dependent on the Prostate Biopsy Methods. Urology, 2019, 129, 153-159.	0.5	18
608	Can SUVmax values of Ga-68-PSMA PET/CT scan predict the clinically significant prostate cancer?. Nuclear Medicine Communications, 2019, 40, 86-91.	0.5	83
609	VERDICT MRI for Prostate Cancer: Intracellular Volume Fraction versus Apparent Diffusion Coefficient. Radiology, 2019, 291, 391-397.	3.6	52
610	Interrelationship Between Health Insurance Status and Prostate Cancer Grade Can Have Critical Impact on Prostate Cancer Disease Control: A Retrospective Cohort Study. Cancer Control, 2019, 26, 107327481983718.	0.7	4
611	Prostate cancer with comedonecrosis is frequently, but not exclusively, intraductal carcinoma: a need for reappraisal of grading criteria. Histopathology, 2019, 74, 1081-1087.	1.6	24
613	False positives in PIRADS (V2) 3, 4, and 5 lesions: relationship with reader experience and zonal location. Abdominal Radiology, 2019, 44, 1044-1051.	1.0	25
614	Analysis of PI-RADS 4 cases: Management recommendations for negatively biopsied patients. European Journal of Radiology, 2019, 113, 1-6.	1.2	11
615	Three-dimensional analysis reveals two major architectural subgroups of prostate cancer growth patterns. Modern Pathology, 2019, 32, 1032-1041.	2.9	30
616	Editorial comment on Evolution, controversies and the future of prostate cancer grading. Pathology International, 2019, 69, 67-67.	0.6	0
617	Physiologic serum 1,25 dihydroxyvitamin D is inversely associated with prostatic Ki67 staining in a diverse sample of radical prostatectomy patients. Cancer Causes and Control, 2019, 30, 207-214.	0.8	6
618	MpMRI of the prostate: is there a role for semi-quantitative analysis of DCE-MRI and late gadolinium enhancement in the characterisation of prostate cancer?. Clinical Radiology, 2019, 74, 259-267.	0.5	7
619	Evolution, controversies and the future of prostate cancer grading. Pathology International, 2019, 69, 55-66.	0.6	6
620	Prediction of extraprostatic extension by MRI tumor contact length: difference between anterior and posterior prostate cancer. Prostate Cancer and Prostatic Diseases, 2019, 22, 539-545.	2.0	17
622	Molecular Characterization of Prostate Cancer with Associated Gleason Score Using Mass Spectrometry Imaging. Molecular Cancer Research, 2019, 17, 1155-1165.	1.5	50
623	â™‚â™€ Prostate and Breast Pathology: Similarities and Differences. , 2019, , 155-170.		1

#	Article	IF	Citations
625	CTHRC1 and PD–1/PD–L1 expression predicts tumor recurrence in prostate cancer. Molecular Medicine Reports, 2019, 20, 4244-4252.	1.1	11
627	Positive STAT5 Protein and Locus Amplification Status Predicts Recurrence after Radical Prostatectomy to Assist Clinical Precision Management of Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1642-1651.	1.1	13
628	HoxB13 expression in ductal type adenocarcinoma of prostate: clinicopathologic characteristics and its utility as potential diagnostic marker. Scientific Reports, 2019, 9, 20205.	1.6	9
629	Estudio de concordancia entre los resultados de la puntuación de Gleason de biopsias de próstata y los de la prostatectomía radical en pacientes con cáncer de próstata localizado. Revista Facultad De Medicina, 2019, 67, 209-214.	0.0	0
630	Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. The Cochrane Library, 2019, 2019, CD012663.	1.5	234
631	Understanding the gleason grading system and its changes. Journal of Pathology of Nepal, 2019, 9, 1580-1585.	0.0	0
632	Magnetic Resonance Imaging–guided In-bore and Magnetic Resonance Imaging-transrectal Ultrasound Fusion Targeted Prostate Biopsies: An Adjusted Comparison of Clinically Significant Prostate Cancer Detection Rate. European Urology Oncology, 2019, 2, 397-404.	2.6	42
633	Prebiopsy Biparametric Magnetic Resonance Imaging Combined with Prostate-specific Antigen Density in Detecting and Ruling out Gleason 7–10 Prostate Cancer in Biopsy-naïve Men. European Urology Oncology, 2019, 2, 311-319.	2.6	74
634	Outcomes of pathologically localized high-grade prostate cancer treated with radical prostatectomy. Medicine (United States), 2019, 98, e17627.	0.4	5
635	Automated Gleason Scoring and Tumor Quantification in Prostate Core Needle Biopsy Images Using Deep Neural Networks and Its Comparison with Pathologist-Based Assessment. Cancers, 2019, 11, 1860.	1.7	32
636	A comparative effectiveness analysis of the PBCG vs. PCPT risks calculators in a multi-ethnic cohort. BMC Urology, 2019, 19, 121.	0.6	16
637	Tumors of the Male Reproductive System. , 2019, , 626-644.		0
638	Evolution of prostate cancer histopathology. Current Opinion in Urology, 2019, 29, 587-592.	0.9	0
639	Risk stratification and avoiding overtreatment in localized prostate cancer. Current Opinion in Urology, 2019, 29, 612-619.	0.9	9
640	4D perfusion CT of prostate cancer for image-guided radiotherapy planning: A proof of concept study. PLoS ONE, 2019, 14, e0225673.	1.1	3
641	Automated acquisition of explainable knowledge from unannotated histopathology images. Nature Communications, 2019, 10, 5642.	5.8	92
642	The value of transperineal apical prostate biopsy in predicting urethral/apical margin status after radical prostatectomy. Medicine (United States), 2019, 98, e17633.	0.4	2
643	Cases Having a Gleason Score 3+4=7 With <5% of Gleason Pattern 4 in Prostate Needle Biopsy Show Similar Failure-free Survival and Adverse Pathology Prevalence to Gleason Score 6 Cases in a Radical Prostatectomy Cohort. American Journal of Surgical Pathology, 2019, 43, 1560-1565.	2.1	19

#	ARTICLE	IF	CITATIONS
644	Impact of the 2014 International Society of Urological Pathology Grading System on Concept of High-Risk Prostate Cancer: Comparison of Long-Term Oncological Outcomes in Patients Undergoing Radical Prostatectomy. Frontiers in Oncology, 2019, 9, 1272.	1.3	9
645	Significance of Time Until PSA Recurrence After Radical Prostatectomy Without Neo- or Adjuvant Treatment to Clinical Progression and Cancer-Related Death in High-Risk Prostate Cancer Patients. Frontiers in Oncology, 2019, 9, 1286.	1.3	19
646	mRNA expressions of androgen receptor and its variants in matched hormone-sensitive and castration-resistant prostate cancer. Scandinavian Journal of Urology, 2019, 53, 365-371.	0.6	5
647	A prospective randomized trial of povidone-iodine suppository before transrectal ultrasonography-guided prostate biopsy. Medicine (United States), 2019, 98, e14854.	0.4	7
648	High Lipoprotein(a) Level Is Independently Associated with Adverse Clinicopathological Features in Patients with Prostate Cancer. Disease Markers, 2019, 2019, 1-7.	0.6	15
649	Prevalence of DNA repair gene mutations in localized prostate cancer according to clinical and pathologic features: association of Gleason score and tumor stage. Prostate Cancer and Prostatic Diseases, 2019, 22, 59-65.	2.0	67
650	Concordance of biopsy and prostatectomy diagnosis of intraductal and cribriform carcinoma in a prospectively collected data set. Histopathology, 2019, 74, 474-482.	1.6	44
651	Sertad1 promotes prostate cancer progression through binding androgen receptor ligand binding domain. International Journal of Cancer, 2019, 144, 558-568.	2.3	3
652	Improved specificity with 68Ga PSMA PET/CT to detect clinically significant lesions â€œinvisibleâ€•on multiparametric MRI of the prostate: a single institution comparative analysis with radical prostatectomy histology. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 20-30.	3.3	79
653	Interreader agreement of PIâ€RADS v. 2 in assessing prostate cancer with multiparametric MRI: A study using wholeâ€mount histology as the standard of reference. Journal of Magnetic Resonance Imaging, 2019, 49, 546-555.	1.9	56
654	Early and late toxicity profiles of patients receiving immediate postoperative radiotherapy versus salvage radiotherapy for prostate cancer after prostatectomy. Strahlentherapie Und Onkologie, 2019, 195, 131-144.	1.0	4
655	Integrating tertiary Gleason pattern 5 into the ISUP grading system improves prediction of biochemical recurrence in radical prostatectomy patients. Modern Pathology, 2019, 32, 122-127.	2.9	16
656	Impact of Multifocality and Multilocation of Positive Surgical Margin After Radical Prostatectomy on Predicting Oncological Outcome. Clinical Genitourinary Cancer, 2019, 17, e44-e52.	0.9	7
657	Simplified Luminal Water Imaging for the Detection of Prostate Cancer From Multiecho T_2 MR Images. Journal of Magnetic Resonance Imaging, 2019, 50, 910-917.	1.9	16
658	The value of MR textural analysis in prostate cancer. Clinical Radiology, 2019, 74, 876-885.	0.5	27
659	Reducing unnecessary biopsies while detecting clinically significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 138-144.	0.8	29
660	Longâ€term outcomes of combining prostate brachytherapy and metastasisâ€directed radiotherapy in newly diagnosed oligometastatic prostate cancer: A retrospective cohort study. Prostate, 2019, 79, 506-514.	1.2	25
661	Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial. Lancet Oncology, The, 2019, 20, 267-281.	5.1	84

#	ARTICLE	IF	CITATIONS
662	Performance of Diffusion Kurtosis Imaging Versus Diffusion Tensor Imaging in Discriminating Between Benign Tissue, Low and High Gleason Grade Prostate Cancer. Academic Radiology, 2019, 26, 1328-1337.	1.3	12
663	Multidimensional analysis of clinicopathological characteristics of false-negative clinically significant prostate cancers on multiparametric MRI of the prostate in Japanese men. Japanese Journal of Radiology, 2019, 37, 154-164.	1.0	7
664	Prostate Cancer Genomic Classifier Relates More Strongly to Gleason Grade Group Than Prostate Imaging Reporting and Data System Score in Multiparametric Prostate Magnetic Resonance Imaging-ultrasound Fusion Targeted Biopsies. Urology, 2019, 125, 64-72.	0.5	11
665	Defining clinically significant prostate cancer on the basis of pathological findings. Histopathology, 2019, 74, 135-145.	1.6	114
666	Grading of prostate cancer: a work in progress. Histopathology, 2019, 74, 146-160.	1.6	47
667	Optimization of prostate cancer cell detection using multiplex tyramide signal amplification. Journal of Cellular Biochemistry, 2019, 120, 4804-4812.	1.2	14
669	Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naÃ¯ve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study. European Urology, 2019, 75, 570-578.	0.9	521
670	Ductal Carcinoma of the Prostate: An Uncommon Entity With Atypical Behaviour. Clinical Oncology, 2019, 31, 108-114.	0.6	18
671	Active surveillance for prostate and thyroid cancers: evolution in clinical paradigms and lessons learned. Nature Reviews Clinical Oncology, 2019, 16, 168-184.	12.5	41
672	Optimal sampling scheme in men with abnormal multiparametric MRI undergoing MRI-TRUS fusion prostate biopsy. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 57-62.	0.8	24
673	Optimizing Time to Treatment to Achieve Durable Biochemical Disease Control after Surgery in Prostate Cancer: A Multi-Institutional Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 570-577.	1.1	9
674	Dataset for the reporting of prostate carcinoma in core needle biopsy and transurethral resection and enucleation specimens: recommendations from the International Collaboration on Cancer Reporting (ICCR). Pathology, 2019, 51, 11-20.	0.3	19
675	Evaluation of Prostate Cancer Stage Groups Updated in the 8th Edition of the American Joint Committee on Cancer Tumorâ€"Nodeâ€"Metastasis Staging Manual. Clinical Genitourinary Cancer, 2019, 17, e221-e226.	0.9	9
676	A blueprint for cancer screening and early detection: Advancing screeningâ€™s contribution to cancer control. Ca-A Cancer Journal for Clinicians, 2019, 69, 50-79.	157.7	84
677	Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncology, The, 2019, 20, 100-109.	5.1	701
678	A multicentric study on accurate grading of prostate cancer with systematic and MRI/US fusion targeted biopsies: comparison with final histopathology after radical prostatectomy. World Journal of Urology, 2019, 37, 2109-2117.	1.2	56
679	The added value of systematic biopsy in men with suspicion of prostate cancer undergoing multiparametric MRI-targeted biopsy. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 298.e1-298.e9.	0.8	26
680	Approaches to urinary detection of prostate cancer. Prostate Cancer and Prostatic Diseases, 2019, 22, 362-381.	2.0	52

#	ARTICLE	IF	CITATIONS
681	Dietary Zinc and Risk of Prostate Cancer in Spain: MCC-Spain Study. Nutrients, 2019, 11, 18.	1.7	13
682	Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate. Molecular Cancer Research, 2019, 17, 446-456.	1.5	44
683	Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9–10 Prostate Cancer. European Urology, 2019, 75, 35-41.	0.9	18
684	Large cribriform growth pattern identifies ISUP grade 2 prostate cancer at high risk for recurrence and metastasis. Modern Pathology, 2019, 32, 139-146.	2.9	71
685	Prospective Inclusion of Apparent Diffusion Coefficients in Multiparametric Prostate MRI Structured Reports: Discrimination of Clinically Insignificant and Significant Cancers. American Journal of Roentgenology, 2019, 212, 109-116.	1.0	24
686	Sex steroids in serum and prostatic tissue of human cancerous prostate (STERKPROSER trial). Prostate, 2019, 79, 272-280.	1.2	9
687	Prostate cancer heterogeneity: texture analysis score based on multiple magnetic resonance imaging sequences for detection, stratification and selection of lesions at time of biopsy. BJU International, 2019, 124, 76-86.	1.3	18
688	Mortality after radical prostatectomy in a matched contemporary cohort in Sweden compared to the Scandinavian Prostate Cancer Group 4 (<scp>SPCG</scp>–4) study. BJU International, 2019, 123, 421-428.	1.3	14
689	Genomic Evaluation of Multiparametric Magnetic Resonance Imaging-visible and -nonvisible Lesions in Clinically Localised Prostate Cancer. European Urology Oncology, 2019, 2, 1-11.	2.6	27
690	Prognostic value of unifocal and multifocal positive surgical margins in a large series of robot-assisted radical prostatectomy for prostate cancer. World Journal of Urology, 2019, 37, 1837-1844.	1.2	16
691	Inflammatory Bowel Disease and the Risk of Prostate Cancer. European Urology, 2019, 75, 846-852.	0.9	47
692	Guideline-Based Physical Activity and Survival Among US Men With Nonmetastatic Prostate Cancer. American Journal of Epidemiology, 2019, 188, 579-586.	1.6	16
693	MRI-guided in-bore biopsy for prostate cancer: what does the evidence say? A case series of 554 patients and a review of the current literature. World Journal of Urology, 2019, 37, 1263-1279.	1.2	25
694	A Prospective Accuracy Study of Prostate Imaging Reporting and Data System Version 2 on Multiparametric Magnetic Resonance Imaging in Detecting Clinically Significant Prostate Cancer With Whole-mount Pathology. Urology, 2019, 123, 191-197.	0.5	10
695	34BetaE12 and Alfa-Methylacyl Coenzyme A Racemase (AMACR) Antibodies Better Than p63 Antibody Distinguish Normal and Neoplastic Glands in Prostatic Tissue With Thermal Artifacts. Applied Immunohistochemistry and Molecular Morphology, 2019, 27, 306-310.	0.6	3
696	Prostate Cancer Patients' Understanding of the Gleason Scoring System: Implications for Shared Decision-Making. Journal of Cancer Education, 2019, 34, 441-445.	0.6	12
697	A Multi-Institutional Validation of Gleason Score Derived from Tissue Microarray Cores. Pathology and Oncology Research, 2019, 25, 979-986.	0.9	4
698	Integrative Genomic Analysis of Coincident Cancer Foci Implicates CTNNB1 and PTEN Alterations in Ductal Prostate Cancer. European Urology Focus, 2019, 5, 433-442.	1.6	27

#	ARTICLE	IF	CITATIONS
699	Procalcitonin as an early indicator of urosepsis following prostate biopsy. Aging Male, 2020, 23, 431-436.	0.9	4
700	Atlas of Ex Vivo Prostate Tissue and Cancer Images Using Confocal Laser Endomicroscopy: A Project for Intraoperative Positive Surgical Margin Detection During Radical Prostatectomy. European Urology Focus, 2020, 6, 941-958.	1.6	9
701	Improved detection and reduced biopsies: the effect of a multiparametric magnetic resonance imaging-based triage prostate cancer pathway in a public teaching hospital. World Journal of Urology, 2020, 38, 371-379.	1.2	23
702	Prostate volume index and prostatic chronic inflammation predicted low tumor load in 945 patients at baseline prostate biopsy. World Journal of Urology, 2020, 38, 957-964.	1.2	11
703	One-Stop MRI and MRI/transrectal ultrasound fusion-guided biopsy: an expedited pathway for prostate cancer diagnosis. World Journal of Urology, 2020, 38, 949-956.	1.2	14
704	Effects of the addition of quantitative apparent diffusion coefficient data on the diagnostic performance of the PI-RADS v2 scoring system to detect clinically significant prostate cancer. World Journal of Urology, 2020, 38, 981-991.	1.2	10
705	Tumor characteristics, oncological and functional outcomes after radical prostatectomy in very young menâ‰â‰â‰Â45Âyears of age. World Journal of Urology, 2020, 38, 95-101.	1.2	8
706	Risk factors of positive surgical margins after robot-assisted radical prostatectomy in high-volume center: results in 732 cases. Journal of Robotic Surgery, 2020, 14, 167-175.	1.0	20
707	Predictive factors of prostate cancer diagnosis with PSA 4.0â€"10.0Âng/ml in a multi-ethnic Asian population, Malaysia. Asian Journal of Surgery, 2020, 43, 87-94.	0.2	4
708	TGF-Î²/PI3K/AKT/mTOR/NF-ƙB pathway. Clinicopathological features in prostate cancer. Aging Male, 2020, 23, 801-811.	0.9	42
709	Analysis of Diffusion-weighted MR Images Based on a Gamma Distribution Model to Differentiate Prostate Cancers with Different Gleason Score. Magnetic Resonance in Medical Sciences, 2020, 19, 40-47.	1.1	4
710	Homeostasis: apoptosis and cell cycle in normal and pathological prostate. Aging Male, 2020, 23, 335-345.	0.9	11
711	Development and Validation of a Lookup Table for the Prediction of Metastatic Prostate Cancer According to Prostatic-specific Antigen Value, Clinical Tumor Stage, and Gleason Grade Groups. European Urology Oncology, 2020, 3, 631-639.	2.6	4
712	Practice Patterns in Reporting Tertiary Grades at Radical Prostatectomy: Survey of a Large Group of Experienced Urologic Pathologists. Archives of Pathology and Laboratory Medicine, 2020, 144, 356-360.	1.2	1
713	Deep Learning-Based Gleason Grading of Prostate Cancer From Histopathology Imagesâ€"Role of Multiscale Decision Aggregation and Data Augmentation. IEEE Journal of Biomedical and Health Informatics, 2020, 24, 1413-1426.	3.9	89
714	Prostate cancer pathology: What has changed in the last 5 years. Urologia, 2020, 87, 3-10.	0.3	6
715	Postoperative biochemical recurrence of pathologically localized high-grade prostate cancer in adjuvant treatment-naÃ¯ve patients. Journal of Cancer Research and Clinical Oncology, 2020, 146, 221-227.	1.2	1
716	Combined clinical characteristics and multiparametric MRI parameters for prediction of cribriform morphology in intermediate-risk prostate cancer patients. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 216-224.	0.8	10

#	Article	IF	Citations
717	Value of Dynamic Contrast-Enhanced (DCE) MR Imaging in Peripheral Lesions in PI-RADS-4 Patients. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2020, 192, 441-447.	0.7	19
718	Methylation Markers in Prostate Biopsies Are Prognosticators for Late Biochemical Recurrence and Therapy after Surgery in Prostate Cancer Patients. Journal of Molecular Diagnostics, 2020, 22, 30-39.	1.2	3
719	Differentiation of prostate cancer and benign prostatic hyperplasia: comparisons of the histogram analysis of intravoxel incoherent motion and monoexponential model with in-bore MR-guided biopsy as pathological reference. Abdominal Radiology, 2020, 45, 3265-3277.	1.0	11
720	Preoperative PI-RADS Version 2 scores helps improve accuracy of clinical nomograms for predicting pelvic lymph node metastasis at radical prostatectomy. Prostate Cancer and Prostatic Diseases, 2020, 23, 116-126.	2.0	13
721	Neoplasms of the Prostate. , 2020, , 415-525.e42.		3
723	PI-RADS Version 2 Is an Excellent Screening Tool for Clinically Significant Prostate Cancer as Designated by the Validated International Society of Urological Pathology Criteria: A Retrospective Analysis. Current Problems in Diagnostic Radiology, 2020, 49, 407-411.	0.6	5
724	Optimising the number of cores for <scp>magnetic resonance imaging</scp>â€guided targeted and systematic transperineal prostate biopsy. BJU International, 2020, 125, 260-269.	1.3	60
725	Prostate Magnetic Resonance Imaging, with or Without Magnetic Resonance Imaging-targeted Biopsy, and Systematic Biopsy for Detecting Prostate Cancer: A Cochrane Systematic Review and Meta-analysis. European Urology, 2020, 77, 78-94.	0.9	224
726	Focused Submission of Tissue for Radical Prostatectomy Following Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion-Targeted Biopsy. International Journal of Surgical Pathology, 2020, 28, 44-50.	0.4	1
727	68Ga-PSMA-11 PET has the potential to improve patient selection for extended pelvic lymph node dissection in intermediate to high-risk prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 147-159.	3.3	43
728	Regulation of PDE 5 expression in normal prostate, benign prostatic hyperplasia, and adenocarcinoma. Andrology, 2020, 8, 427-433.	1.9	5
729	Combining prostate health index and multiparametric magnetic resonance imaging in the diagnosis of clinically significant prostate cancer in an Asian population. World Journal of Urology, 2020, 38, 1207-1214.	1.2	37
730	Improved Prostate Cancer Biopsy Grading by Incorporation of Invasive Cribriform and Intraductal Carcinoma in the 2014 Grade Groups. European Urology, 2020, 77, 191-198.	0.9	57
731	Is There Enough Support for a New Prostate Grading System Factoring in Intraductal Carcinoma and Cribriform Cancer?. European Urology, 2020, 77, 199-200.	0.9	4
732	Radiomics in prostate cancer: basic concepts and current state-of-the-art. Chinese Journal of Academic Radiology, 2020, 2, 47-55.	0.4	15
733	Repeatability of radiomics and machine learning for DWI: Shortâ€term repeatability study of 112 patients with prostate cancer. Magnetic Resonance in Medicine, 2020, 83, 2293-2309.	1.9	23
734	Epithelium segmentation and automated Gleason grading of prostate cancer via deep learning in labelâ€free multiphoton microscopic images. Journal of Biophotonics, 2020, 13, e201900203.	1.1	14
735	Prostate magnetic resonance imaging technique. Abdominal Radiology, 2020, 45, 2109-2119.	1.0	2

#	ARTICLE	IF	CITATIONS
736	Oncological outcome of neoadjuvant low-dose estramustine plus LHRH agonist/antagonist followed by extended radical prostatectomy for Japanese patients with high-risk localized prostate cancer: a prospective single-arm study. Japanese Journal of Clinical Oncology, 2020, 50, 66-72.	0.6	5
737	Clinical and pathologic characteristics of familial prostate cancer in Asian population. Prostate, 2020, 80, 57-64.	1.2	5
738	Histopathological Features of MRIâ€‘Invisible Regions of Prostate Cancer Lesions. Journal of Magnetic Resonance Imaging, 2020, 51, 1235-1246.	1.9	24
739	Prediction of biochemical recurrence in prostate cancer patients who underwent prostatectomy using routine clinical prostate multiparametric MRI and decipher genomic score. Journal of Magnetic Resonance Imaging, 2020, 51, 1075-1085.	1.9	24
740	Prostate Cancer Risk Stratification in Men With a Clinical Suspicion of Prostate Cancer Using a Unique Biparametric MRI and Expression of 11 Genes in Apparently Benign Tissue: Evaluation Using Machineâ€‘Learning Techniques. Journal of Magnetic Resonance Imaging, 2020, 51, 1540-1553.	1.9	3
741	Prebiopsy IMPROD Biparametric Magnetic Resonance Imaging Combined with Prostate-Specific Antigen Density in the Diagnosis of Prostate Cancer: An External Validation Study. European Urology Oncology, 2020, 3, 648-656.	2.6	18
742	Survival outcomes of radical prostatectomy vs. external beam radiation therapy in prostate cancer patients with Gleason Score 9-10 at biopsy: A population-based analysis. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 79.e9-79.e14.	0.8	18
743	Comparison of Tumor Volume Parameters on Prostate Cancer Biopsies. Archives of Pathology and Laboratory Medicine, 2020, 144, 991-996.	1.2	1
744	Investigating the equivalent performance of biparametric compared to multiparametric MRI in detection of clinically significant prostate cancer. Abdominal Radiology, 2020, 45, 547-555.	1.0	10
746	Impact of biparametric prebiopsy prostate magnetic resonance imaging on the diagnostics of clinically significant prostate cancer in biopsy naÃ¯ve men. Scandinavian Journal of Urology, 2020, 54, 7-13.	0.6	0
747	Ex vivo fluorescence confocal microscopy: prostatic and periprostatic tissues atlas and evaluation of the learning curve. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 511-520.	1.4	37
748	Linear extent of positive surgical margin impacts biochemical recurrence after robot-assisted radical prostatectomy in a high-volume center. Journal of Robotic Surgery, 2020, 14, 663-675.	1.0	11
749	Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study. Lancet Oncology, The, 2020, 21, 222-232.	5.1	364
750	Automated deep-learning system for Gleason grading of prostate cancer using biopsies: a diagnostic study. Lancet Oncology, The, 2020, 21, 233-241.	5.1	407
751	Gleason score 5â€‘+â€‘3â€‘=â€‘8 (grade group 4) prostate cancerâ€"a rare occurrence with contemporary grading. Human Pathology, 2020, 97, 40-51.	1.1	14
752	Response of intraductal carcinoma of the prostate to androgen deprivation therapy predicts prostate cancer prognosis in radical prostatectomy patients. Prostate, 2020, 80, 284-290.	1.2	18
753	Automated approach for estimation of grade groups for prostate cancer based on histological image feature analysis. Prostate, 2020, 80, 291-302.	1.2	6
754	Overall, specific, and metastasisâ€‘free survival of Afroâ€‘Caribbean men with pathological Gleason 6 prostate cancer. Prostate, 2020, 80, 329-335.	1.2	0

#	ARTICLE	IF	CITATIONS
755	Prostate Carcinoma Grade and Length But Not Cribriform Architecture at Positive Surgical Margins Are Predictive for Biochemical Recurrence After Radical Prostatectomy. American Journal of Surgical Pathology, 2020, 44, 191-197.	2.1	20
756	False-Negative Histopathologic Diagnosis of Prostatic Adenocarcinoma. Archives of Pathology and Laboratory Medicine, 2020, 144, 326-334.	1.2	14
757	Prostatic Ductal Adenocarcinoma Controlled for Cancer Grade and Tumor Volume Does Not Have an Independent Effect on Adverse Radical Prostatectomy Outcomes Compared to Usual Acinar Prostatic Adenocarcinoma. Urology, 2020, 137, 108-114.	0.5	11
758	Redefining the Concept of Clinically Insignificant Prostate Cancer. Urology, 2020, 136, 176-179.	0.5	8
759	External validation of Cormio nomogram for predicting all prostate cancers and clinically significant prostate cancers. World Journal of Urology, 2020, 38, 2555-2561.	1.2	5
760	Ten-Year Results From a Phase II Study on Image Guided, Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost in High-Risk Prostate Cancer. Advances in Radiation Oncology, 2020, 5, 396-403.	0.6	11
761	Prostate cancer assessment using MR elastography of fresh prostatectomy specimens at 9.4 T. Magnetic Resonance in Medicine, 2020, 84, 396-404.	1.9	13
762	Determining the cut-off values of tumor diameter, degree of extraprostatic extension, and extent of surgical margin positivity with regard to biochemical recurrence of prostate cancer after radical prostatectomy. Annals of Diagnostic Pathology, 2020, 44, 151431.	0.6	8
763	Impact of peri-prostatic fat measurements using MRI on the prediction of prostate cancer with transrectal ultrasound-guided biopsy. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 37.e1-37.e9.	0.8	4
764	Why the UK Should Consider Gene Expression Testing in Prostate Cancer. Clinical Oncology, 2020, 32, 149-155.	0.6	1
765	Propensity score–matched comparison of docetaxel and androgen receptor axis–targeted agents in patients with castration–resistant intraductal carcinoma of the prostate. BJU International, 2020, 125, 702-708.	1.3	16
766	Role of Lipoproteins in the Microenvironment of Hormone-Dependent Cancers. Trends in Endocrinology and Metabolism, 2020, 31, 256-268.	3.1	15
767	Prostate MRI with PI-RADS v2.1: initial detection and active surveillance. Abdominal Radiology, 2020, 45, 2133-2142.	1.0	6
768	Determination of Gleason score discrepancy for risk stratification in magnetic resonance-ultrasound fusion prostate biopsy. Acta Radiologica, 2020, 61, 1134-1142.	0.5	2
769	Financial toxicity associated with treatment of localized prostate cancer. Nature Reviews Urology, 2020, 17, 28-40.	1.9	44
770	Relative Contribution of Sampling and Grading to the Quality of Prostate Biopsy: Results from a Single High-volume Institution. European Urology Oncology, 2020, 3, 474-480.	2.6	15
771	Qualitative and Quantitative Reporting of a Unique Biparametric MRI: Towards Biparametric MRI–Based Nomograms for Prediction of Prostate Biopsy Outcome in Men With a Clinical Suspicion of Prostate Cancer (IMPROD and MULTI–IMPROD Trials). Journal of Magnetic Resonance Imaging, 2020, 51, 1556-1567.	1.9	22
772	Stratification of Atypical Intraepithelial Prostatic Lesions Based on Basal Cell and Architectural Patterns. American Journal of Clinical Pathology, 2020, 153, 407-416.	0.4	6

#	ARTICLE	IF	CITATIONS
774	Prognostic significance of the presence of intraductal carcinoma of the prostate and bone metastasis in needle biopsy for prostate carcinoma patients with Grade Group 5. Pathology Research and Practice, 2020, 216, 152693.	1.0	2
775	How Many Cores Should be Obtained During Saturation Biopsy in the Era of Multiparametric Magnetic Resonance? Experience in 875 Patients Submitted to Repeat Prostate Biopsy. Urology, 2020, 137, 133-137.	0.5	24
776	MRI-targeted biopsy for detecting prostate cancer: have the guidelines changed our practices and our prostate cancer detection rate?. International Urology and Nephrology, 2020, 52, 611-618.	0.6	9
777	Diagnostic Value of ^{68}Ga-PSMA PET/CT for Detection of Phosphatase and Tensin Homolog Expression in Prostate Cancer: A Pilot Study. Journal of Nuclear Medicine, 2020, 61, 873-880.	2.8	8
778	Reporting Practices and Resource Utilization in the Era of Intraductal Carcinoma of the Prostate. American Journal of Surgical Pathology, 2020, 44, 673-680.	2.1	31
779	Age dependence of modern clinical risk groups for localized prostate cancer—A population-based study. Cancer, 2020, 126, 1691-1699.	2.0	25
780	Combination of total length of Gleason pattern 4 and number of Gleason score 3 + 4 = 7 cores detects similar outcome group to Gleason score 6 cancers among cases with ≥5% of Gleason pattern 4. Pathology International, 2020, 70, 992-998.	0.6	2
781	Dual-Time Point [68Ga]Ga-PSMA-11 PET/CT Hybrid Imaging for Staging and Restaging of Prostate Cancer. Cancers, 2020, 12, 2788.	1.7	27
782	Understanding the diagnosis of prostate cancer. Medical Journal of Australia, 2020, 213, 424-429.	0.8	4
784	Improving prostate cancer classification in H&E tissue micro arrays using Ki67 and P63 histopathology. Computers in Biology and Medicine, 2020, 127, 104053.	3.9	2
785	Association between PSA density and pathologically significant prostate cancer: The impact of prostate volume. Prostate, 2020, 80, 1444-1449.	1.2	40
786	Comparison of diagnostic performance between diffusion kurtosis imaging parameters and mono-exponential ADC for determination of clinically significant cancer in patients with prostate cancer. Abdominal Radiology, 2020, 45, 4235-4243.	1.0	9
787	The Role of AMACR, CD10, TMPRSS2-ERG, and p27 Protein Expression Among Different Gleason Grades of Prostatic Adenocarcinoma on Needle Biopsy. Clinical Medicine Insights: Oncology, 2020, 14, 117955492094732.	0.6	5
788	Impact of the MyProstateScore (MPS) Test on the Clinical Decision to Undergo Prostate Biopsy: Results From a Contemporary Academic Practice. Urology, 2020, 145, 204-210.	0.5	3
789	Prostate cancer with cribriform pattern: Exclusion criterion for active surveillance?. Archivio Italiano Di Urologia Andrologia, 2020, 92, .	0.4	3
790	The Impact of HMGB1 Polymorphisms on Prostate Cancer Progression and Clinicopathological Characteristics. International Journal of Environmental Research and Public Health, 2020, 17, 7247.	1.2	8
791	Combined multiple clinical characteristics for prediction of discordance in grade and stage in prostate cancer patients undergoing systematic biopsy and radical prostatectomy. Pathology Research and Practice, 2020, 216, 153235.	1.0	2
792	Utility of a Fifth-Generation Ultrasensitive Prostate-Specific Antigen Assay for Monitoring Prostate Cancer Patients after Radical Prostatectomy with 3 Years of Follow-Up. Clinical Chemistry, 2020, 66, 1329-1338.	1.5	3

#	ARTICLE	IF	CITATIONS
793	A Narrative Overview of Active Surveillance for Clinically Localised Prostate Cancer. Seminars in Oncology Nursing, 2020, 36, 151045.	0.7	3
794	Re: Variability of the Positive Predictive Value of PI-RADS for Prostate MRI Across 26 Centers: Experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel. European Urology, 2020, 78, 633-636.	0.9	9
795	The Importance of Tumor Length in Needle Biopsies of the Prostate. American Journal of Clinical Pathology, 2020, 154, 533-535.	0.4	6
796	The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma. American Journal of Surgical Pathology, 2020, 44, e87-e99.	2.1	292
797	The value of a first MRI and targeted biopsies after several years of active surveillance for low-risk prostate cancer â€" results from the SAMS trial. Scandinavian Journal of Urology, 2020, 54, 318-322.	0.6	2
798	Evolution of Targeted Prostate Biopsy by Adding Micro-Ultrasound to the Magnetic Resonance Imaging Pathway. European Urology Focus, 2021, 7, 1292-1299.	1.6	30
799	Use of 29-MHz Micro-ultrasound for Local Staging of Prostate Cancer in Patients Scheduled for Radical Prostatectomy: A Feasibility Study. European Urology Open Science, 2020, 19, 20-23.	0.2	11
800	Multiparametric magnetic resonance imaging and clinical variables: Which is the best combination to predict reclassification in active surveillance patients?. Prostate International, 2020, 8, 167-172.	1.2	6
801	Stereotactic body radiotherapy for localized prostate cancer â€" 5-year efficacy results. Radiation Oncology, 2020, 15, 173.	1.2	14
802	Quantification of perineural invasion focus after radical prostatectomy could improve predictive power of recurrence. Human Pathology, 2020, 104, 96-104.	1.1	11
803	Comparison of machine learning algorithms to predict clinically significant prostate cancer of the peripheral zone with multiparametric MRI using clinical assessment categories and radiomic features. European Radiology, 2020, 30, 6757-6769.	2.3	33
804	Circulating preoperative testosterone level predicts unfavourable disease at radical prostatectomy in men with International Society of Urological Pathology Grade Group 1 prostate cancer diagnosed with systematic biopsies. World Journal of Urology, 2020, 39, 1861-1867.	1.2	14
805	Prostate cancer growth patterns beyond the Gleason score: entering a new era of comprehensive tumour grading. Histopathology, 2020, 77, 850-861.	1.6	24
806	Prospective assessment of two-gene urinary test with multiparametric magnetic resonance imaging of the prostate for men undergoing primary prostate biopsy. World Journal of Urology, 2021, 39, 1869-1877.	1.2	27
807	Prediction of prostate cancer aggressiveness using 18F-Fluciclovine (FACBC) PET and multisequence multiparametric MRI. Scientific Reports, 2020, 10, 9407.	1.6	3
808	Downstream Neighbor of SON (DONSON) Expression Is Enhanced in Phenotypically Aggressive Prostate Cancers. Cancers, 2020, 12, 3439.	1.7	7
809	Impact of Matrix Metalloproteinase-11 Gene Polymorphisms on Biochemical Recurrence and Clinicopathological Characteristics of Prostate Cancer. International Journal of Environmental Research and Public Health, 2020, 17, 8603.	1.2	7
810	The Genetic Complexity of Prostate Cancer. Genes, 2020, 11, 1396.	1.0	9

#	ARTICLE	IF	CITATIONS
811	Evaluation of the Use of Combined Artificial Intelligence and Pathologist Assessment to Review and Grade Prostate Biopsies. JAMA Network Open, 2020, 3, e2023267.	2.8	56
812	Prediction of clinically significant prostate cancer after negative prostate biopsy: The current value of microscopic findings. Urologic Oncology: Seminars and Original Investigations, 2020, 39, 432.e11-432.e19.	0.8	0
813	Multicenter Multireader Evaluation of an Artificial Intelligenceâ€"Based Attention Mapping System for the Detection of Prostate Cancer With Multiparametric MRI. American Journal of Roentgenology, 2020, 215, 903-912.	1.0	29
814	Effect of core needle biopsy number on intraductal carcinoma of the prostate (IDC-P) diagnosis in patients with metastatic hormone-sensitive prostate cancer. International Journal of Clinical Oncology, 2020, 25, 2130-2137.	1.0	2
815	Turbo Spin-Echo Diffusion-Weighted Imaging in Prostate Magnetic Resonance Imaging of Men With Pelvic Hardware. Journal of Computer Assisted Tomography, 2020, 44, 519-526.	0.5	4
816	Borderline Gleason scores: communication is the key. Journal of Clinical Pathology, 2020, 73, 616-617.	1.0	1
817	Prostate Health Index and Prostate Health Index Density as Diagnostic Tools for Improved Prostate Cancer Detection. BioMed Research International, 2020, 2020, 1-15.	0.9	21
818	Comparison of 68Ga-PSMA-I/T PET-CT and Multiparametric MRI for Locoregional Staging of Prostate Cancer Patients: A Pilot Study. Urologia Internationalis, 2020, 104, 684-691.	0.6	9
819	Prostate cancer screening and treatment: where have we come from and where are we going?. BJU International, 2020, 126, 218-224.	1.3	39
820	The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion. Frontiers in Immunology, 2020, 11, 1680.	2.2	194
821	Variation in adjuvant and early salvage radiotherapy after robot-assisted radical prostatectomy for prostate cancer: a population-based cohort study. Acta OncolÃ³gica, 2020, 59, 904-910.	0.8	1
822	<p>Association Between Contrast-Enhanced Ultrasound Indicators and Prostate Cancer Biochemical Recurrence After Treatment</p>. Cancer Management and Research, 2020, Volume 12, 4959-4968.	0.9	4
823	Predictors of ISUP score upgrade in patients with low-risk prostate cancer. Tumori, 2021, 107, 030089162094395.	0.6	2
824	Texture analysis on bi-parametric MRI for evaluation of aggressiveness in patients with prostate cancer. Abdominal Radiology, 2020, 45, 4214-4222.	1.0	5
825	A novel immunohistochemical scoring system reveals associations of C-terminal MET, ectodomain shedding, and loss of E-cadherin with poor prognosis in oral squamous cell carcinoma. Human Pathology, 2020, 104, 42-53.	1.1	4
826	Zonal regulation of collagenâ€type proteins and posttranslational modifications in prostatic benign and cancer tissues by imaging mass spectrometry. Prostate, 2020, 80, 1071-1086.	1.2	21
827	Development and Validation of a Deep Learning Algorithm for Gleason Grading of Prostate Cancer From Biopsy Specimens. JAMA Oncology, 2020, 6, 1372.	3.4	119
828	Evaluation of MicroRNAs as Non-Invasive Diagnostic Markers in Urinary Cells from Patients with Suspected Prostate Cancer. Diagnostics, 2020, 10, 578.	1.3	13

#	ARTICLE	IF	CITATIONS
829	New additional scoring formula on the Pathological Features in Stage I Lung Adenocarcinoma Patients: Impact on Survival. International Journal of Medical Sciences, 2020, 17, 1871-1878.	1.1	2
830	Modelling the lifetime cost-effectiveness of radical prostatectomy, radiotherapy and active monitoring for men with clinically localised prostate cancer from median 10-year outcomes in the ProtecT randomised trial. BMC Cancer, 2020, 20, 971.	1.1	7
831	PSA testing patterns in a large Swedish cohort before the implementation of organized PSA testing. Scandinavian Journal of Urology, 2020, 54, 376-381.	0.6	10
832	Real life data of MRI-targeted biopsy â€" experience from a single nonacademic centre using cognitive fusion and 1.5 tesla scanning. Scandinavian Journal of Urology, 2020, 54, 387-392.	0.6	1
833	A critical evaluation of visual proportion of Gleason 4 and maximum cancer core length quantified by histopathologists. Scientific Reports, 2020, 10, 17177.	1.6	4
834	Deep Radiomic Analysis to Predict Gleason Score in Prostate Cancer. IEEE Access, 2020, 8, 167767-167778.	2.6	22
835	How Often Does Magnetic Resonance Imaging Detect Prostate Cancer Missed by Transrectal Ultrasound?. European Urology Focus, 2021, 7, 1268-1273.	1.6	6
836	Prospective PI-RADS v2.1 Atypical Benign Prostatic Hyperplasia Nodules With Marked Restricted Diffusion: Detection of Clinically Significant Prostate Cancer on Multiparametric MRI. American Journal of Roentgenology, 2021, 217, 395-403.	1.0	16
837	Risk Factors for Pathologically Confirmed Lymph Nodes Metastasis in Patients With Clinical T2N0M0 Stage Prostate Cancer. Frontiers in Oncology, 2020, 10, 1547.	1.3	10
838	Impact of H19 Polymorphisms on Prostate Cancer Clinicopathologic Characteristics. Diagnostics, 2020, 10, 656.	1.3	8
839	Automated detection of cribriform growth patterns in prostate histology images. Scientific Reports, 2020, 10, 14904.	1.6	16
840	Reduced cytoplasmic expression of MAGE-A2 predicts tumor aggressiveness and survival: an immunohistochemical analysis. World Journal of Urology, 2020, 39, 1831-1843.	1.2	2
841	PTEN Loss in a Prostate Cancer Cohort From Jordan. Applied Immunohistochemistry and Molecular Morphology, 2020, 28, 389-394.	0.6	6
842	Racial and ethnic differences in risk of second primary cancers among prostate cancer survivors. Cancer Causes and Control, 2020, 31, 1011-1019.	0.8	3
843	Expanding Active Surveillance Inclusion Criteria: A Novel Nomogram Including Preoperative Clinical Parameters and Magnetic Resonance Imaging Findings. European Urology Oncology, 2022, 5, 187-194.	2.6	20
844	Clinical outcome of surgical management for symptomatic metastatic spinal cord compression from prostate cancer. BMC Urology, 2020, 20, 143.	0.6	1
845	Night Shift Work, Chronotype, Sleep Duration, and Prostate Cancer Risk: CAPLIFE Study. International Journal of Environmental Research and Public Health, 2020, 17, 6300.	1.2	26
846	Prediction of Radioresistant Prostate Cancer Based on Differentially Expressed Proteins. Urologia Internationalis, 2021, 105, 316-327.	0.6	3

#	Article	IF	Citations
847	Added value of systematic biopsy in men with a clinical suspicion of prostate cancer undergoing biparametric MRI-targeted biopsy: multi-institutional external validation study. World Journal of Urology, 2020, 39, 1879-1887.	1.2	15
848	Equivocal PI-RADS Three Lesions on Prostate Magnetic Resonance Imaging: Risk Stratification Strategies to Avoid MRI-Targeted Biopsies. Journal of Personalized Medicine, 2020, 10, 270.	1.1	7
849	An Artificial Intelligence—based Support Tool for Automation and Standardisation of Gleason Grading in Prostate Biopsies. European Urology Focus, 2020, 7, 995-1001.	1.6	17
850	Predicting Prostate Cancer Upgrading of Biopsy Gleason Grade Group at Radical Prostatectomy Using Machine Learning-Assisted Decision-Support Models. Cancer Management and Research, 2020, Volume 12, 13099-13110.	0.9	10
851	Convergent network effects along the axis of gene expression during prostate cancer progression. Genome Biology, 2020, 21, 302.	3.8	17
852	Oligometastatic Prostate Adenocarcinoma. Clinical-Pathologic Study of a Histologically Under-Recognized Prostate Cancer. Journal of Personalized Medicine, 2020, 10, 265.	1.1	3
853	The Prognostic Role of Baseline Metabolic Tumor Burden and Systemic Inflammation Biomarkers in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Radium-223: A Proof of Concept Study. Cancers, 2020, 12, 3213.	1.7	22
854	Multiparametric MRI: Local Staging of Prostate Cancer. Current Radiology Reports, 2020, 8, 1.	0.4	2
856	Use of Warfarin or Direct Oral Anticoagulants and Risk of Prostate Cancer in PCBaSe: A Nationwide Case-Control Study. Frontiers in Oncology, 2020, 10, 571838.	1.3	4
857	Quantification of the individual risk of each Gleason pattern, including tertiary Gleason pattern 5, after radical prostatectomy: development of the modified Gleason grade grouping (mGGG) model. BMC Cancer, 2020, 20, 371.	1.1	4
858	Grading of prostate cancer: the impact of including intraductal carcinoma on the overall Grade Group assigned in diagnostic biopsies. Histopathology, 2020, 77, 503-507.	1.6	15
859	Shape Analysis of Peripheral Zone Observations on Prostate DWI: Correlation to Histopathology Outcomes After Radical Prostatectomy. American Journal of Roentgenology, 2020, 214, 1239-1247.	1.0	11
860	Prostatic chronic inflammation and prostate cancer risk at baseline random biopsy: Analysis of predictors. Arab Journal of Urology Arab Association of Urology, 2020, 18, 148-154.	0.7	3
861	Predictive model using prostate MRI findings can predict candidates for nerve sparing radical prostatectomy among low-intermediate risk prostate cancer patients. Translational Andrology and Urology, 2020, 9, 437-444.	0.6	4
862	Robotic-assisted magnetic resonance imaging ultrasound fusion results in higher significant cancer detection compared to cognitive prostate targeting in biopsy naive men. Translational Andrology and Urology, 2020, 9, 601-608.	0.6	12
863	Proteomic Tissue-Based Classifier for Early Prediction of Prostate Cancer Progression. Cancers, 2020, 12, 1268.	1.7	8
864	Prostate cancer screening research can benefit from network medicine: an emerging awareness. Npj Systems Biology and Applications, 2020, 6, 13.	1.4	17
865	Comparison of Likert and PI-RADS version 2 MRI scoring systems for the detection of clinically significant prostate cancer. British Journal of Radiology, 2020, 93, 20200298.	1.0	18

#	Article	IF	Citations
866	Personalized histopathology reporting for personalized medicine: a plea for improved communication. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 323-325.	1.4	1
867	Negative Biopsy Histology in Men With PI-RADS Score 5 in Daily Clinical Practice: Incidence of Granulomatous Prostatitis. Clinical Genitourinary Cancer, 2020, 18, e684-e687.	0.9	8
868	External validation of the Briganti nomogram predicting lymph node invasion in patients with intermediate and high-risk prostate cancer diagnosed with magnetic resonance imaging-targeted and systematic biopsies: A European multicenter study. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 847.e9-847.e16.	0.8	11
869	Isolated Intraductal Carcinoma of the Prostate in Prostatectomy Specimens: Report of 2 Cases and Review of the Literature. International Journal of Surgical Pathology, 2020, 28, 918-924.	0.4	7
870	Multiparametric MRIâ€ultrasonography software fusion prostate biopsy: initial results using a stereotactic roboticâ€assisted transperineal prostate biopsy platform comparing systematic vs targeted biopsy. BJU International, 2020, 126, 568-576.	1.3	17
871	Upregulation of the heterogeneous nuclear ribonucleoprotein hnRNPA1 is an independent predictor of early biochemical recurrence in TMPRSS2:ERG fusion-negative prostate cancers. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 625-636.	1.4	6
872	Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer. European Urology, 2020, 78, 327-332.	0.9	18
873	Bioptic intraprostatic chronic inflammation predicts adverse pathology at radical prostatectomy in patients with low-grade prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 793.e19-793.e25.	0.8	13
874	Discrimination between clinical significant and insignificant prostate cancer with apparent diffusion coefficient â€" a systematic review and meta analysis. BMC Cancer, 2020, 20, 482.	1.1	17
875	Intraductal carcinoma has a minimal impact on Grade Group assignment in prostate cancer biopsy and radical prostatectomy specimens. Histopathology, 2020, 77, 742-748.	1.6	16
876	The Use of Multiparametric Magnetic Resonance Imaging for Follow-up of Patients Included in Active Surveillance Protocol. Can PSA Density Discriminate Patients at Different Risk of Reclassification?. Clinical Genitourinary Cancer, 2020, 18, e698-e704.	0.9	24
877	Prospective development of a prostate cancer risk calculator in a racially diverse population: The Kaiser Permanente Prostate Cancer Risk Calculator. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 847.e1-847.e8.	0.8	3
878	DNA Damage Repair Deficiency in Prostate Cancer. Trends in Cancer, 2020, 6, 974-984.	3.8	25
879	Identification of areas of grading difficulties in prostate cancer and comparison with artificial intelligence assisted grading. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 777-786.	1.4	20
880	Is there a correlation between the aggressiveness of chronic asymptomatic prostatitis NIH category IV and the Gleason score in patients with prostate cancer?. Canadian Urological Association Journal, 2020, 14, E568-E573.	0.3	4
881	Histologic tissue components provide major cues for machine learning-based prostate cancer detection and grading on prostatectomy specimens. Scientific Reports, 2020, 10, 9911.	1.6	22
882	Clinico-radiological characteristic-based machine learning in reducing unnecessary prostate biopsies of PI-RADS 3 lesions with dual validation. European Radiology, 2020, 30, 6274-6284.	2.3	22
883	Compliance with the 2018 World Cancer Research Fund/American Institute for Cancer Research Cancer Prevention Recommendations and Prostate Cancer. Nutrients, 2020, 12, 768.	1.7	22

#	ARTICLE	IF	CITATIONS
884	Knowing what's growing: Why ductal and intraductal prostate cancer matter. Science Translational Medicine, 2020, 12, .	5.8	27
885	Spatial density and diversity of architectural histology in prostate cancer: influence on diffusion weighted magnetic resonance imaging. Quantitative Imaging in Medicine and Surgery, 2020, 10, 326-339.	1.1	7
886	Effect of observation size and apparent diffusion coefficient (ADC) value in PI-RADS v2.1 assessment category 4 and 5 observations compared to adverse pathological outcomes. European Radiology, 2020, 30, 4251-4261.	2.3	16
887	Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes. Nature Reviews Urology, 2020, 17, 259-270.	1.9	100
888	Elevated Tumor Lactate and Efflux in High-grade Prostate Cancer demonstrated by Hyperpolarized 13C Magnetic Resonance Spectroscopy of Prostate Tissue Slice Cultures. Cancers, 2020, 12, 537.	1.7	14
889	MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis. New England Journal of Medicine, 2020, 382, 917-928.	13.9	515
890	The Challenges of Optimizing Biomarkers to Guide Clinical Decision Making. Journal of the National Cancer Institute, 2020, 112, 1079-1080.	3.0	1
891	Using decision curve analysis to benchmark performance of a magnetic resonance imaging–based deep learning model for prostate cancer risk assessment. European Radiology, 2020, 30, 6867-6876.	2.3	18
892	Prostate Volume Estimation on MRI: Accuracy and Effects of Ellipsoid and Bullet-Shaped Measurements on PSA Density. Academic Radiology, 2021, 28, e219-e226.	1.3	16
893	Clinically significant prostate cancer detection and segmentation in low-risk patients using a convolutional neural network on multi-parametric MRI. European Radiology, 2020, 30, 6582-6592.	2.3	61
894	Prostate cancer management: long-term beliefs, epidemic developments in the early twenty-first century and 3PM dimensional solutions. EPMA Journal, 2020, 11, 399-418.	3.3	58
895	Obesity strongly predicts clinically undetected multiple lymph node metastases in intermediate- and high-risk prostate cancer patients who underwent robot assisted radical prostatectomy and extended lymph node dissection. International Urology and Nephrology, 2020, 52, 2097-2105.	0.6	13
896	Dietary Diversity and Prostate Cancer in a Spanish Adult Population: CAPLIFE Study. Nutrients, 2020, 12, 1694.	1.7	8
897	Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2020, 31, 1119-1134.	0.6	485
898	Prostate Cancer Incidence under Androgen Deprivation: Nationwide Cohort Study in Trans Women Receiving Hormone Treatment. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3293-e3299.	1.8	47
899	Long-term outcomes of incidental prostate cancer at radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 848.e17-848.e22.	0.8	6
900	Validation of the four-miRNA biomarker panel MiCaP for prediction of long-term prostate cancer outcome. Scientific Reports, 2020, 10, 10704.	1.6	8
901	Epigenetic Regulation of Gfi1 in Endocrine-Related Cancers: A Role Regulating Tumor Growth. International Journal of Molecular Sciences, 2020, 21, 4687.	1.8	4

#	ARTICLE	IF	CITATIONS
902	Thioredoxin interacting protein (TXNIP) acts as a tumor suppressor in human prostate cancer. Cell Biology International, 2020, 44, 2094-2106.	1.4	26
903	Basal total testosterone serum levels predict biopsy and pathological ISUP grade group in a large cohort of Caucasian prostate cancer patients who underwent radical prostatectomy. Therapeutic Advances in Urology, 2020, 12, 175628722092948.	0.9	3
904	Human Prostate Cancer Is Characterized by an Increase in Urea Cycle Metabolites. Cancers, 2020, 12, 1814.	1.7	37
905	Tracking prostate cancer development at the single-cell level. Nature Reviews Urology, 2020, 17, 545-546.	1.9	3
906	Detection of Significant Prostate Cancer Using Target Saturation in Transperineal Magnetic Resonance Imaging/Transrectal Ultrasonographyâ€"fusion Biopsy. European Urology Focus, 2021, 7, 1300-1307.	1.6	44
907	Going deeper through the Gleason scoring scale: An automatic end-to-end system for histology prostate grading and cribriform pattern detection. Computer Methods and Programs in Biomedicine, 2020, 195, 105637.	2.6	53
908	Concordance Between Biopsy and Radical Prostatectomy Gleason Scores: Evaluation of Determinants in a Large-Scale Study of Patients Undergoing RARP in Belgium. Pathology and Oncology Research, 2020, 26, 2605-2612.	0.9	6
909	The Impact of Prostate Cancer Upgrading and Upstaging on Biochemical Recurrence and Cancer-Specific Survival. Medicina (Lithuania), 2020, 56, 61.	0.8	12
910	Updates in Staging and Reporting of Genitourinary Malignancies. Archives of Pathology and Laboratory Medicine, 2020, 144, 305-319.	1.2	30
911	Imaging and Management of Prostate Cancer. Seminars in Ultrasound, CT and MRI, 2020, 41, 207-221.	0.7	8
912	Comparative expression of immunohistochemical biomarkers in cribriform and pattern 4 non-cribriform prostatic adenocarcinoma. Experimental and Molecular Pathology, 2020, 114, 104400.	0.9	11
913	The effect of age on cancer-specific mortality in patients with prostate cancer: a population-based study across all stages. Cancer Causes and Control, 2020, 31, 283-290.	0.8	9
914	Genitourinary Pathology (Including Adrenal Gland). , 2020, , 1523-1726.		0
915	Prospective evaluation of fexapotide triflutate injection treatment of Grade Group 1 prostate cancer: 4-year results. World Journal of Urology, 2020, 38, 3101-3111.	1.2	2
916	Clinicopathological characteristics of glomeruloid architecture in prostate cancer. Modern Pathology, 2020, 33, 1618-1625.	2.9	11
917	Lower urinary tract symptoms (LUTS) are not associated with an increased risk of prostate cancer in men 50â€"69 years with PSA â‰¥3â€‰ng/ml. Scandinavian Journal of Urology, 2020, 54, 1-6.	0.6	11
918	Targeted Biopsy With Reduced Number of Cores: Optimal Sampling Scheme in Patients Undergoing Magnetic Resonance Imaging/Transrectal Ultrasound Fusion Prostate Biopsy. Ultrasound in Medicine and Biology, 2020, 46, 1197-1207.	0.7	9
919	Evaluation of T1 relaxation time in prostate cancer and benign prostate tissue using a Modified Look-Locker inversion recovery sequence. Scientific Reports, 2020, 10, 3121.	1.6	17

#	ARTICLE	IF	CITATIONS
920	Neoadjuvant Approaches Prior To Radical Prostatectomy. Cancer Journal (Sudbury, Mass), 2020, 26, 2-12.	1.0	5
921	Updates in Histologic Grading of Urologic Neoplasms. Archives of Pathology and Laboratory Medicine, 2020, 144, 335-343.	1.2	12
922	Combination of Multiparametric Magnetic Resonance Imaging With Elastic-fusion Biopsy Has a High Sensitivity in Detecting Clinically Significant Prostate Cancer in Daily Practice. Clinical Genitourinary Cancer, 2020, 18, e501-e509.	0.9	7
923	Gleason pattern 4 with cribriform morphology on biopsy is associated with adverse clinicopathological findings in a prospective radical prostatectomy cohort. Human Pathology, 2020, 98, 74-80.	1.1	21
924	Reduced cancer-specific survival of low prostate-specific antigen in high-grade prostate cancer: A population-based retrospective cohort study. International Journal of Surgery, 2020, 76, 64-68.	1.1	8
925	The Significance of Primary Biopsy Gleason 5 in Patients with Grade Group 5 Prostate Cancer. European Urology Focus, 2020, 6, 255-258.	1.6	9
926	Intraoperative ^{68}Ga-PSMA Cerenkov Luminescence Imaging for Surgical Margins in Radical Prostatectomy: A Feasibility Study. Journal of Nuclear Medicine, 2020, 61, 1500-1506.	2.8	32
927	The performance of intravoxel-incoherent motion diffusion-weighted imaging derived hypoxia for the risk stratification of prostate cancer in peripheral zone. European Journal of Radiology, 2020, 125, 108865.	1.2	8
928	ECCO Essential Requirements for Quality Cancer Care: Prostate cancer. Critical Reviews in Oncology/Hematology, 2020, 148, 102861.	2.0	29
929	Can multiparametric magnetic resonance of the prostate avoid biopsies in patients with elevated PSA and surgical indication for benign prostatic enlargement?. Abdominal Radiology, 2020, 45, 3278-3282.	1.0	3
930	Assessing Extraprostatic Extension with Multiparametric MRI of the Prostate: Mehralivand Extraprostatic Extension Grade or Extraprostatic Extension Likert Scale?. Radiology Imaging Cancer, 2020, 2, e190071.	0.7	17
931	Nuclear magnetic resonance spectroscopy of human body fluids and in vivo magnetic resonance spectroscopy: Potential role in the diagnosis and management of prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 150-173.	0.8	15
932	Clinical outcome comparison of Grade Group 1 and Grade Group 2 prostate cancer with and without cribriform architecture at the time of radical prostatectomy. Histopathology, 2020, 76, 755-762.	1.6	18
933	The impact of extended pelvic lymph node dissection on the risk of hospital readmission within 180 days after robot assisted radical prostatectomy. World Journal of Urology, 2020, 38, 2799-2809.	1.2	14
934	Aggressive prostate cancer with somatic loss of the homologous recombination repair gene FANCA: a case report. Diagnostic Pathology, 2020, 15, 5.	0.9	7
935	Predictive Factors of the Risk of Long-Term Hospital Readmission after Primary Prostate Surgery at a Single Tertiary Referral Center: Preliminary Report. Urologia Internationalis, 2020, 104, 465-475.	0.6	8
936	Prediction of metastatic prostate cancer by prostate-specific antigen in combination with T stage and Gleason Grade: Nationwide, population-based register study. PLoS ONE, 2020, 15, e0228447.	1.1	23
937	Mucinous Prostate Cancer Shows Similar Prognosis to Typical Prostate Acinar Carcinoma: A Large Population-Based and Propensity Score-Matched Study. Frontiers in Oncology, 2019, 9, 1467.	1.3	13

#	ARTICLE	IF	CITATIONS
938	Prostate cancer in kidney transplant recipients â€" a nationwide register study. BJU International, 2020, 125, 679-685.	1.3	19
939	68Ga-PSMA PET/CT better characterises localised prostate cancer after MRI and transperineal prostate biopsy: Is 68Ga-PSMA PET/CT guided biopsy the future?. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1843-1851.	3.3	67
940	Race, tumor location, and disease progression among lowâ€risk prostate cancer patients. Cancer Medicine, 2020, 9, 2235-2242.	1.3	8
941	Development and validation of a preoperative nomogram for predicting survival of patients with locally advanced prostate cancer after radical prostatectomy. BMC Cancer, 2020, 20, 97.	1.1	12
942	Diagnosis and Grading of Prostate Cancer by Relaxation Maps From Synthetic MRI. Journal of Magnetic Resonance Imaging, 2020, 52, 552-564.	1.9	49
943	Biopsy core length in white versus African descendant prostate cancer patients. Scandinavian Journal of Urology, 2020, 54, 188-193.	0.6	0
944	Functional summaries of persistence diagrams. Journal of Applied and Computational Topology, 2020, 4, 211-262.	1.0	41
945	Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier. Prostate Cancer and Prostatic Diseases, 2020, 23, 646-653.	2.0	17
946	Prostate cancer upgrading with serial prostate magnetic resonance imaging and repeat biopsy in men on active surveillance: are confirmatory biopsies still necessary?. BJU International, 2020, 126, 124-132.	1.3	30
947	Incidence of prostate cancer in Eritrea: Data from the National Health Laboratory, Orotta Referral Hospital and Sembel Hospital 2011-2018. PLoS ONE, 2020, 15, e0232091.	1.1	3
948	Prospective Evaluation of 68Ga-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography in Primary Prostate Cancer Diagnosis. European Urology Focus, 2021, 7, 764-771.	1.6	32
949	Association of Triiodothyronine Levels With Prostate Cancer Histopathological Differentiation and Tumor Stage. Anticancer Research, 2020, 40, 2323-2329.	0.5	4
950	Expansile cribriform Gleason pattern 4 has histopathologic and molecular features of aggressiveness and greater risk of biochemical failure compared to glomerulation Gleason pattern 4. Prostate, 2020, 80, 653-659.	1.2	17
951	Corpora amylacea in benign prostatic acini are associated with concurrent, predominantly lowâ€grade cancer. Prostate, 2020, 80, 687-697.	1.2	3
952	Manual prostate cancer segmentation in MRI: interreader agreement and volumetric correlation with transperineal template core needle biopsy. European Radiology, 2020, 30, 4806-4815.	2.3	15
953	Independent external validation of nomogram to predict extracapsular extension in patients with prostate cancer. European Radiology, 2020, 30, 5004-5010.	2.3	9
954	Volume of Gleason pattern 4 stratifies risk of metastasis and death in patients with Gleason score 3+5=8/5+3=8 positive prostate core biopsies. Human Pathology, 2020, 99, 62-74.	1.1	4
955	Multicenter analysis of clinical and MRI characteristics associated with detecting clinically significant prostate cancer in PI-RADS (v2.0) category 3 lesions. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 637.e9-637.e15.	0.8	17

#	Article	IF	Citations
956	Detection of clinically significant prostate cancer in biopsyâ€naÃ¯ve men: direct comparison of systematic biopsy, multiparametric MRIâ€•and contrastâ€ultrasoundâ€dispersion imagingâ€targeted biopsy. BJU International, 2020, 126, 481-493.	1.3	17
957	Perineural invasion by prostate adenocarcinoma in needle biopsies predicts bone metastasis: Ten year data from the TROG 03.04 RADAR Trial. Histopathology, 2020, 77, 284-292.	1.6	19
958	Can we improve the detection rate of prostate cancer using standard 12â€core TRUSâ€guided prostate biopsy? Focused on the location of prostate biopsy. Cancer Medicine, 2020, 9, 3758-3764.	1.3	1
959	A 17-Gene Panel Genomic Prostate Score Has Similar Predictive Accuracy for Adverse Pathology at Radical Prostatectomy in African American and European American Men. Urology, 2020, 142, 166-173.	0.5	10
960	Validation of the updated eighth edition of AJCC for prostate cancer: Removal of pT2 substages â€" Does extent of tumor involvement matter?. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 637.e1-637.e7.	0.8	1
961	Combined systematic versus stand-alone multiparametric MRI-guided targeted fusion biopsy: nomogram prediction of non-organ-confined prostate cancer. World Journal of Urology, 2021, 39, 81-88.	1.2	11
962	Telomere-based risk models for the early diagnosis of clinically significant prostate cancer. Prostate Cancer and Prostatic Diseases, 2021, 24, 88-95.	2.0	1
963	PSMA-PET/CTâ€"based Lymph Node Atlas for Prostate Cancer Patients Recurring After Primary Treatment: Clinical Implications for Salvage Radiation Therapy. European Urology Oncology, 2021, 4, 73-83.	2.6	30
964	Peri-prostatic adipose tissue measurements using MRI predict prostate cancer aggressiveness in men undergoing radical prostatectomy. Journal of Endocrinological Investigation, 2021, 44, 287-296.	1.8	8
965	Retzius-sparing robotic-assisted laparoscopic radical prostatectomy: racial considerations for 250 consecutive cases. Journal of Robotic Surgery, 2021, 15, 221-228.	1.0	8
966	Personalised biopsy schedules based on risk of Gleason upgrading for patients with lowâ€risk prostate cancer on active surveillance. BJU International, 2021, 127, 96-107.	1.3	15
967	Artificial intelligence methods for predictive image-based grading of human cancers. , 2021, , 175-210.		3
968	The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer. Archives of Pathology and Laboratory Medicine, 2021, 145, 461-493.	1.2	143
969	Comparison of Biparametric and Multiparametric <scp>MRI</scp> for Clinically Significant Prostate Cancer Detection With <scp>PIâ€RADS</scp> Version 2.1. Journal of Magnetic Resonance Imaging, 2021, 53, 283-291.	1.9	69
970	Standardized Magnetic Resonance Imaging Reporting Using the Prostate Cancer Radiological Estimation of Change in Sequential Evaluation Criteria and Magnetic Resonance Imaging/Transrectal Ultrasound Fusion with Transperineal Saturation Biopsy to Select Men on Active Surveillance. European Urology Focus, 2021, 7, 102-110.	1.6	28
971	Evaluation of the clinical use of PET/CT with 68Ga-PSMA for the assessment of biochemical recurrence of low or intermediate-risk prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 73.e9-73.e18.	0.8	3
972	Differences in survival of prostate cancer Gleason 8â€"10 disease and the establishment of a new Gleason survival grading system. Cancer Medicine, 2021, 10, 87-97.	1.3	4
973	EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancerâ€"2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. European Urology, 2021, 79, 243-262.	0.9	1,545

#	Article	IF	Citations
974	The effect of delaying transperineal fusion biopsy of the prostate for patients with suspicious MRI findingsâ€"Implications for the COVID-19 era. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 73.e1-73.e8.	0.8	5
975	First Molecular Genetic Characterization of Skeneâ€™s Gland Adenocarcinoma. International Journal of Surgical Pathology, 2021, 29, 447-453.	0.4	6
976	Who can safely evade a magnetic resonance imaging fusion-targeted biopsy (MRIFTB) for prostate imaging reporting and data system (PI-RADS) 3 lesion?. World Journal of Urology, 2021, 39, 1463-1471.	1.2	7
977	Diagnostic Accuracy and Interobserver Agreement of PI-RADS Version 2 and Version 2.1 for the Detection of Transition Zone Prostate Cancers. American Journal of Roentgenology, 2021, 216, 1247-1256.	1.0	34
978	Artificial intelligence assistance significantly improves Gleason grading of prostate biopsies by pathologists. Modern Pathology, 2021, 34, 660-671.	2.9	84
979	Prevalence of Prostate Cancer in PI-RADS Version 2.1 Transition Zone Atypical Nodules Upgraded by Abnormal DWI: Correlation With MRI-Directed TRUS-Guided Targeted Biopsy. American Journal of Roentgenology, 2021, 216, 683-690.	1.0	19
980	Ethnic variation in prostate cancer detection: a feasibility study for use of the Stockholm3 test in a multiethnic U.S. cohort. Prostate Cancer and Prostatic Diseases, 2021, 24, 120-127.	2.0	5
981	Conditional Survival and Time of Biochemical Recurrence of Localized Prostate Cancer in Japanese Patients Undergoing Laparoscopic Radical Prostatectomies. Annals of Surgical Oncology, 2021, 28, 1247-1253.	0.7	5
982	Cribriform architecture in radical prostatectomies predicts oncological outcome in Gleason score 8 prostate cancer patients. Modern Pathology, 2021, 34, 184-193.	2.9	32
983	Head to head: should the intraductal component of invasive prostate cancer be graded?. Histopathology, 2021, 78, 231-239.	1.6	26
984	68Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 477-482.	3.3	54
985	Evaluating F-18-PSMA-1007-PET in primary prostate cancer and comparing it to multi-parametric MRI and histopathology. Prostate Cancer and Prostatic Diseases, 2021, 24, 423-430.	2.0	37
986	Effect of time of day of recreational and household physical activity on prostate and breast cancer risk (MCCâ€Spain study). International Journal of Cancer, 2021, 148, 1360-1371.	2.3	18
987	Practice patterns related to prostate cancer grading: results of a 2019 Genitourinary Pathology Society clinician survey. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 295.e1-295.e8.	0.8	6
988	Evaluation of Gleason Grade Group 5 in a Contemporary Prostate Cancer Grading System and Literature Review. Clinical Genitourinary Cancer, 2021, 19, 69-75.e5.	0.9	6
989	Predictors of Lymph Node Invasion in Patients with Clinically Localized Prostate Cancer Who Undergo Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: The Role of Obesity. Urologia Internationalis, 2021, 105, 362-369.	0.6	4
990	Optimized <scp>MRI</scp> Assessment for Clinically Significant Prostate Cancer: A <scp>STARD</scp>â€Compliant Twoâ€Center Study. Journal of Magnetic Resonance Imaging, 2021, 53, 1210-1219.	1.9	5
992	Using biomarkers in patients with positive multiparametric magnetic resonance imaging: 4Kscore predicts the presence of cancer outside the index lesion. International Journal of Urology, 2021, 28, 47-52.	0.5	11

#	ARTICLE	IF	CITATIONS
993	Stratifying patients with intermediate-risk prostate cancer: Validation of a new model based on MRI parameters and targeted biopsy and comparison with NCCN and AUA subclassifications. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 296.e1-296.e9.	0.8	2
994	Computational methods for automated mitosis detection in histopathology images: A review. Biocybernetics and Biomedical Engineering, 2021, 41, 64-82.	3.3	16
995	The Impact of Histopathological Features of Prostate Cancerous Lesions on Multiparametric Magnetic Resonance Imaging Findings using PI-RADS Version 2. Urology, 2021, 149, 174-180.	0.5	1
996	Correlation of Stiffness of Prostate Cancer Measured by Shear Wave Elastography with Grade Group: A Preliminary Study. Ultrasound in Medicine and Biology, 2021, 47, 288-295.	0.7	6
997	Uncovering the invisibleâ€"prevalence, characteristics, and radiomics featureâ€"based detection of visually undetectable intraprostatic tumor lesions in 68GaPSMA-11 PET images of patients with primary prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1987-1997.	3.3	37
998	The characteristics and spatial distributions of prostate cancer in autopsy specimens. Prostate, 2021, 81, 135-141.	1.2	4
999	Prognostic significance of architectural subtypes of Gleason grade 4 prostate cancer in radical prostatectomy: A semiquantitative method of evaluation. Annals of Diagnostic Pathology, 2021, 50, 151678.	0.6	4
1000	Promoting cell proliferation, cell cycle progression, and glycolysis: Glycometabolismâ€"related genes act as prognostic signatures for prostate cancer. Prostate, 2021, 81, 157-169.	1.2	8
1001	Trends for Stage and Grade Group of Prostate Cancer in the US (2010-2016). Urology, 2021, 149, 110-116.	0.5	4
1002	The diagnostic accuracy of multiparametric MRI for detection and localization of prostate cancer depends on the affected region. BJUI Compass, 2021, 2, 178-187.	0.7	3
1003	Simulation model of disease incidence driven by diagnostic activity. Statistics in Medicine, 2021, 40, 1172-1188.	0.8	4
1004	Prostate cancer grading, time to go back to the future. BJU International, 2021, 127, 165-168.	1.3	4
1005	Suboptimal Prediction of Clinically Significant Prostate Cancer in Radical Prostatectomy Specimens by mpMRI-Targeted Biopsy. Urology, 2021, 148, 217-223.	0.5	1
1006	The Complexity and Dynamics of the Tissue Glycoproteome Associated With Prostate Cancer Progression. Molecular and Cellular Proteomics, 2021, 20, 100026.	2.5	39
1007	Comparison of TRUS and combined MRIâ€"targeted plus systematic prostate biopsy for the concordance between biopsy and radical prostatectomy pathology. International Journal of Clinical Practice, 2021, 75, e13797.	0.8	7
1008	â€˜One Stop Prostate Clinicâ€™: prospective analysis of 1000 men attending a public sameâ€"day prostate cancer assessment and/or diagnostic clinic. ANZ Journal of Surgery, 2021, 91, 558-564.	0.3	7
1009	Multiparametric magnetic resonance imaging facilitates reclassification during active surveillance for prostate cancer. BJU International, 2021, 127, 712-721.	1.3	11
1010	Diagnosis of prostate cancer in one day: The benefits of cytology in tumour detection. Cytopathology, 2021, 32, 211-216.	0.4	0

#	Article	IF	Citations
1011	Sectoral cancer detection and tolerability of freehand transperineal prostate biopsy under local anaesthesia. Prostate Cancer and Prostatic Diseases, 2021, 24, 431-438.	2.0	10
1012	Gleason Score Evolution and the Effect on Prostate Cancer Outcomes. American Journal of Clinical Pathology, 2021, 155, 711-717.	0.4	22
1013	The potential of convolutional neural network diagnosing prostate cancer. Research on Biomedical Engineering, 2021, 37, 25-31.	1.5	5
1014	Multiparametric Magnetic Resonance Imaging Should Be Preferred Over Digital Rectal Examination for Prostate Cancer Local Staging and Disease Risk Classification. Urology, 2021, 147, 205-212.	0.5	23
1015	Managing Patients with Prostate Cancer During COVID-19 Pandemic: The Experience of a High-Volume Robotic Surgery Center. Journal of Endourology, 2021, 35, 305-311.	1.1	9
1016	Possible role of the receptor of advanced glycation end products (RAGE) in the clinical course of prostate neoplasia in patients with and without type 2 diabetes mellitus. International Journal of Clinical Practice, 2021, 75, e13723.	0.8	5
1017	Clinical indicators for predicting prognosis after radium-223 administration in castration-resistant prostate cancer with bone metastases. International Journal of Clinical Oncology, 2021, 26, 192-198.	1.0	21
1018	Inter-observer variability of cribriform architecture and percent Gleason pattern 4 in prostate cancer: relation to clinical outcome. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 249-256.	1.4	22
1019	The 2019 International Society of Urological Pathology Consensus Conference on Prostate Cancer Grading. European Urology, 2021, 79, 707-709.	0.9	13
1020	Letter to the Editor: â€œAssociation between metformin medication, genetic variation and prostate cancer riskâ€â€"genotyping and patient categorizations, do they matter?. Prostate Cancer and Prostatic Diseases, 2021, 24, 278-279.	2.0	1
1021	Performance of Combined Magnetic Resonance Imaging/Ultrasound Fusion-guided and Systematic Biopsy of the Prostate in Biopsy-naÃ¯ve Patients and Patients with Prior Biopsies. European Urology Focus, 2021, 7, 39-46.	1.6	31
1022	Outcomes of Serial Multiparametric Magnetic Resonance Imaging and Subsequent Biopsy in Men with Low-risk Prostate Cancer Managed with Active Surveillance. European Urology Focus, 2021, 7, 47-54.	1.6	22
1023	Development of a Deep Learning Algorithm for the Histopathologic Diagnosis and Gleason Grading of Prostate Cancer Biopsies: A Pilot Study. European Urology Focus, 2021, 7, 347-351.	1.6	44
1024	Metastatic prostate adenocarcinoma and high-grade appendiceal mucinous neoplasm mimicking acute appendicitis in a post-radiation therapy patient. SAGE Open Medical Case Reports, 2021, 9, 2050313X2098842.	0.2	1
1025	Effect of lesion diameter and prostate volume on prostate cancer detection rate of magnetic resonance imaging: Transrectal-ultrasonography-guided fusion biopsies using cognitive targeting. Turkish Journal of Urology, 2021, 47, 22-29.	1.3	5
1026	Benefits and harms of the new prostate cancer grade grouping on the prediction of longâ€term oncological outcomes in patients after radical prostatectomy. International Journal of Urology, 2021, 28, 390-395.	0.5	2
1027	Establishment and validation of a novel predictive model to quantify the risk of bone metastasis in patients with prostate cancer. Translational Andrology and Urology, 2021, 10, 310-325.	0.6	7
1028	Recent developments and applications of quantitative proteomics strategies for high-throughput biomolecular analyses in cancer research. RSC Chemical Biology, 2021, 2, 1050-1072.	2.0	5

#	Article	IF	Citations
1029	Does Multiparametric Magnetic Resonance of Prostate Outperform Risk Calculators in Predicting Prostate Cancer in Biopsy NaÃ¯ve Patients?. Frontiers in Oncology, 2020, 10, 603384.	1.3	8
1030	Relevance of Circulating Nucleosomes, HMGB1 and sRAGE for Prostate Cancer Diagnosis. In Vivo, 2021, 35, 2207-2212.	0.6	1
1031	2019 Gleason grading recommendations from ISUP and GUPS: broadly concordant but with significant differences. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 813-815.	1.4	5
1032	Nuclear Imaging for Bone Metastases in Prostate Cancer: The Emergence of Modern Techniques Using Novel Radiotracers. Diagnostics, 2021, 11, 117.	1.3	6
1033	Prostate cancer: a presentation of clinicopathologic prognosticators among Filipino and American men at radical prostatectomy. Asian Journal of Andrology, 2021, 23, 516.	0.8	0
1034	A second opinion pathology review improves the diagnostic concordance between prostate cancer biopsy and radical prostatectomy specimens. Urology Annals, 2021, 13, 119.	0.3	0
1035	Prostatic ductal adenocarcinoma variant predicts worse pathological and oncological outcomes: Insight from over 1000 consecutive patients from a large prospective uroâ€oncology registry. Prostate, 2021, 81, 242-251.	1.2	5
1036	Systemic Coagulation Markers Especially Fibrinogen Are Closely Associated with the Aggressiveness of Prostate Cancer in Patients Who Underwent Transrectal Ultrasound-Guided Prostate Biopsy. Disease Markers, 2021, 2021, 1-7.	0.6	4
1037	Systematic and MRI-Cognitive Targeted Transperineal Prostate Biopsy Accuracy in Detecting Clinically Significant Prostate Cancer after Previous Negative Biopsy and Persisting Suspicion of Malignancy. Medicina (Lithuania), 2021, 57, 57.	0.8	9
1038	Predictive clinical features for negative histopathology of MRI/Ultrasound-fusion-guided prostate biopsy in patients with high likelihood of cancer at prostate MRI: Analysis from a urologic outpatient clinic1. Clinical Hemorheology and Microcirculation, 2021, 76, 503-511.	0.9	3
1039	MR-Guided High-Intensity Directional Ultrasound Ablation of Prostate Cancer. Current Urology Reports, 2021, 22, 3.	1.0	9
1040	Gleason grade 5 prostate cancer: sub-patterns and prognosis. Pathology, 2021, 53, 3-11.	0.3	6
1041	The presence of prostate-specific antigen checked more than 1 year before diagnostic biopsy is an independent prognostic factor in patients undergoing radical prostatectomy. Investigative and Clinical Urology, 2021, 62, 438-446.	1.0	0
1042	Predicting Insignificant Prostate Cancer: Analysis of the Pathological Outcomes of Candidates for Active Surveillance according to the Pre-International Society of Urological Pathology (Pre-ISUP) 2014 Era Versus the Post-ISUP2014 Era. World Journal of Men?s Health, 2021, 39, 550.	1.7	2
1043	The presence of intraductal carcinoma of the prostate is closely associated with poor prognosis: a systematic review and meta-analysis. Asian Journal of Andrology, 2021, 23, 103.	0.8	3
1044	High BMI, Aggressive Tumours and Long Console Time Are Independent Predictive Factors for Symptomatic Lymphocele Formation after Robot-Assisted Radical Prostatectomy and Pelvic Lymph Node Dissection. Urologia Internationalis, 2021, 105, 453-459.	0.6	9
1045	Dynamic contrast-enhanced magnetic resonance imaging for risk stratification in patients with prostate cancer. Quantitative Imaging in Medicine and Surgery, 2022, 12, 742-751.	1.1	6
1046	Endogenous testosterone as a predictor of prostate growing disorders in the aging male. International Urology and Nephrology, 2021, 53, 843-854.	0.6	13

#	ARTICLE	IF	CITATIONS
1047	Transperineal systematic biopsies in addition to targeted biopsies are important in the detection of clinically significant prostate cancer. ANZ Journal of Surgery, 2021, 91, 584-589.	0.3	3
1048	Editorial Comment to Prognostic significance of tertiary Gleason pattern in the contemporary era of Gleason grade grouping: A narrative review. International Journal of Urology, 2021, 28, 621-622.	0.5	0
1049	Predictors of complications occurring after open and robot-assisted prostate cancer surgery: a retrospective evaluation of 1062 consecutive patients treated in a tertiary referral high volume center. Journal of Robotic Surgery, 2022, 16, 45-52.	1.0	6
1050	Prognostic significance of morphological patterns of Gleason grade 5 prostatic adenocarcinoma diagnosed on needle biopsy. Pathology, 2021, 53, 199-204.	0.3	3
1051	The epithelialâ€"mesenchymal transition regulators Twist, Slug, and Snail are associated with aggressive tumour features and poor outcome in prostate cancer patients. Journal of Pathology: Clinical Research, 2021, 7, 253-270.	1.3	20
1052	Comparison of initial and second opinion reads of multiparametric magnetic resonance imaging of the prostate for transperineal template-guided biopsies with MRI-Ultrasound fusion. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 781.e1-781.e7.	0.8	4
1053	PSA and obesity among men with localized prostate cancer: results of the ANDROCAN study. World Journal of Urology, 2021, 39, 2945-2951.	1.2	5
1054	Prediction of Pathological Upgrading at Radical Prostatectomy in Prostate Cancer Eligible for Active Surveillance: A Texture Features and Machine Learning-Based Analysis of Apparent Diffusion Coefficient Maps. Frontiers in Oncology, 2020, 10, 604266.	1.3	12
1055	Is Additional Systematic Biopsy Necessary in All Initial Prostate Biopsy Patients With Abnormal MRI?. Frontiers in Oncology, 2021, 11, 643051.	1.3	4
1056	The GÃ—TEBORG prostate cancer screening 2 trial: a prospective, randomised, population-based prostate cancer screening trial with prostate-specific antigen testing followed by magnetic resonance imaging of the prostate. Scandinavian Journal of Urology, 2021, 55, 116-124.	0.6	27
1057	Exploration on Gleason score variation trend of patients with prostate carcinoma from 1996 to 2019: a retrospective single center study. Gland Surgery, 2021, 10, 607-617.	0.5	1
1058	Prostate cancer detection with magnetic resonance imaging (MRI)/cognitive fusion biopsy: Comparing standard and targeted prostate biopsy with final prostatectomy histology. Canadian Urological Association Journal, 2021, 15, E483-E487.	0.3	4
1059	Role of primary care in the management of prostate cancer. The Prescriber, 2021, 32, 11-17.	0.1	2
1060	Docetaxel chemotherapy response in PC3 prostate cancer mouse model detected by rotating frame relaxations and water diffusion. NMR in Biomedicine, 2021, 34, e4483.	1.6	1
1061	Histological grading of the prostate carcinoma using deep learning: an unsupervised approach. , 2021, , .		0
1062	Evaluation of 68Ga-PSMA PET/CT with volumetric parameters for staging of prostate cancer patients. Nuclear Medicine Communications, 2021, 42, 503-509.	0.5	10
1063	Study protocol for a single-centre non-inferior randomised controlled trial on a novel three-dimensional matrix positioning-based cognitive fusion-targeted biopsy and software-based fusion-targeted biopsy for the detection rate of clinically significant prostate cancer in men without a prior biopsy. BMJ Open, 2021, 11, e041427.	0.8	0
1064	Grading Evolution and Contemporary Prognostic Biomarkers of Clinically Significant Prostate Cancer. Cancers, 2021, 13, 628.	1.7	7

#	ARTICLE	IF	CITATIONS
1065	Magnetic Resonance Imaging Based Radiomic Models of Prostate Cancer: A Narrative Review. Cancers, 2021, 13, 552.	1.7	21
1066	Diagnostic and prognostic factors in patients with prostate cancer: a systematic review protocol. BMJ Open, 2021, 11, e040531.	0.8	4
1067	Prognostic significance of tertiary Gleason pattern in the contemporary era of Gleason grade grouping: A narrative review. International Journal of Urology, 2021, 28, 614-621.	0.5	3
1068	De novo neuroendocrine transdifferentiation in primary prostate cancerâ€"a phenotype associated with advanced clinico-pathologic features and aggressive outcome. Medical Oncology, 2021, 38, 26.	1.2	18
1069	Deep Learning Regression for Prostate Cancer Detection and Grading in Bi-Parametric MRI. IEEE Transactions on Biomedical Engineering, 2021, 68, 374-383.	2.5	77
1070	Interchangeability of light and virtual microscopy for histopathological evaluation of prostate cancer. Scientific Reports, 2021, 11, 3257.	1.6	11
1071	Robotic-assisted radical prostatectomy with preceptorâ€™s assistance: the training experience and outcomes in South America. Journal of Robotic Surgery, 2022, 16, 207-213.	1.0	9
1073	Population-Based Prostate Cancer Screening With Magnetic Resonance Imaging or Ultrasonography. JAMA Oncology, 2021, 7, 395.	3.4	87
1074	Is Retzius-sparing robot-assisted laparoscopic radical prostatectomy effective in early continence? A single-center experience of the first 50 patients. Turkish Journal of Urology, 2021, 47, 25-130.	1.3	1
1075	Focal Treatment of Prostate Cancer: MRI Helps Guide the Way Forward. Radiology, 2021, 298, 704-706.	3.6	0
1076	Laparoscopic surgery experience does not influence oncological and functional results of robotic-assisted laparoscopic prostatectomy. Urologia, 2022, 89, 240-243.	0.3	1
1077	Analysis of risk factors for determining the need for prostate biopsy in patients with negative MRI. Scientific Reports, 2021, 11, 6048.	1.6	10
1078	The Prostate Health Index aids multi-parametric MRI in diagnosing significant prostate cancer. Scientific Reports, 2021, 11, 1286.	1.6	21
1079	Detection limits of significant prostate cancer using multiparametric MR and digital rectal examination in men with low serum PSA: Up-date of the Italian Society of Integrated Diagnostic in Urology. Archivio Italiano Di Urologia Andrologia, 2021, 93, 92-100.	0.4	9
1080	A Deep Learning Approach to Diagnostic Classification of Prostate Cancer Using Pathologyâ€"Radiology Fusion. Journal of Magnetic Resonance Imaging, 2021, 54, 462-471.	1.9	41
1081	Prospective Validation of Pentraxin-3 as a Novel Serum Biomarker to Predict the Risk of Prostate Cancer in Patients Scheduled for Prostate Biopsy. Cancers, 2021, 13, 1611.	1.7	16
1082	Comparing the Approach to Radical Prostatectomy Using the Multiport da Vinci Xi and da Vinci SP Robots: A Propensity Score Analysis of Perioperative Outcomes. European Urology, 2021, 79, 393-404.	0.9	47
1083	Using the Method of â€œOptical Biopsyâ€•of Prostatic Tissue to Diagnose Prostate Cancer. Molecules, 2021, 26, 1961.	1.7	5

#	ARTICLE	IF	CITATIONS
1084	Carcinoma intraductal de prÃ³stata concomitante y respuesta al tratamiento hormonal en el carcinoma de prÃ³stata metastÃ¡sico. Actas UrolÃ³gicas EspaÃ±olas, 2021, 45, 455-460.	0.3	4
1085	68Ga-PSMA PET/CT for Patients with PSA Relapse after Radical Prostatectomy or External Beam Radiotherapy. Diagnostics, 2021, 11, 622.	1.3	6
1086	Serum lipids and prostate cancer. Journal of Clinical Laboratory Analysis, 2021, 35, e23705.	0.9	10
1087	External validation and comparison of magnetic resonance imaging-based predictive models for clinically significant prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 783.e1-783.e10.	0.8	4
1088	Transcript analysis of commercial prostate cancer risk stratification panels in hardâ€toâ€predict grade group 2â€"4 prostate cancers. Prostate, 2021, 81, 368-376.	1.2	6
1089	For men enrolled in active surveillance, pre-biopsy biparametric magnetic resonance imaging significantly reduces the risk of reclassification and disease progression after 1 year. Scandinavian Journal of Urology, 2021, 55, 215-220.	0.6	2
1090	FGF21 facilitates autophagy in prostate cancer cells by inhibiting the PI3Kâ€"Aktâ€"mTOR signaling pathway. Cell Death and Disease, 2021, 12, 303.	2.7	31
1091	Inverse Stage Migration in Radical Prostatectomyâ€"A Sustaining Phenomenon. Frontiers in Surgery, 2021, 8, 612813.	0.6	14
1092	Narrative review of prostate cancer grading systems: will the Gleason scores be replaced by the Grade Groups?. Translational Andrology and Urology, 2021, 10, 1530-1540.	0.6	10
1093	Decoding the heterogeneous landscape in the development prostate cancer (Review). Oncology Letters, 2021, 21, 376.	0.8	2
1094	Outcomes of Patients With Spinal Metastases From Prostate Cancer Treated With Conventionally-Fractionated External Beam Radiation Therapy. Global Spine Journal, 2021, , 219256822199479.	1.2	1
1095	Impact of Chronic Prostatitis on the PI-RADS Score 3: Proposal for the Addition of a Novel Binary Suffix. Diagnostics, 2021, 11, 623.	1.3	1
1096	Predictive role of T2WI and ADC-derived texture parameters in differentiating Gleason score 3Š+Š4 and 4Š+Š3 prostate cancer. Journal of X-Ray Science and Technology, 2021, 29, 307-315.	0.7	1
1097	Radiomics Models Based on Apparent Diffusion Coefficient Maps for the Prediction of Highâ€Grade Prostate Cancer at Radical Prostatectomy: Comparison With Preoperative Biopsy. Journal of Magnetic Resonance Imaging, 2021, 54, 1892-1901.	1.9	16
1098	Head-to-Head Comparison of Two Nomograms Predicting Probability of Lymph Node Invasion in Prostate Cancer and the Therapeutic Impact of Higher Nomogram Threshold. Journal of Clinical Medicine, 2021, 10, 999.	1.0	8
1099	Evaluation of PSA and PSA Density in a Multiparametric Magnetic Resonance Imaging-Directed Diagnostic Pathway for Suspected Prostate Cancer: The INNOVATE Trial. Cancers, 2021, 13, 1985.	1.7	10
1100	Development and internal validation of a prediction model of prostate cancer on initial transperineal template-guided prostate biopsy. BMC Urology, 2021, 21, 68.	0.6	2
1101	The Weight of HLA-DPA1 rs3077 Single Nucleotide Polymorphism in Prostate Cancer, a Multicenter Study. Prostate Cancer, 2021, 2021, 1-5.	0.4	6

#	ARTICLE	IF	CITATIONS
1102	The discriminative ability of Prostate Health Index to detect prostate cancer is enhanced in combination with miR-222-3p. Cancer Biomarkers, 2021, 30, 381-393.	0.8	1
1103	Feasibility study for ex vivo fluorescence confocal microscopy (FCM) on diagnostic prostate biopsies. Quantitative Imaging in Medicine and Surgery, 2021, 11, 1322-1332.	1.1	6
1104	Nuclear overexpression levels of MAGEâ€A3 predict poor prognosis in patients with prostate cancer. Apmis, 2021, 129, 291-303.	0.9	6
1105	Can 68Ga-PSMA-11 PET/CT predict pathological upgrading of prostate cancer from MRI-targeted biopsy to radical prostatectomy?. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3693-3701.	3.3	10
1106	Prostate Cancer Staging Based On High B-Value Diffusion Weighted Magnetic Resonance Imaging. , 2021, , .		0
1107	The Value of Low Prostate Imagingâ€"Reporting and Data System (PI-RADS) Scores in Preventing Unnecessary Prostate Biopsies. Medicina (Lithuania), 2021, 57, 413.	0.8	0
1108	Primary malignant teratoma of the kidney: a rare case report and literature review. Translational Andrology and Urology, 2021, 10, 1807-1812.	0.6	1
1109	Impact of Grade Groups on Prostate Cancer-Specific and Other-Cause Mortality: Competing Risk Analysis from a Large Single Institution Series. Cancers, 2021, 13, 1963.	1.7	9
1110	De Novo Radiomics Approach Using Image Augmentation and Features From T1 Mapping to Predict Gleason Scores in Prostate Cancer. Investigative Radiology, 2021, 56, 661-668.	3.5	18
1111	Limitations of overlapping cores in systematic and MRI-US fusion biopsy. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 782.e15-782.e21.	0.8	6
1112	Diagnostic Accuracy of Single-plane Biparametric and Multiparametric Magnetic Resonance Imaging in Prostate Cancer: A Randomized Noninferiority Trial in Biopsy-naÃ¯ve Men. European Urology Oncology, 2021, 4, 855-862.	2.6	15
1113	Pattern of Biopsy Gleason Grade Group 5 (4 + 5 vs 5 + 4 vs 5 + 5) Predicts Survival After Radical Prostatectomy or External Beam Radiation Therapy. European Urology Focus, 2022, 8, 710-717.	1.6	12
1114	Prostate Cancer Diagnostic Algorithm as a â€œRoad Mapâ€•from the First Stratification of the Patient to the Final Treatment Decision. Life, 2021, 11, 324.	1.1	3
1115	SelectMDx and Multiparametric Magnetic Resonance Imaging of the Prostate for Men Undergoing Primary Prostate Biopsy: A Prospective Assessment in a Multi-Institutional Study. Cancers, 2021, 13, 2047.	1.7	45
1116	Apparent Diffusion Coefficient and Other Preoperative Magnetic Resonance Imaging Features for the Prediction of Positive Surgical Margins in Prostate Cancer Patients Undergoing Radical Prostatectomy. Clinical Genitourinary Cancer, 2021, 19, e335-e345.	0.9	7
1117	How Much Reliable Is the Current Belief on Grade Group 1 Prostate Cancer?. Pathology and Oncology Research, 2021, 27, 629489.	0.9	0
1118	Neoadjuvant Chemohormonal Therapy before Radical Prostatectomy for Japanese Patients with High-Risk Localized Prostate Cancer. Medical Sciences (Basel, Switzerland), 2021, 9, 24.	1.3	2
1119	Impact of qualitative, semi-quantitative, and quantitative analyses of dynamic contrast-enhanced magnet resonance imaging on prostate cancer detection. PLoS ONE, 2021, 16, e0249532.	1.1	9

#	ARTICLE	IF	CITATIONS
1120	Optimizing the diagnosis and management of ductal prostate cancer. Nature Reviews Urology, 2021, 18, 337-358.	1.9	21
1121	Extracellular vesicles in prostate cancer: a narrative review. Translational Andrology and Urology, 2021, 10, 1890-1907.	0.6	17
1122	Prevalence of prostate cancer at autopsy in Nigeriaâ€"A preliminary report. Prostate, 2021, 81, 553-559.	1.2	6
1123	Transmembrane and Tetratricopeptide Repeat Containing 4 Is a Novel Diagnostic Marker for Prostate Cancer with High Specificity and Sensitivity. Cells, 2021, 10, 1029.	1.8	5
1124	Urinary proteomic profiles of prostate cancer with different risk of progression and correlation with histopathological features. Annals of Diagnostic Pathology, 2021, 51, 151704.	0.6	1
1125	Consumption of ultra-processed foods and drinks and colorectal, breast, and prostate cancer. Clinical Nutrition, 2021, 40, 1537-1545.	2.3	44
1126	Reasons for missing clinically significant prostate cancer by targeted magnetic resonance imaging/ultrasound fusion-guided biopsy. European Journal of Radiology, 2021, 137, 109587.	1.2	9
1127	The Significance of Prostate Specific Antigen Persistence in Prostate Cancer Risk Groups on Long-Term Oncological Outcomes. Cancers, 2021, 13, 2453.	1.7	6
1128	Impact of MRI/US fusionâ€guided prostate biopsy on biopsyâ€naÃ¯ve patients: A single urologistâ€™s experience. BJUI Compass, 2022, 3, 19-25.	0.7	2
1129	How Has Prostate Cancer Radiotherapy Changed in Italy between 2004 and 2011? An Analysis of the National Patterns-Of-Practice (POP) Database by the Uro-Oncology Study Group of the Italian Society of Radiotherapy and Clinical Oncology (AIRO). Cancers, 2021, 13, 2702.	1.7	4
1130	A Multi-Channel and Multi-Spatial Attention Convolutional Neural Network for Prostate Cancer ISUP Grading. Applied Sciences (Switzerland), 2021, 11, 4321.	1.3	6
1131	Artificial intelligence is a promising prospect for the detection of prostate cancer extracapsular extension with mpMRI: a two-center comparative study. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3805-3816.	3.3	24
1132	Twelve-year outcomes of prostate cancer after radical prostatectomy for T3 and/or positive margins managed with surveillance or salvage radiation therapy, based on risk groups. Prostate International, 2021, 9, 190-196.	1.2	1
1133	The prognostic power of 18F-FDG PET/CT extends to estimating systemic treatment response duration in metastatic castration-resistant prostate cancer (mCRPC) patients. Prostate Cancer and Prostatic Diseases, 2021, 24, 1198-1207.	2.0	24
1134	Identification and Validation of a Prognostic 5-Protein Signature for Biochemical Recurrence Following Radical Prostatectomy for Prostate Cancer. Frontiers in Surgery, 2021, 8, 665115.	0.6	1
1135	Diagnostic accuracy of 68 Gaâ€PSMA PET/MRI and multiparametric MRI in detecting index tumours in radical prostatectomy specimen. International Journal of Clinical Practice, 2021, 75, e14287.	0.8	4
1136	Does a screening digital rectal exam provide actionable clinical utility in patients with an elevated PSA and positive MRI?. BJUI Compass, 2021, 2, 188-193.	0.7	7
1137	Multi-scale fully convolutional neural networks for histopathology image segmentation: From nuclear aberrations to the global tissue architecture. Medical Image Analysis, 2021, 70, 101996.	7.0	52

#	Article	IF	Citations
1138	External Validation of the Briganti Nomogram to Predict Lymph Node Invasion in Prostate Cancerâ€"Setting a New Threshold Value. Life, 2021, 11, 479.	1.1	5
1139	The end of â€œvery low riskâ€•in localized prostate cancer?. Prostate, 2021, 81, 615-617.	1.2	1
1140	PSA Density Help to Identify Patients With Elevated PSA Due to Prostate Cancer Rather Than Intraprostatic Inflammation: A Prospective Single Center Study. Frontiers in Oncology, 2021, 11, 693684.	1.3	32
1141	Value of MRI texture analysis for predicting new Gleason grade group. British Journal of Radiology, 2021, 94, 20210005.	1.0	2
1142	Can we use neutrophil to lymphocyte ratio in the diagnosis and prediction of extracapsular extension in localized prostate cancer?. Urologia, 2021, , 039156032110148.	0.3	0
1143	68Ga-PSMA-11 PET, 18F-PSMA-1007 PET, and MRI for Gross Tumor Volume Delineation in Primary Prostate Cancer: Intermodality and Intertracer Variability. Practical Radiation Oncology, 2021, 11, 202-211.	1.1	13
1144	Correlation of MRI-Lesion Targeted Biopsy vs. Systematic Biopsy Gleason Score with Final Pathological Gleason Score after Radical Prostatectomy. Diagnostics, 2021, 11, 882.	1.3	13
1145	Differential prognostic impact of different Gleason patterns in grade group 4 in radical prostatectomy specimens. European Journal of Surgical Oncology, 2021, 47, 1172-1178.	0.5	7
1146	Association between environmental quality and prostate cancer stage at diagnosis. Prostate Cancer and Prostatic Diseases, 2021, 24, 1129-1136.	2.0	9
1147	Presence of biopsy Gleason pattern 5â€‰+â€‰3 is associated with higher mortality after radical prostatectomy but not after external beam radiotherapy compared to other Gleason Grade Group IV patterns+. Prostate, 2021, 81, 778-784.	1.2	2
1148	Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-naÃ¯ve men. Prostate Cancer and Prostatic Diseases, 2021, 24, 1110-1119.	2.0	40
1149	Clinical significance and risk factors of International Society of Urological Pathology (ISUP) grade upgrading in prostate cancer patients undergoing robot-assisted radical prostatectomy. BMC Cancer, 2021, 21, 501.	1.1	6
1150	The Pathogenesis of Prostate Cancer. , 0, , 29-42.		6
1151	Biorepositories and Databanks for the Development of Novel Biomarkers for Genitourinary Cancer Prevention and Management. European Urology Focus, 2021, 7, 513-521.	1.6	0
1152	ISUP Consensus Definition of Cribriform Pattern Prostate Cancer. American Journal of Surgical Pathology, 2021, 45, 1118-1126.	2.1	36
1153	Reassessment of Prostate Biopsy Specimens for Patients Referred for Robot-assisted Radical Prostatectomy Rarely Influences Surgical Planning. European Urology Open Science, 2021, 28, 36-42.	0.2	2
1154	Comparative study of immunohistochemical expression of ERG and MAGI2 in prostatic carcinoma. Annals of Diagnostic Pathology, 2021, 52, 151727.	0.6	2
1155	Comedonecrosis Gleason pattern 5 is associated with worse clinical outcome in operated prostate cancer patients. Modern Pathology, 2021, 34, 2064-2070.	2.9	10

#	ARTICLE	IF	CITATIONS
1156	Risk stratification in men with a negative prostate biopsy: an interim analysis of a prospective cohort study. BJU International, 2021, 128, 702-712.	1.3	0
1157	Yet Another Automated Gleason Grading System (YAAGGS) by weakly supervised deep learning. Npj Digital Medicine, 2021, 4, 99.	5.7	29
1158	Single center results of magnetic resonance imaging ultrasound guided fusion prostate biopsy obtained patients. Yeni Ãœroloji Dergisi, 2021, 16, 140-147.	0.1	0
1159	Can high b-value 3.0ÂT biparametric MRI with the Simplified Prostate Image Reporting and Data System (S-PI-RADS) be used in biopsy-naÃ¯ve men?. Clinical Imaging, 2021, , .	0.8	6
1160	Prognostic Impact of Different Gleason Patterns on Biopsy Within Grade Group 4 Prostate Cancer. Annals of Surgical Oncology, 2021, 28, 9179-9187.	0.7	3
1161	Expression and Clinical Significance of HKII and HIF-1Î± in Grade Groups of Prostate Cancer. Frontiers in Genetics, 2021, 12, 680928.	1.1	5
1162	Comparative analysis of 1152 African-American and European-American men with prostate cancer identifies distinct genomic and immunological differences. Communications Biology, 2021, 4, 670.	2.0	50
1163	Usability and diagnostic accuracy of different MRI/ultrasound-guided fusion biopsy systems for the detection of clinically significant and insignificant prostate cancer: a prospective cohort study. World Journal of Urology, 2021, 39, 4101-4108.	1.2	6
1164	Diagnostic accuracy of the Novel 29 MHz micro-ultrasound â€œExactVuTMâ€•for the detection of clinically significant prostate cancer: A prospective single institutional study. A step forward in the diagnosis of prostate cancer. Archivio Italiano Di Urologia Andrologia, 2021, 93, 132-138.	0.4	8
1165	Temporal changes in causeâ€specific death in men with localised prostate cancer treated with radical prostatectomy: a populationâ€based, nationwide study. Journal of Surgical Oncology, 2021, 124, 867-875.	0.8	1
1166	What is the consistency between the results of needle biopsy and prostatectomy specimen pathology results? A pilot study. Turkish Journal of Medical Sciences, 2021, 51, 1360-1364.	0.4	3
1167	Integration of clinicopathologic identification and deep transferrable image feature representation improves predictions of lymph node metastasis in prostate cancer. EBioMedicine, 2021, 68, 103395.	2.7	19
1168	A nomogram based on PI-RADS v2.1 and clinical indicators for predicting clinically significant prostate cancer in the transition zone. Translational Andrology and Urology, 2021, 10, 2435-2446.	0.6	4
1169	Active surveillance for prostate cancerâ€"will the discoveries of the last 5 years change the future?. Translational Andrology and Urology, 2021, 10, 2828-2831.	0.6	6
1170	Diagnosis of advanced prostate cancer at the community level in Rwanda. International Urology and Nephrology, 2021, 53, 1977-1985.	0.6	5
1171	Cribriform prostate cancer: Morphologic criteria enabling a diagnosis, based on survey of experts. Annals of Diagnostic Pathology, 2021, 52, 151733.	0.6	9
1172	Diagnostic algorithms in prostate cancer - 1st part. Urologie Pro Praxi, 2021, 22, 88-91.	0.0	0
1173	External validation of two MRI-based risk calculators in prostate cancer diagnosis. World Journal of Urology, 2021, 39, 4109-4116.	1.2	5

#	Article	IF	Citations
1174	Are Proinflammatory Cytokines Relevant for the Diagnosis of Prostate Cancer?. Anticancer Research, 2021, 41, 3067-3073.	0.5	7
1175	A cohort analysis of patients receiving neoadjuvant androgen deprivation therapy prior to robot-assisted laparoscopic prostatectomy during the Covid-19 pandemic. Journal of Clinical Urology, 2023, 16, 131-139.	0.1	0
1176	Prostate Cancer Screening in Brazil: a single center experience in the public health system. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2021, 47, 558-565.	0.7	6
1177	A disease by any other name: Effects of cancer grading nomenclature on perception of prostate cancer risk. Cancer, 2021, 127, 3290-3293.	2.0	0
1178	Increased Body Mass Index Is a Risk Factor for Poor Clinical Outcomes after Radical Prostatectomy in Men with International Society of Urological Pathology Grade Group 1 Prostate Cancer Diagnosed with Systematic Biopsies. Urologia Internationalis, 2022, 106, 75-82.	0.6	4
1179	Functional outcomes rather than complications predict poor health-related quality of life at 6 months after robot-assisted radical prostatectomy. Journal of Robotic Surgery, 2022, 16, 453-462.	1.0	1
1180	Do not underestimate anterior prostate cancer. Biomedical Papers of the Medical Faculty of the University Palacký&#x0301;, Olomouc, Czechoslovakia, 2021, 165, 198-202.	0.2	2
1181	Extraprostatic extension of gleason 6 prostate cancer: single center experience. Yeni Ãœroloji Dergisi, 2021, 16, 165-170.	0.1	0
1182	Basic factors predicting prostate cancer in Prostate Imaging Reporting and Data System-3 lesions. Yeni Ãœroloji Dergisi, 2021, 16, 184-189.	0.1	1
1183	It's all in the name: Does nomenclature for indolent prostate cancer impact management and anxiety?. Cancer, 2021, 127, 3354-3360.	2.0	5
1184	HO-1 Modulates Aerobic Glycolysis through LDH in Prostate Cancer Cells. Antioxidants, 2021, 10, 966.	2.2	9
1185	Correlation of Lesional Uptake Parameters and Ratios with miPSMA Score and Estimating Normal Physiologic Concentration: An Exploratory Analysis in Metastatic Castration-Resistant Prostatic Carcinoma Patients with 68Ga-PSMA-11 PET/CT. Journal of Nuclear Medicine Technology, 2021, 49, 235-240.	0.4	3
1186	Understanding and overcoming tumor heterogeneity in metastatic breast cancer treatment. Nature Cancer, 2021, 2, 680-692.	5.7	56
1187	High expression of miR-17-5p in tumor epithelium is a predictor for poor prognosis for prostate cancer patients. Scientific Reports, 2021, 11, 13864.	1.6	21
1188	Current Understanding and Management of Intraductal Carcinoma of the Prostate. Current Oncology Reports, 2021, 23, 110.	1.8	1
1189	Communicating prostate biopsy results. Diagnostic Histopathology, 2021, 27, 283-289.	0.2	3
1190	Personalized histopathology reporting for personalized medicine. Diagnostic Histopathology, 2021, 27, 275-278.	0.2	4
1191	Platelet-to-lymphocyte ratio is not a predictor of clinically significant prostate cancer at the prostate biopsy: A large cohort study. Scientific Reports, 2021, 11, 14240.	1.6	4

#	ARTICLE	IF	CITATIONS
1192	Artificial intelligence in urological oncology: An update and future applications. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 379-399.	0.8	13
1193	Clinical utility of pathology data: prostate and kidney cancer. Diagnostic Histopathology, 2021, 27, 297-304.	0.2	3
1194	Concomitant intraductal carcinoma of the prostate and response to hormonal therapy in metastatic prostate carcinoma. Actas Urológicas Españolas (English Edition), 2021, 45, 455-460.	0.2	1
1195	Intraductal Carcinoma of the Prostate. American Journal of Surgical Pathology, 2021, Publish Ahead of Print, 1527-1533.	2.1	6
1196	Does PSA level affect the choice of prostate puncture methods among MRI-ultrasound fusion targeted biopsy, transrectal ultrasound systematic biopsy or the combination of both?. British Journal of Radiology, 2021, 94, 20210312.	1.0	1
1197	The prostate health index and the percentage of [-2]proPSA maintain their diagnostic performance when calculated with total and free PSA from different manufacturers. Clinical Chemistry and Laboratory Medicine, 2021, 59, 1869-1877.	1.4	2
1198	Influence of Tumor Burden on Serum Prostate-Specific Antigen in Prostate Cancer Patients Undergoing Radical Prostatectomy. Frontiers in Oncology, 2021, 11, 656444.	1.3	2
1199	Characterization of Novel Progression Factors in Castration-Resistant Prostate Cancer Based on Global Comparative Proteome Analysis. Cancers, 2021, 13, 3432.	1.7	4
1200	Prognostic model with alkaline phosphatase, lactate dehydrogenase and presence of Gleason pattern 5 for worse overall survival in low-risk metastatic hormone-sensitive prostate cancer. Japanese Journal of Clinical Oncology, 2021, 51, 1665-1671.	0.6	2
1201	Validation of the Brazilian Version of Functional Assessment of Cancer Therapy-Prostate—FACT-P (Version 4) in Prostate Cancer Patients. Journal of Cancer Education, 2021, , 1.	0.6	0
1202	Total thiol can contribute to differentiating prostate cancer from BPH: Prostate Thiol Index as a new player. Andrologia, 2021, 53, e14190.	1.0	1
1203	Tumor contact length of prostate cancer determined by a three‐dimensional method on multiparametric magnetic resonance imaging predicts extraprostatic extension and biochemical recurrence. International Journal of Urology, 2021, 28, 1012-1018.	0.5	3
1204	The Association of Nighttime Fasting Duration and Prostate Cancer Risk: Results from the Multicase-Control (MCC) Study in Spain. Nutrients, 2021, 13, 2662.	1.7	10
1205	MRI Targeted Prostate Biopsy Techniques: <i>AJR</i> Expert Panel Narrative Review. American Journal of Roentgenology, 2021, 217, 1263-1281.	1.0	7
1206	Development and validation of a predictive model for determining clinically significant prostate cancer in men with negative magnetic resonance imaging after transrectal ultrasound‐guided prostate biopsy. Prostate, 2021, 81, 983-991.	1.2	3
1207	HOXB5 Overexpression Is Associated with Neuroendocrine Differentiation and Poor Prognosis in Prostate Cancer. Biomedicines, 2021, 9, 893.	1.4	2
1208	Significance of the prostate central gland and total gland volume ratio in the diagnosis of prostate cancer patients in the prostate specific antigen grey zone. Journal of International Medical Research, 2021, 49, 030006052110198.	0.4	2
1209	Prostate Cancer in 2021: Novelties in Prognostic and Therapeutic Biomarker Evaluation. Cancers, 2021, 13, 3471.	1.7	9

#	Article	IF	Citations
1210	Clinicopathological Analysis of the ISUP Grade Group And Other Parameters in Prostate Cancer: Elucidation of Mutual Impact of the Various Parameters. Frontiers in Oncology, 2021, 11, 695251.	1.3	7
1211	A drug comorbidity index to predict mortality in men with castration resistant prostate cancer. PLoS ONE, 2021, 16, e0255239.	1.1	3
1212	IVIM Parameters on MRI Could Predict ISUP Risk Groups of Prostate Cancers on Radical Prostatectomy. Frontiers in Oncology, 2021, 11, 659014.	1.3	1
1213	Does Adding Standard Systematic Biopsy to Targeted Prostate Biopsy in PI-RADS 3 to 5 Lesions Enhance the Detection of Clinically Significant Prostate Cancer? Should All Patients with PI-RADS 3 Undergo Targeted Biopsy?. Diagnostics, 2021, 11, 1335.	1.3	8
1214	CAD systems for colorectal cancer from WSI are still not ready for clinical acceptance. Scientific Reports, 2021, 11, 14358.	1.6	30
1215	Detection of Prostate Cancer Using Biparametric Prostate <scp>MRI</scp>, Radiomics, and Kallikreins: A Retrospective Multicenter Study of Men With a Clinical Suspicion of Prostate Cancer. Journal of Magnetic Resonance Imaging, 2022, 55, 465-477.	1.9	9
1216	A Comprehensive Study of Data Augmentation Strategies for Prostate Cancer Detection in Diffusion-Weighted MRI Using Convolutional Neural Networks. Journal of Digital Imaging, 2021, 34, 862-876.	1.6	37
1217	Isomer-Resolved Imaging of Prostate Cancer Tissues Reveals Specific Lipid Unsaturation Profiles Associated With Lymphocytes and Abnormal Prostate Epithelia. Frontiers in Endocrinology, 2021, 12, 689600.	1.5	15
1218	Robotic surgery costs: Revealing the real villains. International Journal of Medical Robotics and Computer Assisted Surgery, 2021, 17, e2311.	1.2	3
1219	Cribriform glands are associated with worse outcome than other pattern 4 subtypes: A study of prognostic and clinicopathological characteristics of prostate adenocarcinoma with an emphasis on Grade Groups. International Journal of Clinical Practice, 2021, 75, e14722.	0.8	1
1220	Overexpression of miR-20a-5p in Tumor Epithelium Is an Independent Negative Prognostic Indicator in Prostate Cancerâ€"A Multi-Institutional Study. Cancers, 2021, 13, 4096.	1.7	11
1221	Toward a Platform for Structured Data Acquisition in Oncology: A Pilot Study on Prostate Cancer Screening. Oncology, 2021, 99, 1-11.	0.9	1
1222	External validation of a prostate cancer nomogram on magnetic resonance/transrectal ultrasound fusion biopsy in men with prior negative systematic biopsy. International Journal of Clinical Practice, 2021, 75, e14654.	0.8	0
1223	Evaporationâ€Induced rGO Coatings for Highly Sensitive and Nonâ€Invasive Diagnosis of Prostate Cancer in the PSA Gray Zone. Advanced Materials, 2021, 33, e2103999.	11.1	18
1225	In prostatic transition zone lesions (PI-RADS v2.1): which subgroup should be biopsied?. Egyptian Journal of Radiology and Nuclear Medicine, 2021, 52, .	0.3	0
1226	The current recommendation for the management of isolated highâ€grade prostatic intraepithelial neoplasia. BJU International, 2022, 129, 627-633.	1.3	4
1227	Identification of Cancer Cell Stemness-Associated Long Noncoding RNAs for Predicting Prognosis of Patients with Hepatocellular Carcinoma. DNA and Cell Biology, 2021, 40, 1087-1100.	0.9	20
1228	Urbanâ€"Rural Differences in Clinical Characteristics of Prostate Cancer at Initial Diagnosis: A Single-Center Observational Study in Anhui Province, China. Frontiers in Oncology, 2021, 11, 704645.	1.3	1

#	ARTICLE	IF	CITATIONS
1229	Incidence of incidental cancer in transurethral resection of prostate specimens: a 10-year retrospective analysis. African Journal of Urology, 2021, 27, .	0.1	2
1230	Initial Prostate Health Index (phi) and phi density predicts future risk of clinically significant prostate cancer in men with initial negative prostate biopsy: a 6-year follow-up study. Prostate Cancer and Prostatic Diseases, 2021, , .	2.0	5
1231	Wherein is the concept of disease normative? From weak normativity to value-conscious naturalism. Medicine, Health Care and Philosophy, 2022, 25, 47-60.	0.9	6
1233	Whatâ€™s behind 68Ga-PSMA-11 uptake in primary prostate cancer PET? Investigation of histopathological parameters and immunohistochemical PSMA expression patterns. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 4042-4053.	3.3	47
1234	The visibility of prostate cancer concerning underlying histopathological variances: A single-center multiparametric magnetic resonance imaging study. European Journal of Radiology, 2021, 141, 109791.	1.2	4
1235	How accurate is 68Gallium-prostate specific membrane antigen positron emission tomography / computed tomography (68Ga-PSMA PET/CT) on primary lymph node staging before radical prostatectomy in intermediate and high risk prostate cancer? A study of patient- and lymph node- based analyses. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 6.e1-6.e9.	0.8	4
1236	Prostate Cancer in Older Adults: Risk of Clinically Meaningful Disease, the Role of Screening and Special Considerations. Current Oncology Reports, 2021, 23, 130.	1.8	4
1237	Multicentre, prospective study on local treatment of metastatic prostate cancer (LoMP study). BJU International, 2022, 129, 699-707.	1.3	19
1238	Results from a PI-RADS-based MRI-directed diagnostic pathway for biopsy-naive patients in a non-university hospital. Abdominal Radiology, 2021, 46, 5639-5646.	1.0	2
1239	Role of prostate health index to predict Gleason score upgrading and high-risk prostate cancer in radical prostatectomy specimens. Scientific Reports, 2021, 11, 17447.	1.6	3
1240	Which Prostate Biopsy in Men Enrolled in Active Surveillance? Experience in 110 Men Submitted to Scheduled Three-Years Transperineal Saturation Biopsy Combined With Fusion Targeted Cores. Clinical Genitourinary Cancer, 2021, 19, 305-308.	0.9	9
1241	The Percentage of [â^2]Proâ€"Prostate-Specific Antigen and the Prostate Health Index Outperform Prostate-Specific Antigen and the Percentage of Free Prostate-Specific Antigen in the Detection of Clinically Significant Prostate Cancer and Can Be Used as Reflex Tests. Archives of Pathology and Laboratory Medicine, 2021, , .	1.2	6
1242	Pathology grade influences competing mortality risks in elderly men with prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 493.e1-493.e7.	0.8	0
1243	PTEN and DNA Ploidy Status by Machine Learning in Prostate Cancer. Cancers, 2021, 13, 4291.	1.7	4
1244	Expression and subcellular localization of Discoidin Domain Receptor 1 (DDR1) define prostate cancer aggressiveness. Cancer Cell International, 2021, 21, 507.	1.8	8
1245	Prognostic value of cribriform size, percentage, and intraductal carcinoma in Gleason score 7 prostate cancer with cribriform Gleason pattern 4. Human Pathology, 2021, 118, 18-29.	1.1	9
1246	The clinical significance of circulating miR-21, miR-142, miR-143, and miR-146a in patients with prostate cancer. Journal of Medical Biochemistry, 2022, 41, 191-198.	0.7	3
1247	Analysis of risk factors for Gleason score upgrading after radical prostatectomy in a Chinese cohort. Cancer Medicine, 2021, 10, 7772-7780.	1.3	10

#	ARTICLE	IF	CITATIONS
1248	Survival trends for patients with primary metastatic prostate cancer before and after the introduction of new antitumor drugs. Prostate Cancer and Prostatic Diseases, 2023, 26, 53-58.	2.0	7
1249	Incidental prostate cancer after transurethral resection of the prostate: analysis of incidence and risk factors in 458 patients. Minerva Urology and Nephrology, 2021, 73, 471-480.	1.3	5
1250	MRI-Targeted or Standard Biopsy in Prostate Cancer Screening. New England Journal of Medicine, 2021, 385, 908-920.	13.9	184
1251	Angiogenesis and Anti-Angiogenic Treatment in Prostate Cancer: Mechanisms of Action and Molecular Targets. International Journal of Molecular Sciences, 2021, 22, 9926.	1.8	47
1252	Clinical impact of ultra-high b-value (3000 s/mm^2) diffusion-weighted magnetic resonance imaging in prostate cancer at 3T: comparison with b-value of 2000 s/mm^2. British Journal of Radiology, 2022, 95, 20210465.	1.0	2
1253	Absolute choline tissue concentration mapping for prostate cancer localization and characterization using 3D 1 H MRSI without water€signal suppression. Magnetic Resonance in Medicine, 2022, 87, 561-573.	1.9	5
1254	Prostate Health Index and Multiparametric MRI: Partners in Crime Fighting Overdiagnosis and Overtreatment in Prostate Cancer. Cancers, 2021, 13, 4723.	1.7	32
1255	A Hybrid Human–Machine Learning Approach for Screening Prostate Biopsies Can Improve Clinical Efficiency Without Compromising Diagnostic Accuracy. Archives of Pathology and Laboratory Medicine, 2022, 146, 727-734.	1.2	4
1256	Contemporary update of SPECT tracers and novelties in radioguided surgery: a perspective based on urology. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2021, 65, 215-228.	0.4	3
1257	High-throughput proteomics and AI for cancer biomarker discovery. Advanced Drug Delivery Reviews, 2021, 176, 113844.	6.6	54
1258	Differences in sex hormone recovery profile after cessation of 12€week gonadotropin€releasing hormone antagonist versus agonist therapy. Andrology, 2021, , .	1.9	2
1259	PTEN expression and morphological patterns in prostatic adenocarcinoma. Histopathology, 2021, 79, 1061-1071.	1.6	10
1260	Optimizing Spatial Biopsy Sampling for the Detection of Prostate Cancer. Journal of Urology, 2021, 206, 595-603.	0.2	19
1261	Comparison of enhanced recovery after surgery protocol and conventional approach after laparoscopic transperitoneal radical prostatectomy: a retrospective analysis. African Journal of Urology, 2021, 27, .	0.1	1
1262	Short Androgen Suppression and Radiation Dose Escalation in Prostate Cancer: 12-Year Results of EORTC Trial 22991 in Patients With Localized Intermediate-Risk Disease. Journal of Clinical Oncology, 2021, 39, 3022-3033.	0.8	24
1263	Health-related quality of life in men with localized prostate cancer treated with radiotherapy: validation of an abbreviated version of the Expanded Prostate Cancer Index Composite for Clinical Practice in Spain. Health and Quality of Life Outcomes, 2021, 19, 223.	1.0	1
1264	Proteomic Landscape of Prostate Cancer: The View Provided by Quantitative Proteomics, Integrative Analyses, and Protein Interactomes. Cancers, 2021, 13, 4829.	1.7	9
1265	The prostate health index (PHI) density: Are there advantages over PHI or over the prostate-specific antigen density?. Clinica Chimica Acta, 2021, 520, 133-138.	0.5	10

#	ARTICLE	IF	CITATIONS
1266	Combination MRI-targeted and systematic prostate biopsy may overestimate gleason grade on final surgical pathology and impact risk stratification. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 59.e1-59.e5.	0.8	7
1267	Non-invasive Urine Test for Molecular Classification of Clinical Significance in Newly Diagnosed Prostate Cancer Patients. Frontiers in Medicine, 2021, 8, 721554.	1.2	0
1268	High Inter- and Intratumoral Variability of Ki67 Labeling Index in Newly Diagnosed Prostate Cancer with High Gleason Scores. Pathobiology, 2022, 89, 74-80.	1.9	4
1269	Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial. Lancet Oncology, The, 2021, 22, 1240-1249.	5.1	83
1270	Endogenous testosterone density predicts unfavorable disease at final pathology in intermediate risk prostate cancer. International Urology and Nephrology, 2021, 53, 2517-2526.	0.6	3
1271	Multiparametric Magnetic Resonance Imaging-Ultrasound Fusion Transperineal Prostate Biopsy: Diagnostic Accuracy from a Single Center Retrospective Study. Cancers, 2021, 13, 4833.	1.7	4
1272	Diagnostic outcomes from transrectal and transperineal prostate biopsies â€" experiences from a Swedish tertiary care Centre. Scandinavian Journal of Urology, 2021, 55, 434-440.	0.6	2
1273	A 25 year perspective on advances in the pathologic assessment and diagnosis of urologic cancers. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 582-594.	0.8	4
1274	Utility of PSA Density in Predicting Upgraded Gleason Score in Men on Active Surveillance With Negative MRI. Urology, 2021, 155, 96-100.	0.5	7
1275	Systematic biopsy should not be omitted in the era of combined magnetic resonance imaging/ultrasound fusion-guided biopsies of the prostate. International Urology and Nephrology, 2021, 53, 2251-2259.	0.6	3
1276	The Microultrasound-Guided Prostate Biopsy in Detection of Prostate Cancer: A Systematic Review and Meta-Analysis. Journal of Endourology, 2022, 36, 394-402.	1.1	9
1277	Serum Levels of the Cytokine TWEAK Are Associated with Metabolic Status in Patients with Prostate Cancer and Modulate Cancer Cell Lipid Metabolism In Vitro. Cancers, 2021, 13, 4688.	1.7	2
1278	Semi-supervised training of deep convolutional neural networks with heterogeneous data and few local annotations: An experiment on prostate histopathology image classification. Medical Image Analysis, 2021, 73, 102165.	7.0	30
1279	Artificial Intelligenceâ€"assisted Prostate Cancer Diagnosis: Radiologic-Pathologic Correlation. Radiographics, 2021, 41, 1676-1697.	1.4	17
1280	A Fully Automatic Artificial Intelligence System Able to Detect and Characterize Prostate Cancer Using Multiparametric MRI: Multicenter and Multi-Scanner Validation. Frontiers in Oncology, 2021, 11, 718155.	1.3	16
1281	Diagnostic Yield of Incremental Biopsy Cores and Second Lesion Sampling for In-Gantry MRI-Guided Prostate Biopsy. American Journal of Roentgenology, 2021, 217, 908-918.	1.0	6
1282	End-to-end prostate cancer detection in bpMRI via 3D CNNs: Effects of attention mechanisms, clinical priori and decoupled false positive reduction. Medical Image Analysis, 2021, 73, 102155.	7.0	74
1283	Transperineal multiparametric magnetic resonance imaging-ultrasound fusionâ€"targeted prostate biopsy combined with standard template improves perineural invasion detection. Human Pathology, 2021, 117, 101-107.	1.1	4

#	ARTICLE	IF	CITATIONS
1284	Quantitative diffusion-weighted imaging and dynamic contrast-enhanced MR imaging for assessment of tumor aggressiveness in prostate cancer at 3T. Magnetic Resonance Imaging, 2021, 83, 152-159.	1.0	7
1285	Which measurement method should be used for prostate volume for PI-RADS? A comparison of ellipsoid and segmentation methods. Clinical Imaging, 2021, 80, 454-458.	0.8	9
1286	Editorial Comment to Benefits and harms of the new prostate cancer grade grouping on the prediction of longâ€term oncological outcomes in patients after radical prostatectomy. International Journal of Urology, 2021, 28, 396-396.	0.5	0
1288	Prostate specific membrane antigen-radio guided surgery using Cerenkov luminescence imagingâ€"utilization of a short-pass filter to reduce technical pitfalls. Translational Andrology and Urology, 2021, 10, 3972-3985.	0.6	4
1289	Bioptic prostatic inflammation correlates with false positive rates of multiparametric magnetic resonance imaging in detecting clinically significant prostate cancer. Central European Journal of Urology, 2021, 74, 308-314.	0.2	0
1290	Analysis of the usefulness of magnetic resonance imaging and clinical parameters in the detection of prostate cancer in the first systematic biopsy combined with targeted cognitive biopsy. Central European Journal of Urology, 2021, 74, 321-326.	0.2	1
1291	Establishment and prospective validation of an SUV_{max} cutoff value to discriminate clinically significant prostate cancer from benign prostate diseases in patients with suspected prostate cancer by ^{68}Ga-PSMA PET/CT: a real-world study. Theranostics, 2021, 11, 8396-8411.	4.6	24
1292	Diagnostic utility of a-methylacyl COA racemase in prostate cancer of the Iranian population. Journal of Research in Medical Sciences, 2021, 26, 46.	0.4	0
1293	Liquid Biopsy-Based Exo-oncomiRNAs Can Predict Prostate Cancer Aggressiveness. Cancers, 2021, 13, 250.	1.7	23
1294	Prostate Cancer Prevention. , 2019, , 607-628.		1
1296	Pathology of Prostate Cancer. , 2018, , 47-52.		1
1297	Endogenous testosterone mirrors prostate cancer aggressiveness: correlation between basal testosterone serum levels and prostate cancer European Urology Association clinical risk classes in a large cohort of Caucasian patients. International Urology and Nephrology, 2020, 52, 1261-1269.	0.6	10
1298	PSMA-PET and micro-ultrasound potential in the diagnostic pathway of prostate cancer. Clinical and Translational Oncology, 2021, 23, 172-178.	1.2	16
1301	Spatial maps of prostate cancer transcriptomes reveal an unexplored landscape of heterogeneity. Nature Communications, 2018, 9, 2419.	5.8	374
1302	Postoperative change in Gleason score of prostate cancer in fusion targeted biopsy: a matched pair analysis. Scandinavian Journal of Urology, 2021, 55, 27-32.	0.6	4
1303	Hemigland Cryoablation of Localized Low, Intermediate and High Risk Prostate Cancer: Oncologic and Functional Outcomes at 5 Years. Journal of Urology, 2019, 202, 1188-1198.	0.2	47
1304	High Intensity Focused Ultrasound Hemigland Ablation for Prostate Cancer: Initial Outcomes of a United States Series. Journal of Urology, 2020, 204, 741-747.	0.2	43
1305	Identification and evaluation of clinically significant prostate cancer. Current Opinion in Urology, 2017, 27, 217-224.	0.9	8

#	Article	IF	Citations
1306	Similarities and Differences in the 2019 ISUP and GUPS Recommendations on Prostate Cancer Grading: A Guide for Practicing Pathologists. Advances in Anatomic Pathology, 2021, 28, 1-7.	2.4	18
1308	Identification of novel oncogenic events occurring early in prostate carcinogenesis using purified autologous malignant and nonâ€malignant prostate epithelial cells. BJU International, 2019, 123, 27-35.	1.3	1
1309	Value of extraâ€target prostate biopsy for the detection of magnetic resonance imagingâ€missed adverse pathology according to the Prostate Imaging Reporting and Data System scores: Spatial analysis using magnetic resonanceâ€"ultrasound fusion images. International Journal of Urology, 2020, 27, 760-766.	0.5	4
1310	Optimized b-value selection for the discrimination of prostate cancer grades, including the cribriform pattern, using diffusion weighted imaging. Journal of Medical Imaging, 2017, 5, 1.	0.8	30
1311	PROSTATEx Challenges for computerized classification of prostate lesions from multiparametric magnetic resonance images. Journal of Medical Imaging, 2018, 5, 1.	0.8	98
1312	Radio-pathomic mapping model generated using annotations from five pathologists reliably distinguishes high-grade prostate cancer. Journal of Medical Imaging, 2020, 7, 054501.	0.8	15
1313	Transcriptomic heterogeneity in multifocal prostate cancer. JCI Insight, 2018, 3, .	2.3	71
1314	Voxel-based comparison of [68Ga]Ga-RM2-PET/CT and [68Ga]Ga-PSMA-11-PET/CT with histopathology for diagnosis of primary prostate cancer. EJNMMI Research, 2020, 10, 62.	1.1	23
1315	Evaluating Prostate Cancer Using Fractional Tissue Composition of Radical Prostatectomy Specimens and Pre-Operative Diffusional Kurtosis Magnetic Resonance Imaging. PLoS ONE, 2016, 11, e0159652.	1.1	24
1316	Automated analysis of co-localized protein expression in histologic sections of prostate cancer. PLoS ONE, 2017, 12, e0178362.	1.1	4
1317	Diagnostic value and relative weight of sequence-specific magnetic resonance features in characterizing clinically significant prostate cancers. PLoS ONE, 2017, 12, e0178901.	1.1	5
1318	Heterogeneity of miRNA expression in localized prostate cancer with clinicopathological correlations. PLoS ONE, 2017, 12, e0179113.	1.1	20
1319	Evaluation of the proliferation marker Ki-67 in a large prostatectomy cohort. PLoS ONE, 2017, 12, e0186852.	1.1	39
1320	Assessment of the prognostic value of the 8th AJCC staging system for patients with clinically staged prostate cancer; A time to sub-classify stage IV?. PLoS ONE, 2017, 12, e0188450.	1.1	15
1321	Expression of phosphatase of regenerating liver (PRL)-3, is independently associated with biochemical failure, clinical failure and death in prostate cancer. PLoS ONE, 2017, 12, e0189000.	1.1	2
1322	Transrectal ultrasound-guided prostate biopsy versus combined magnetic resonance imaging-ultrasound fusion and systematic biopsy for prostate cancer detection in routine clinical practice. Ultrasonography, 2020, 39, 137-143.	1.0	4
1323	Association of polymorphisms of PTEN, AKT1, PI3K, AR, and AMACR genes in patients with prostate cancer. Genetics and Molecular Biology, 2020, 43, e20180329.	0.6	11
1325	Oncological results of neoadjuvant chemohormonal therapy in patients with high and very high-risk prostate cancer. Onkourologiya, 2020, 16, 54-63.	0.1	2

#	Article	IF	Citations
1326	Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer. Oncotarget, 2016, 7, 64447-64470.	0.8	130
1327	Reduced Connexin 43 expression is associated with tumor malignant behaviors and biochemical recurrence-free survival of prostate cancer. Oncotarget, 2016, 7, 67476-67484.	0.8	22
1328	Prostate-specific membrane antigen (PSMA) assembles a macromolecular complex regulating growth and survival of prostate cancer cells â€œ<i>in vitro</i>â€•and correlating with progression â€œ<i>in vivo</i>â€• Oncotarget, 2016, 7, 74189-74202.	0.8	21
1329	Understanding PSA and its derivatives in prediction of tumor volume: addressing health disparities in prostate cancer risk stratification. Oncotarget, 2017, 8, 20802-20812.	0.8	11
1330	Gene polymorphisms in the PI3K/AKT/mTOR signaling pathway contribute to prostate cancer susceptibility in Chinese men. Oncotarget, 2017, 8, 61305-61317.	0.8	11
1331	Decreased expression of <i>MT1E</i> is a potential biomarker of prostate cancer progression. Oncotarget, 2017, 8, 61709-61718.	0.8	17
1332	A new metabolic gene signature in prostate cancer regulated by JMJD3 and EZH2. Oncotarget, 2018, 9, 23413-23425.	0.8	27
1333	Increased HSF1 expression predicts shorter disease-specific survival of prostate cancer patients following radical prostatectomy. Oncotarget, 2018, 9, 31200-31213.	0.8	19
1334	Nuclear ELAC2 overexpression is associated with increased hazard for relapse after radical prostatectomy. Oncotarget, 2019, 10, 4973-4986.	0.8	5
1335	Novel diagnostic and prognostic classifiers for prostate cancer identified by genome-wide microRNA profiling. Oncotarget, 2016, 7, 30760-30771.	0.8	70
1336	Gene-expression analysis of gleason grade 3 tumor glands embedded in low- and high-risk prostate cancer. Oncotarget, 2016, 7, 37846-37856.	0.8	14
1337	Can active surveillance really reduce the harms of overdiagnosing prostate cancer? A reflection of real life clinical practice in the PRIAS study. Translational Andrology and Urology, 2018, 7, 98-105.	0.6	24
1338	Effects of androgen deprivation therapy duration and Gleason grade on survival outcomes of high risk prostate cancer. Translational Cancer Research, 2019, 8, 715-718.	0.4	1
1339	Serum Testosterone Level Can Be Predictive Factor for Upstaging in Clinically Localized Prostate Cancer. The Korean Journal of Urological Oncology, 2020, 18, 116-123.	0.1	1
1340	Role of Holmium laser enucleation of the prostate to increase cancer detection rate in patients with gray-zone PSA level. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2019, 71, 72-78.	3.9	7
1341	Extended pelvic lymphadenectomy for prostate cancer: should the Cloquet's nodes dissection be considered only an option?. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2019, 71, 136-145.	3.9	27
1343	Open approach, extended pelvic lymph node dissection, and seminal vesicle invasion are independent predictors of hospital readmission after prostate cancer surgery: a large retrospective study. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2020, 72, 72-81.	3.9	9
1344	Performance of prostate multiparametric MRI for prediction of prostate cancer extra-prostatic extension according to NCCN risk categories: implication for surgical planning. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2020, 72, 746-754.	3.9	18

#	Article	IF	Citations
1345	⁶⁸Ga-PSMA PET/CT for Primary Lymph Node and Distant Metastasis NM Staging of High-Risk Prostate Cancer. Journal of Nuclear Medicine, 2021, 62, 214-220.	2.8	64
1346	Prostatic Adenocarcinoma: A Grading from Gleason to the New Grade-Group System: A Historical and Critical Review. Asian Pacific Journal of Cancer Prevention, 2019, 20, 661-666.	0.5	16
1347	Partial ablation versus radical prostatectomy in intermediate-risk prostate cancer: the PART feasibility RCT. Health Technology Assessment, 2018, 22, 1-96.	1.3	33
1348	TERF1 downregulation promotes the migration and invasion of the PC3 prostate cancer cell line as a target of miRâ€'155. Molecular Medicine Reports, 2020, 22, 5209-5218.	1.1	9
1349	Altered expression of lncRNA NCK1â€'AS1 distinguished patients with prostate cancer from those with benign prostatic hyperplasia. Oncology Letters, 2019, 18, 6379-6384.	0.8	8
1350	ZNF24 is upregulated in prostate cancer and facilitates the epithelialâ€'toâ€'mesenchymal transition through the regulation of Twist1. Oncology Letters, 2020, 19, 3593-3601.	0.8	8
1351	Diagnostic performance of a nomogram incorporating cribriform morphology for the prediction of adverse pathology in prostate cancer at radical prostatectomy. Oncology Letters, 2020, 20, 2797-2805.	0.8	4
1352	Altered expression of microRNAâ€'92bâ€'3p predicts survival outcomes of patients with prostate cancer and functions as an oncogene in tumor progression. Oncology Letters, 2020, 21, 1-1.	0.8	15
1353	The evolving Gleason grading system. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2016, 28, 58-64.	0.7	42
1354	Predictive efficacy of the 2014 International Society of Urological Pathology Gleason grading system in initially diagnosed metastatic prostate cancer. Asian Journal of Andrology, 2017, 19, 573.	0.8	3
1355	Reporting Gleason grade/score in synoptic reports of radical prostatectomies. Journal of Pathology Informatics, 2016, 7, 54.	0.8	10
1356	Intraductal carcinoma of the prostate in prostate biopsy samples: correlation with aggressive pathological features after radical prostatectomy and prognostic value in high-risk prostate cancer. Asian Journal of Andrology, 2020, 22, 519.	0.8	13
1357	The performance of the new prognostic grade and stage groups in conservatively treated prostate cancer. Asian Journal of Andrology, 2018, 20, 366.	0.8	2
1358	High body mass index predicts multiple prostate cancer lymph node metastases after radical prostatectomy and extended pelvic lymph node dissection. Asian Journal of Andrology, 2020, 22, 323.	0.8	32
1359	Next Generation Quality: Assessing the Physician in Clinical History Completeness and Diagnostic Interpretations Using Funnel Plots and Normalized Deviations Plots in 3,854 Prostate Biopsies. Journal of Pathology Informatics, 2017, 8, 43.	0.8	7
1360	Incidence of metastasis and prostate-specific antigen levels at diagnosis in Gleason 3+4 versus 4+3 prostate cancer. Urology Annals, 2018, 10, 203.	0.3	14
1361	Validation of the WHO 2016 new Gleason score of prostatic carcinoma. Urology Annals, 2018, 10, 324.	0.3	7
1362	BRCA1-associated protein 1 expression and prognostic role in prostate adenocarcinoma. Investigative and Clinical Urology, 2020, 61, 166.	1.0	2

#	ARTICLE	IF	CITATIONS
1363	Long-term oncologic outcomes after radical prostatectomy in clinically localized prostate cancer: 10-year follow-up in Korea. Investigative and Clinical Urology, 2020, 61, 269.	1.0	7
1364	Complementing the active surveillance criteria with multiparametric magnetic resonance imaging. Investigative and Clinical Urology, 2020, 61, 573.	1.0	2
1365	Automated Gleason grading of prostate cancer using transfer learning from general-purpose deep-learning networks. Romanian Journal of Morphology and Embryology, 2020, 61, 149-155.	0.4	11
1366	Agreement of two pre-trained deep-learning neural networks built with transfer learning with six pathologists on 6000 patches of prostate cancer from Gleason2019 Challenge. Romanian Journal of Morphology and Embryology, 2020, 61, 513-519.	0.4	10
1367	The factors predicting upgrading of prostate cancer by using International Society for Urological Pathology (ISUP) 2014 Gleason grading system. Turkish Journal of Urology, 2019, 45, 36-41.	1.3	5
1368	Multiparametric MRI fusion-guided prostate biopsy in biopsy naive patients: Preliminary results from 80 patients. Turkish Journal of Urology, 2019, 45, 196-201.	1.3	7
1369	A multiparametric magnetic resonance imaging-based virtual reality surgical navigation tool for robotic-assisted radical prostatectomy. Turkish Journal of Urology, 2019, 45, 357-365.	1.3	18
1370	Initial Evaluation of Rapid, Direct-to-Digital Prostate Biopsy Pathology. Archives of Pathology and Laboratory Medicine, 2021, 145, 583-591.	1.2	8
1371	Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 479-505.	2.3	943
1372	Quality Measurement in Cancer Care: A Review and Endorsement of High-Impact Measures and Concepts. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 250-259.	2.3	17
1373	Radiologist-like artificial intelligence for grade group prediction of radical prostatectomy for reducing upgrading and downgrading from biopsy. Theranostics, 2020, 10, 10200-10212.	4.6	22
1374	Prostate Cancer: Locoregional Disease. UNIPA Springer Series, 2021, , 791-803.	0.1	0
1375	Clinical Outcomes of Hydrogel Spacer Injection Space OAR in Men Submitted to Hypofractionated Radiotherapy for Prostate Cancer. In Vivo, 2021, 35, 3385-3389.	0.6	6
1376	Prostate Magnetic Resonance Imaging Analyses, Clinical Parameters, and Preoperative Nomograms in the Prediction of Extraprostatic Extension. Clinics and Practice, 2021, 11, 763-775.	0.6	2
1378	Improving the prediction of biochemical recurrence after radical prostatectomy with the addition of detailed pathology of the positive surgical margin and cribriform growth. Annals of Diagnostic Pathology, 2022, 56, 151842.	0.6	3
1379	Transperineal prostate biopsy identifies locations of clinically significant prostate cancer in men considering focal therapy with PIâ€RADS 3â€"5 regions of interest. BJUI Compass, 2021, 2, 395-401.	0.7	2
1380	A Prospective Study and Single Center Experience: Effectivity of Fusion Prostate Biopsy in Biopsy-NaÃ¯ve Patients. Cureus, 2021, 13, e19002.	0.2	0
1381	Semen as a rich source of diagnostic biomarkers for prostate cancer: latest evidence and implications. Molecular and Cellular Biochemistry, 2022, 477, 213-223.	1.4	0

#	ARTICLE	IF	CITATIONS
1382	The Role of PSA Density among PI-RADS v2.1 Categories to Avoid an Unnecessary Transition Zone Biopsy in Patients with PSA 4-20â€‰ng/mL. BioMed Research International, 2021, 2021, 1-10.	0.9	8
1383	Ratio of the expression levels of androgen receptor splice variant 7 to androgen receptor in castration refractory prostate cancer. Oncology Letters, 2021, 22, 831.	0.8	3
1384	Multiphoton Microscopy for Identifying Collagen Signatures Associated with Biochemical Recurrence in Prostate Cancer Patients. Journal of Personalized Medicine, 2021, 11, 1061.	1.1	7
1385	Relationship between socioeconomic status and prostate cancer (incidence, aggressiveness, treatment) Tj ETQq1 1 0.784314 rgBT /O Revue D'Epidemiologie Et De Sante Publique, 2021, 69, 329-336.	0.3	2
1386	A Deep Learning Pipeline for Grade Groups Classification Using Digitized Prostate Biopsy Specimens. Sensors, 2021, 21, 6708.	2.1	11
1387	Prostate zones and cancer: lost in transition?. Nature Reviews Urology, 2022, 19, 101-115.	1.9	25
1388	Gland context networks: a novel approach for improving prostate cancer identification. Computerized Medical Imaging and Graphics, 2021, 94, 101999.	3.5	0
1389	Common Diagnostic Challenges and Pitfalls in Genitourinary Organs, With Emphasis on Immunohistochemical and Molecular Updates. Archives of Pathology and Laboratory Medicine, 2021, 145, 1387-1404.	1.2	2
1391	Anaesthesia in PROstate Biopsy Pain Obstruction Study: A Study Protocol for a Multicentre Randomised Controlled Study Evaluating the Efficacy of Perineal Nerve Block in Controlling Pain in Patients Undergoing Transperineal Prostate Biopsy. Frontiers in Surgery, 2021, 8, 649822.	0.6	2
1392	Single-center versus multi-center biparametric MRI radiomics approach for clinically significant peripheral zone prostate cancer. Insights Into Imaging, 2021, 12, 150.	1.6	15
1393	A novel 5x multiplex immunohistochemical staining reveals PSMA as a helpful marker in prostate cancer with low p504s expression.. Pathology Research and Practice, 2021, 228, 153667.	1.0	5
1394	Performance Characteristics of 3-D Power Doppler Ultrasound (3-D-PD) with the Virtual Organ Computer-Aided Analysis (VOCAL) Technique in the Detection of Prostate Cancer. Ultrasound in Medicine and Biology, 2021, 48, 91-97.	0.7	1
1395	Magnetic resonance elastography of the prostate in patients with lower urinary tract symptoms: feasibility of the modified driver at high multi-frequencies. Abdominal Radiology, 2022, 47, 399-408.	1.0	1
1398	Prostate. , 2016, , 1751-1788.		0
1399	Acinar Adenocarcinoma. , 2016, , 608-625.		0
1401	Why do we keep reporting high-grade prostatic intraepithelial neoplasia (HGPIN)?. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2016, 42, 180-182.	0.7	0
1402	Anatomo-pathology. , 2017, , 57-75.		0
1403	Pathologic Assessment and Implications Following Focal Therapy of Prostate Cancer. Current Clinical Urology, 2017, , 417-429.	0.0	0

#	ARTICLE	IF	CITATIONS
1404	Prostate Cancer Risk Grouping and Selection Criteria Based on Radiation Oncology Perspective. , 2017, , 191-204.		0
1405	Prostate. , 2017, , 337-352.		0
1406	Low-Risk Prostate Cancer in North America: Rationale, Uptake, and Limitations of Active Surveillance and Opportunities for Focal Therapy. Current Clinical Urology, 2017, , 51-56.	0.0	0
1408	Risk-Based Selection for Active Surveillance. Current Clinical Urology, 2018, , 53-64.	0.0	0
1409	Prostatakarzinom beim alten und geriatrischen Patienten. , 2018, , 1-8.		0
1410	Can MRI Replace Biopsy in Men on Surveillance?. Current Clinical Urology, 2018, , 111-119.	0.0	0
1411	Outcomes of Active Surveillance in Localized Prostate Cancer. The Korean Journal of Urological Oncology, 2017, 15, 93-102.	0.1	0
1413	Biochemical Recurrence After Radiation Therapy. , 2018, , 101-119.		0
1414	Prostatakarzinom beim alten und geriatrischen Patienten. , 2018, , 473-480.		0
1415	Adjuvant Radiation Therapy for High-Risk Post-prostatectomy Patients. , 2018, , 81-99.		0
1416	Prostate Cancer: Management in Elderly Men Population in 2017. , 2018, , 1-16.		0
1417	Mucinous adenocarcinoma of the prostate: case report and review of the literature. International Clinical Pathology Journal, 2018, 6, .	0.1	0
1418	Prognostic implications of ERG, PTEN, and fatty acid synthase expression in localized prostate cancer. Egyptian Journal of Pathology, 2018, 38, 162-168.	0.0	0
1419	The current status of renal cell carcinoma and prostate carcinoma grading. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2018, 44, 1057-1062.	0.7	1
1420	Molecular Pathology of Genitourinary Cancers: Translating the Cancer Genome to theÂClinic. , 2019, , 419-443.		0
1422	Cribriform Pattern at the Surgical Margin is Highly Predictive of Biochemical Recurrence in Patients Undergoing Radical Prostatectomy. Kosin Medical Journal, 2019, 34, 95.	0.1	1
1423	Dual-view Inverted Selective Plane Illumination Microscopy for Accurate 3D Digital Pathology on Large Specimens. , 2019, , .		0
1424	Contemporary grading of prostate cancer: 2017 update for pathologists and clinicians. Asian Journal of Andrology, 2019, 21, 19.	0.8	2

#	ARTICLE	IF	CITATIONS
1427	Intraductal Carcinoma of Prostate (IDC-P), Grade Group, and Molecular Pathology: Recent Advances and Practical Implication. Annals of Urologic Oncology, 2019, , 1-10.	0.0	0
1431	Characterization of different ozonized sunflower oils II. Triacylglycerol condensation and physical properties. Grasas Y Aceites, 2019, 70, 330.	0.3	1
1435	Clinical implications of prostatic capsular abutment or bulging on multiparametric magnetic resonance imaging. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2019, 71, 502-507.	3.9	6
1436	Expression differences between proteins responsible for DNA damage repair according to the Gleason grade as a new heterogeneity marker in prostate cancer. Archives of Medical Science, 2023, 19, 499-506.	0.4	1
1438	A Single-center Experience: Does MRI-guided Target Prostate Biopsy Meet Expectations?. Cureus, 2019, 11, e6160.	0.2	0
1440	Prostate Cancer: Management in Elderly Men Population in 2017. , 2020, , 655-670.		0
1441	Multi-scale tissue architecture analysis of favorable-risk prostate cancer: Correlation with biochemical recurrence. Investigative and Clinical Urology, 2020, 61, 482.	1.0	2
1442	Use of artificial intelligence in the diagnosis and treatment of prostate cancer. Indian Journal of Health Sciences and Biomedical Research KLEU, 2020, 13, 1.	0.1	1
1444	The auxiliary diagnostic value of prostate‐specific antigen and α‐methylacyl‐CoA racemase in prostate cancer. Oncology Letters, 2020, 20, 1418-1422.	0.8	1
1445	Developing Pathology Measures for the Quality Payment Program—Part I: A Quest for Meaningful Measures. Archives of Pathology and Laboratory Medicine, 2020, 144, 686-696.	1.2	2
1446	Optimizing size thresholds for detection of clinically significant prostate cancer on MRI: Peripheral zone cancers are smaller and more predictable than transition zone tumors. European Journal of Radiology, 2020, 129, 109071.	1.2	2
1447	Comparison of Gleason scoring and the new Grade-Group System in prostate cancers: a 15-year retrospective study. Journal of Health Sciences and Medicine, 0, , .	0.0	0
1448	The impact of receptor of advanced glycation end‐products polymorphisms on prostate cancer progression and clinicopathological characteristics. Journal of Cellular and Molecular Medicine, 2021, 25, 10761-10769.	1.6	6
1449	Contemporary Grading of Prostate Cancer: The Impact of Grading Criteria and the Significance of the Amount of Intraductal Carcinoma. Cancers, 2021, 13, 5454.	1.7	6
1450	Significant Inter- and Intralaboratory Variation in Gleason Grading of Prostate Cancer: A Nationwide Study of 35,258 Patients in The Netherlands. Cancers, 2021, 13, 5378.	1.7	12
1451	Assessing the diagnostic performance of systematic freehand precisionpoint transperineal prostate biopsy: Comparison of observed outcomes to PBCG nomogram predictions. Urologic Oncology: Seminars and Original Investigations, 2021, 40, 4.e9-4.e17.	0.8	0
1452	Prostate Cancer Aggressiveness Prediction Using CT Images. Life, 2021, 11, 1164.	1.1	5
1453	Prospective analysis of clinically significant prostate cancer detection with [18F]DCFPyL PET/MRI compared to multiparametric MRI: a comparison with the histopathology in the radical prostatectomy specimen, the ProStaPET study. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1731-1742.	3.3	13

#	ARTICLE	IF	CITATIONS
1454	ERG expression in prostate cancer: diagnostic significance and histopathological correlations. Egyptian Journal of Pathology, 2020, 40, 212.	0.0	0
1455	Immunoexpression of estrogen receptor-Î² and progesterone receptor in prostate adenocarcinoma, does it inhibit neoplastic proliferation and invasion?. Indian Journal of Pathology and Microbiology, 2020, 63, 30.	0.1	2
1456	External validation of the Gleason grade group system in Argentinian patients that underwent surgery for prostate cancer. Central European Journal of Urology, 2020, 73, 146-151.	0.2	1
1457	Semi-automated PIRADS scoring via mpMRI analysis. Journal of Medical Imaging, 2020, 7, 064501.	0.8	1
1458	Optimised architecture-based grading system as an independent prognostic factor in resected lung adenocarcinoma. Journal of Clinical Pathology, 2022, 75, 176-184.	1.0	1
1459	Association between prostate cancer characteristics and BRCA1/2-associated family cancer history in a Japanese cohort. PLoS ONE, 2020, 15, e0244149.	1.1	4
1460	Case Report: Prostate Adenocarcinoma With Mucinous Features of Normal-Level Serum PSA, Atypical Imaging, Biopsy-Negative, and Peculiar Urethrocystoscopic Manifestation. Frontiers in Oncology, 2020, 10, 504381.	1.3	2
1461	Should We Reconsider the Necessity of a Refinement of Prostate Cancer Risk Classification and Radiotherapy Treatment Strategy? Experiences from a Retrospective Analysis of Data from a Single Institution. Journal of Clinical Medicine, 2021, 10, 110.	1.0	0
1462	Predicting the risk of prostate cancer in asymptomatic men: a cohort study to develop and validate a novel algorithm. British Journal of General Practice, 2021, 71, e364-e371.	0.7	9
1463	Histopathological Ratios to Predict Gleason Score Agreement between Biopsy and Radical Prostatectomy. Diagnostics, 2021, 11, 10.	1.3	13
1464	Prostate Specific Membrane Antigen Based Imaging. , 2021, , 109-129.		0
1465	Hidden clues in prostate cancer â€" Lessons learned from clinical and pre-clinical approaches on diagnosis and risk stratification. Cancer Letters, 2022, 524, 182-192.	3.2	3
1466	Prostatakarzinom beim geriatrischen Patienten. , 2020, , 141-172.		0
1467	Obesity leads to a higher rate of positive surgical margins in the context of robot-assisted radical prostatectomy. Results of a prospective multicenter study. Central European Journal of Urology, 2020, 73, 457-465.	0.2	1
1468	Detecting and grading prostate cancer in radical prostatectomy specimens through deep learning techniques. Clinics, 2021, 76, e3198.	0.6	4
1469	Prostatic Acinar Adenocarcinoma. Encyclopedia of Pathology, 2020, , 1-4.	0.0	0
1470	Pathology of the Benign and Malignant Diseases of the Prostate. , 2020, , 1-12.		0
1471	Transurethral resection of the prostate is an independent risk factor for biochemical recurrence after radical prostatectomy for prostate cancer. Asian Journal of Andrology, 2020, 22, 217.	0.8	2

#	Article	IF	Citations
1472	Varianten des Prostatakarzinoms und weitere Entitäten. , 2020, , 115-158.		0
1473	Prostate Carcinoma. , 2020, , 377-393.		0
1474	Prostatic Acinar Adenocarcinoma. Encyclopedia of Pathology, 2020, , 307-310.	0.0	0
1475	A grading dilemma; Gleason scoring system: Are we sufficiently compatible? A multi center study. Indian Journal of Pathology and Microbiology, 2020, 63, 25.	0.1	5
1476	Expectations of Artificial Intelligence for Pathology. Lecture Notes in Computer Science, 2020, , 1-15.	1.0	3
1478	S179D Prolactin Sensitizes Human PC3 Prostate Cancer Xenografts to Anti-tumor Effects of Well-Tolerated Doses of Calcitriol. Journal of Cancer Science and Clinical Therapeutics, 2020, 04, 442-456.	0.2	0
1479	Aktuelles Grading und Befunderstellung. , 2020, , 105-113.		0
1480	Prostatakarzinom: Onkologische Kennzeichen. Springer Reference Medizin, 2020, , 1-18.	0.0	0
1481	Factors predicting pathological upgrading after prostatectomy in patients with Gleason grade group 1 prostate cancer based on opinion€matched biopsy specimens. Molecular and Clinical Oncology, 2020, 12, 384-389.	0.4	7
1482	Relation of Serum Prostate-Specific Antigen with Histological Features and Grading of Prostate Adenocarcinoma in Prostatic Biopsies. Indian Journal of Medical and Paediatric Oncology, 2020, 41, 193-197.	0.1	0
1483	Computer Aided Diagnosis of Clinically Significant Prostate Cancer in Low-Risk Patients on Multi-Parametric MR Images Using Deep Learning. , 2020, , .		4
1484	Comparison of prostate cancer detection rates in patients undergoing MRI/TRUS fusion prostate biopsy with two different software€based systems. Prostate, 2021, , .	1.2	5
1485	Urinary Volatiles and Chemical Characterisation for the Non-Invasive Detection of Prostate and Bladder Cancers. Biosensors, 2021, 11, 437.	2.3	22
1486	Outcome of 5-year follow-up in men with negative findings on initial biparametric MRI. Heliyon, 2021, 7, e08325.	1.4	4
1487	Targeting prostate cancer with Clostridium perfringens enterotoxin functionalized nanoparticles co-encapsulating imaging cargo enhances magnetic resonance imaging specificity. Nanomedicine: Nanotechnology, Biology, and Medicine, 2022, 40, 102477.	1.7	5
1488	Association of MyProstateScore (MPS) with prostate cancer grade in the radical prostatectomy specimen. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 4.e1-4.e7.	0.8	2
1489	Automatic cancer detection on digital histopathology images of mid-gland radical prostatectomy specimens. Journal of Medical Imaging, 2020, 7, 1.	0.8	2
1491	Long-term Oncologic Impact of Positive Anterior and Posterior Surgical Margins After Radical Prostatectomy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 872-879.	0.6	0

#	Article	IF	Citations
1492	Clinicopathologic Study of Gleason Pattern 5 Prostatic Adenocarcinoma With â€œSingle-cellâ€•Growth Reveals 2 Distinct Types, One With â€œPlasmacytoidâ€•Features. American Journal of Surgical Pathology, 2020, 44, 1635-1642.	2.1	1
1493	Active Surveillance of Prostate Cancer. Oncology, 2017, 31, 67-70.	0.4	7
1495	Prostate Cancer Pathology: Recent Updates and Controversies. Missouri Medicine, 2018, 115, 151-155.	0.3	18
1496	Histologic Changes in Prostate Cancer Detected Subsequent to the 2012 United States Preventive Services Task Force (USPSTF) Prostate Cancer Screening Recommendation. Reviews in Urology, 2018, 20, 125-130.	0.9	3
1497	The clinicopathologic significance of Notch3 expression in prostate cancer. International Journal of Clinical and Experimental Pathology, 2019, 12, 3535-3541.	0.5	3
1498	The loss of CD44 and HSP70 overexpression is related to aggressive clinicopathologic factors in prostate cancer. International Journal of Clinical and Experimental Pathology, 2018, 11, 5466-5472.	0.5	1
1499	Seminal plasma microRNAs improve diagnosis/prognosis of prostate cancer in men with moderately altered prostate-specific antigen. American Journal of Translational Research (discontinued), 2020, 12, 2041-2051.	0.0	6
1500	Morphological and functional alterations of the prostate tissue during clinical progression in hormonally-naÃ¯ve, hormonally-treated and castration-resistant patients with metastatic prostate cancer. Oncology Letters, 2020, 20, 201.	0.8	0
1501	The Role of Ga-68 PSMA PET/CT Scan on Differentiating of Oligometastatic and High Risk Prostate Cancer. Molecular Imaging and Radionuclide Therapy, 2020, 29, 98-104.	0.3	0
1502	Oncoxin-Viusid may improve quality of life and survival in patients with hormone-refractory prostate cancer undergoing onco-specific treatments. Molecular and Clinical Oncology, 2021, 14, 5.	0.4	2
1503	Prostate hyperplasia in St Mary's Hospital Lacor: utility of prostate specific antigen in screening for prostate malignancy. African Health Sciences, 2020, 20, 1259-1263.	0.3	0
1504	Diagnosis of "cribriform" prostatic adenocarcinoma: an interobserver reproducibility study among urologic pathologists with recommendations. American Journal of Cancer Research, 2021, 11, 3990-4001.	1.4	4
1505	Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 4: Transperineal Magnetic Resonanceâ€"Ultrasound Fusion Guided Biopsy Using Local Anesthesia. European Urology, 2022, 81, 110-117.	0.9	17
1506	How to read biparametric MRI in men with a clinical suspicious of prostate cancer: Pictorial review for beginners with public access to imaging, clinical and histopathological database. Acta Radiologica Open, 2021, 10, 205846012110607.	0.3	1
1507	A Polygenic Risk Score Predicts Incident Prostate Cancer Risk in Older Men but Does Not Select for Clinically Significant Disease. Cancers, 2021, 13, 5815.	1.7	7
1508	RADÄ°KAL SÄ°STOPROSTATEKTOMÄ° MATERYALÄ°NDE Ä°NSÄ°DENTAL PROSTAT KANSERÄ° SAPTANAN OLGULARIN KLÄ°NÄ°KOPATOLOJÄ°K Ã–ZELLÄ°KLERÄ°. UludaÄŸ Ãœniversitesi TÄ±p FakÃ¼ltesi Dergisi, 0, , .	0.2	0
1509	Proteomic Analysis Identifies NDUFS1 and ATP5O as Novel Markers for Survival Outcome in Prostate Cancer. Cancers, 2021, 13, 6036.	1.7	7
1510	Dose-escalated pelvic radiotherapy for prostate cancer in definitive or postoperative setting. Radiologia Medica, 2021, , 1.	4.7	6

#	ARTICLE	IF	CITATIONS
1511	RNA m6A Methylation Regulators Multi-Omics Analysis in Prostate Cancer. Frontiers in Genetics, 2021, 12, 768041.	1.1	10
1512	The impact of multiparametric MRI features to identify the presence of prevalent cribriform pattern in the peripheral zone tumors. Radiologia Medica, 2022, 127, 174-182.	4.7	3
1514	Neuroendocrine cells in prostate cancer correlate with poor outcomes: A systematic review and metaâ€analysis.. BJU International, 2021, , .	1.3	5
1515	Comparison of different thresholds of PSA density for risk stratification of PI-RADSv2.1 categories on prostate MRI. British Journal of Radiology, 2022, 95, 20210886.	1.0	12
1516	Predicting Cancer-Specific Survival Among Patients With Prostate Cancer After Radical Prostatectomy Based on the Competing Risk Model: Population-Based Study. Frontiers in Surgery, 2021, 8, 770169.	0.6	3
1517	A nationwide trend away from radical prostatectomy for Gleason grade group 1 prostate cancer. BJU International, 2021, , .	1.3	1
1518	Combining prostate health index and multiparametric magnetic resonance imaging in estimating the histological diameter of prostate cancer. BMC Urology, 2021, 21, 161.	0.6	5
1519	Diagnostic Performance of Ex Vivo Fluorescence Confocal Microscopy in the Assessment of Diagnostic Biopsies of the Prostate. Cancers, 2021, 13, 5685.	1.7	3
1520	An analysis of three different prostate cancer risk calculators applied prior to prostate biopsy: A Turkish cohort validation study. Andrologia, 2022, 54, e14329.	1.0	2
1521	Advanced glycation endâ€products (AGEs) are lower in prostate tumor tissue and inversely related to proportion of West African ancestry. Prostate, 2021, , .	1.2	1
1522	Cytological grading of prostate carcinoma: A comparative study with the international society of urologic pathology grading system. Acta Medica International, 2021, 8, 163.	0.2	1
1523	Definition of â€œTissue-Based Biomarker,â€•its Place in Medicine, and Molecular Pathology. , 2022, , 1-19.		0
1524	The Clinical Impact of pT3a Lesions in Patients With pT3b Prostate Cancer Undergoing Radical Prostatectomy. Archives of Pathology and Laboratory Medicine, 2022, 146, 619-625.	1.2	5
1525	Investigating the heterogeneity of viscoelastic properties in prostate cancer using MR elastography at 9.4T in fresh prostatectomy specimens. Magnetic Resonance Imaging, 2022, 87, 113-118.	1.0	4
1526	Diagnostic significance of reassessment of prostate biopsy specimens by experienced urological pathologists at a high-volume institution. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 979-987.	1.4	7
1527	Beurteilung des Prostatakarzinoms: Gleason-Score â€“ Status 2016. , 0, , .		0
1528	Papel y EvoluciÃ³n de la Resonancia MagnÃ©tica MultiparamÃ©trica en la DetecciÃ³n del CÃ¡ncer de PrÃ³stata. , 2020, 8, 1-6.		0
1529	Morphological and functional alterations of the prostate tissue during clinical progression in hormonallyâ€naïve, hormonallyâ€treated and castrationâ€resistant patients with metastatic prostate cancer. Oncology Letters, 2020, 20, 1-1.	0.8	2

#	ARTICLE	IF	CITATIONS
1530	Prostate hyperplasia in St Mary's Hospital Lacor: utility of prostate specific antigen in screening for prostate malignancy. African Health Sciences, 2020, 20, 1259-1263.	0.3	1
1531	The Role of Ga-68 PSMA PET/CT Scan on Differentiating of Oligometastatic and High Risk Prostate Cancer. Molecular Imaging and Radionuclide Therapy, 2020, 29, 98-104.	0.3	5
1532	Oncoxinâ€'Viusid<sup>&reg;</sup> may improve quality of life and survival in patients with hormoneâ€'refractory prostate cancer undergoing oncoâ€'specific treatments. Molecular and Clinical Oncology, 2020, 14, 1-1.	0.4	3
1533	Learning a Triplet Embedding Distance to Represent Gleason Patterns. , 2021, 2021, 3229-3232.		0
1534	Artificial intelligence for diagnosis and Gleason grading of prostate cancer: the PANDA challenge. Nature Medicine, 2022, 28, 154-163.	15.2	143
1535	Evaluation of Predictors of Biochemical Recurrence in Prostate Cancer Patients, as Detected by 68Ga-PSMA PET/CT. Diagnostics, 2022, 12, 195.	1.3	5
1536	Combining CAPRA-S With Tumor IDC/C Features Improves the Prognostication of Biochemical Recurrence in Prostate Cancer Patients. Clinical Genitourinary Cancer, 2022, 20, e217-e226.	0.9	3
1537	Machine and Deep Learning Prediction Of Prostate Cancer Aggressiveness Using Multiparametric MRI. Frontiers in Oncology, 2021, 11, 802964.	1.3	27
1538	Predictors of upgrading from low-grade cancer at prostatectomy in men with biparametric magnetic resonance imaging. Central European Journal of Urology, 2022, 75, 35-40.	0.2	1
1539	Prognostic Utility of the Gleason Grading System Revisions and Histopathological Factors Beyond Gleason Grade. Clinical Epidemiology, 2022, Volume 14, 59-70.	1.5	2
1540	TRUS-Guided Target Biopsy for a PI-RADS 3â€"5 Index Lesion to Reduce Gleason Score Underestimation: A Propensity Score Matching Analysis. Frontiers in Oncology, 2021, 11, 824204.	1.3	4
1541	Two-year quality of life after robot-assisted radical prostatectomy according to pentafecta criteria and cancer of the prostate risk assessment (CAPRA-S). Scientific Reports, 2022, 12, 244.	1.6	5
1542	US lesion visibility predicts clinically significant upgrade of prostate cancer by systematic biopsy. Abdominal Radiology, 2022, 47, 1133.	1.0	0
1543	The Clinical Significance of Perineural Invasion by Prostate Cancer on Needle Core Biopsy: Involvement of Single Versus Multiple Sextant Sites. Archives of Pathology and Laboratory Medicine, 2022, 146, 1252-1257.	1.2	8
1544	Clinical significance of perineural invasion by prostate cancer on magnetic resonance imagingâ€"targeted biopsy. Human Pathology, 2022, 121, 65-72.	1.1	5
1546	Up- and downgrading in single intermediate-risk positive biopsy core prostate cancer. Prostate International, 2022, 10, 21-27.	1.2	3
1547	Value of T_2 Mapping MRI for Prostate Cancer Detection and Classification. Journal of Magnetic Resonance Imaging, 2022, 56, 413-422.	1.9	8
1548	Prediction of recurrence from metabolites and expression of TOP2A and EZH2 in prostate cancer patients treated with radiotherapy. NMR in Biomedicine, 2023, 36, e4694.	1.6	4

#	ARTICLE	IF	CITATIONS
1549	Reducing the number of systematic biopsy cores in the era of MRI targeted biopsyâ€"implications on clinically-significant prostate cancer detection and relevance to focal therapy planning. Prostate Cancer and Prostatic Diseases, 2022, 25, 720-726.	2.0	16
1550	Nanoemulsion Applications. Advances in Chemical and Materials Engineering Book Series, 2022, , 259-276.	0.2	0
1551	Dual time point imaging of staging PSMA PET/CT quantification; spread and radiomic analyses. Annals of Nuclear Medicine, 2022, 36, 310-318.	1.2	7
1552	Limited Adenocarcinoma of the Prostate on Needle Core Biopsy. Archives of Pathology and Laboratory Medicine, 2022, 146, 469-477.	1.2	3
1553	Clinicopathological and genetic analyses of small cell neuroendocrine carcinoma of the prostate: Histological features for accurate diagnosis and toward future novel therapies. Pathology Research and Practice, 2022, 229, 153731.	1.0	7
1554	Prostate-specific antigen nomogram to predict advanced prostate cancer using area under the receiver operating characteristic curve boosting. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 162.e9-162.e16.	0.8	2
1555	The Influence of Endogenous Testosterone Density on Unfavorable Disease and Tumor Load at Final Pathology in Intermediate-Risk Prostate Cancer: Results in 338 Patients Treated with Radical Prostatectomy and Extended Pelvic Lymph Node Dissection. Urologia Internationalis, 2022, 106, 928-939.	0.6	2
1556	Does type of robotic platform make a difference in the final cost of robotic-assisted radical prostatectomy?. Journal of Robotic Surgery, 2022, 16, 1329-1335.	1.0	3
1557	Prediction of early biochemical response after 177Lu-PSMA radioligand therapy with 68Ga-PSMA PET, a different perspective with quantitative parameters. Nuclear Medicine Communications, 2022, Publish Ahead of Print, .	0.5	1
1558	Percentage grade 4 tumour predicts outcome for prostate adenocarcinoma in needle biopsies from patients with advanced disease: 10-year data from the TROG 03.04 RADAR trial. Pathology, 2022, 54, 49-54.	0.3	7
1559	Spectral decoupling for training transferable neural networks in medical imaging. IScience, 2022, 25, 103767.	1.9	2
1560	Deep Learning Reconstruction of Diffusion-weighted MRI Improves Image Quality for Prostatic Imaging. Radiology, 2022, 303, 373-381.	3.6	51
1561	Value of Targeted Biopsies and Combined PSMA PET/CT and mp-MRI Imaging in Locally Recurrent Prostate Cancer after Primary Radiotherapy. Cancers, 2022, 14, 781.	1.7	8
1562	Improving the Early Detection of Clinically Significant Prostate Cancer in Men in the Challenging Prostate Imaging-Reporting and Data System 3 Category. European Urology Open Science, 2022, 37, 38-44.	0.2	5
1563	ProstAttention-Net: A deep attention model for prostate cancer segmentation by aggressiveness in MRI scans. Medical Image Analysis, 2022, 77, 102347.	7.0	44
1564	Patient with prostatic adenocarcinoma with plasmacytoid features and an aberrant immunohistochemical phenotype diagnosed by biopsy and a miniâ€‹review of plasmacytoid features in the genitourinary system: A case report. Molecular and Clinical Oncology, 2022, 16, 67.	0.4	2
1565	Analysis of separate training and validation radical prostatectomy cohorts identifies 0.25 mm diameter as an optimal definition for â€œlargeâ€•cribriform prostatic adenocarcinoma. Modern Pathology, 2022, 35, 1092-1100.	2.9	10
1566	The potential of prostate gland radiomic features in identifying the Gleason score. Computers in Biology and Medicine, 2022, 144, 105318.	3.9	12

#	ARTICLE	IF	CITATIONS
1567	Safety of robot-assisted radical prostatectomy in an Italian spoke hospital: Long-term oncologic and functional outcomes with median 11.3 years follow-up. Urologia, 2022, , 039156032210775.	0.3	0
1568	A Ferroptosis-Related Gene Prognostic Index Associated With Biochemical Recurrence and Radiation Resistance for Patients With Prostate Cancer Undergoing Radical Radiotherapy. Frontiers in Cell and Developmental Biology, 2022, 10, 803766.	1.8	21
1570	Intraductal Carcinoma of the Prostate as a Cause of Prostate Cancer Metastasis: A Molecular Portrait. Cancers, 2022, 14, 820.	1.7	13
1571	Comparison of 68Ga-PSMA PET/CT and multiparametric MRI for the detection of low- and intermediate-risk prostate cancer. EJNMMI Research, 2022, 12, 10.	1.1	14
1572	Shared decision making of burdensome surveillance tests using personalized schedules and their burden and benefit. Statistics in Medicine, 2022, 41, 2115-2131.	0.8	5
1573	Importance of considering interest in sex when evaluating satisfaction after robotâ€assisted radical prostatectomy. International Journal of Urology, 2022, 29, 446-454.	0.5	4
1574	Risk Stratification of Prostatic Adenocarcinoma Metastatic to the Lymph Nodes. Archives of Pathology and Laboratory Medicine, 2022, 146, 1345-1352.	1.2	1
1575	Development of a Semiautomated Search Tool to Identify Grading From Pathology Reports for Tumors of the CNS and Prostate Cancers. JCO Clinical Cancer Informatics, 2021, 5, 1189-1196.	1.0	0
1576	Accuracy of fractal analysis and PI-RADS assessment of prostate magnetic resonance imaging for prediction of cancer grade groups: a clinical validation study. European Radiology, 2022, 32, 2372-2383.	2.3	3
1577	Prediction of prostate cancer grade using fractal analysis of perfusion MRI: retrospective proof-of-principle study. European Radiology, 2021, , 1.	2.3	11
1578	Useful predictors of progressionâ€free survival for Japanese patients with LATITUDEâ€highâ€risk metastatic castrationâ€sensitive prostate cancer who received upfront abiraterone acetate. International Journal of Urology, 2022, 29, 229-234.	0.5	8
1579	The Efficiency and Safety of Transperitoneal versus Extraperitoneal Robotic-Assisted Radical Prostatectomy for Patients with Prostate Cancer: A Single Center Experience with 1-year Follow-up. Urology Journal, 2020, 17, 480-485.	0.3	4
1580	Artificial Intelligence Based Prostate Cancer Classification Model Using Biomedical Images. Computers, Materials and Continua, 2022, 72, 3799-3813.	1.5	7
1582	PET imaging of prostate cancer. , 2022, , .		0
1584	Deep learning for fully automatic detection, segmentation, and Gleason grade estimation of prostate cancer in multiparametric magnetic resonance images. Scientific Reports, 2022, 12, 2975.	1.6	34
1585	Utility of Clinicalâ€"Radiomic Model to Identify Clinically Significant Prostate Cancer in Biparametric MRI PI-RADS V2.1 Category 3 Lesions. Frontiers in Oncology, 2022, 12, 840786.	1.3	4
1586	Efficacy and safety of Androgen Deprivation Therapy (ADT) combined with modified docetaxel chemotherapy versus ADT combined with standard docetaxel chemotherapy in patients with metastatic castration-resistant prostate cancer: study protocol for a multicentre prospective randomized controlled trial. BMC Cancer, 2022, 22, 177.	1.1	2
1587	Expressed prognostic biomarkers for primary prostate cancer independent of multifocality and transcriptome heterogeneity. Cancer Gene Therapy, 2022, 29, 1276-1284.	2.2	3

#	Article	IF	Citations
1588	Complete androgen blockade vs. medical castration alone as adjuvant androgen deprivation therapy for prostate cancer patients following radical prostatectomy. Chinese Medical Journal, 2022, Publish Ahead of Print, .	0.9	0
1589	Targeting PSMA Revolutionizes the Role of Nuclear Medicine in Diagnosis and Treatment of Prostate Cancer. Cancers, 2022, 14, 1169.	1.7	15
1590	Artificial intelligence trained with integration of multiparametric MR–US imaging data and fusion biopsy trajectory–proven pathology data for 3D prediction of prostate cancer: A proof–of–concept study. Prostate, 2022, 82, 793-803.	1.2	5
1592	Alternative prostate cancer grading systems incorporating percent pattern 4/5 (IQ-Gleason) and cribriform architecture (cGrade) improve prediction of outcome after radical prostatectomy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 1149-1157.	1.4	2
1593	Prevalence of Cognitive Impairment before Prostate Cancer Treatment. Cancers, 2022, 14, 1355.	1.7	4
1594	Tomotherapy-based moderate hypofractionation for localized prostate cancer: a mono-institutional analysis. Reports of Practical Oncology and Radiotherapy, 2022, 27, 142-151.	0.3	2
1595	How frequent and dangerous is overactive bladder syndrome after radical prostatectomy?. Urologie Pro Praxi, 2022, 23, 38-43.	0.0	0
1597	Incidental prostate cancer after holmium laser enucleation of the prostate: incidence and predictive factors for clinical progression. International Journal of Clinical Oncology, 2022, 27, 1077-1083.	1.0	6
1598	The Barcelona Predictive Model of Clinically Significant Prostate Cancer. Cancers, 2022, 14, 1589.	1.7	13
1599	mEPE-score: a comprehensive grading system for predicting pathologic extraprostatic extension of prostate cancer at multiparametric magnetic resonance imaging. European Radiology, 2022, 32, 4942-4953.	2.3	7
1600	Time-Dependent Diffusion MRI for Quantitative Microstructural Mapping of Prostate Cancer. Radiology, 2022, 303, 578-587.	3.6	15
1601	Association of Androgenic Regulation and MicroRNAs in Acinar Adenocarcinoma of Prostate. Genes, 2022, 13, 622.	1.0	2
1602	A deep learning system for prostate cancer diagnosis and grading in whole slide images of core needle biopsies. Scientific Reports, 2022, 12, 3383.	1.6	33
1603	A Deep Learning Model for Prostate Adenocarcinoma Classification in Needle Biopsy Whole-Slide Images Using Transfer Learning. Diagnostics, 2022, 12, 768.	1.3	16
1604	The Comparison of Conventional and Retzius-Sparing Robot-Assisted Radical Prostatectomy for Clinical, Pathological, and Oncological Outcomes. Journal of Urological Surgery, 2022, 9, 1-8.	0.2	1
1605	Unravelling Prostate Cancer Heterogeneity Using Spatial Approaches to Lipidomics and Transcriptomics. Cancers, 2022, 14, 1702.	1.7	13
1606	The association between perineural invasion in mpMRI-targeted and/or systematic prostate biopsy and adverse pathological outcomes in robot-assisted radical prostatectomy. Actas Urológicas Españolas (English Edition), 2022, , .	0.2	0
1607	The Global Research of Artificial Intelligence on Prostate Cancer: A 22-Year Bibliometric Analysis. Frontiers in Oncology, 2022, 12, 843735.	1.3	45

#	ARTICLE	IF	CITATIONS
1608	Diagnostic value of integrated 18F-PSMA-1007 PET/MRI Compared with that of Biparametric MRI for the detection of Prostate Cancer. Prostate International, 2022, 10, 108-116.	1.2	3
1609	The ETS Homologous Factor (EHF) Represents a Useful Immunohistochemical Marker for Predicting Prostate Cancer Metastasis. Diagnostics, 2022, 12, 800.	1.3	2
1610	Standardised uptake values as determined on prostateâ€specific membrane antigen positron emission tomography/computed tomography is associated with oncological outcomes in patients with prostate cancer. BJU International, 2022, 129, 768-776.	1.3	7
1611	A Prospective Multicenter Comparison Study of Risk-adapted Ultrasound-directed and Magnetic Resonance Imagingâ€"directed Diagnostic Pathways for Suspected Prostate Cancer in Biopsy-naÃ¯ve Men. European Urology, 2022, 82, 318-326.	0.9	9
1612	The role of PSMA radioligands in the diagnosis and treatment of prostate carcinoma. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2022, 41, 126-135.	0.1	1
1613	Diffusion Restriction Comparison between Gleason 4 Fused Glands and Cribriform Glands within Patient Using Whole-Mount Prostate Pathology as Ground Truth. Tomography, 2022, 8, 635-643.	0.8	3
1614	The waiting time for prostate cancer treatment in Italy: analysis from the PROS-IT CNR Study. Minerva Urology and Nephrology, 2022, 74, .	1.3	1
1615	A Head-to-head Comparison of Prostate Cancer Diagnostic Strategies Using the Stockholm3 Test, Magnetic Resonance Imaging, and Swedish National Guidelines: Results from a Prospective Population-based Screening Study. European Urology Open Science, 2022, 38, 32-39.	0.2	2
1616	Radical prostatectomy findings and oncologic outcomes in patients with prostate cancer detected on systematic sextant biopsy only, MRI-targeted biopsy only, or both. Urologic Oncology: Seminars and Original Investigations, 2022, , .	0.8	2
1617	Multiparametric Magnetic Resonance Imaging Grades the Aggressiveness of Prostate Cancer. Cancers, 2022, 14, 1828.	1.7	5
1618	Modified Prostate Health Index Density Significantly Improves Clinically Significant Prostate Cancer (csPCa) Detection. Frontiers in Oncology, 2022, 12, 864111.	1.3	4
1619	Alternatives for MRI in Prostate Cancer Diagnosticsâ€"Review of Current Ultrasound-Based Techniques. Cancers, 2022, 14, 1859.	1.7	6
1620	Machine Learning-Based Prediction of Pathological Upgrade From Combined Transperineal Systematic and MRI-Targeted Prostate Biopsy to Final Pathology: A Multicenter Retrospective Study. Frontiers in Oncology, 2022, 12, 785684.	1.3	1
1621	Automatic Prostate Gleason Grading Using Pyramid Semantic Parsing Network in Digital Histopathology. Frontiers in Oncology, 2022, 12, 772403.	1.3	5
1622	Androgen-deprivation therapy and cognitive decline in the NEON-PC prospective study during the COVID-19 pandemic. ESMO Open, 2022, 7, 100448.	2.0	5
1623	Diagnostic and prognostic factors in patients with prostate cancer: a systematic review. BMJ Open, 2022, 12, e058267.	0.8	4
1624	Large and small cribriform architecture have similar adverse clinical outcome on prostate cancer biopsies. Histopathology, 2022, 80, 1041-1049.	1.6	8
1625	Virtual biopsy in prostate cancer: can machine learning distinguish low and high aggressive tumors on MRI?. , 2021, 2021, 3374-3377.		3

#	Article	IF	Citations
1626	Radical or Not-So-Radical Prostatectomy: Do Surgical Margins Matter?. Cancers, 2022, 14, 13.	1.7	38
1627	MRI Radiomics in Prostate Cancer: A Reliability Study. Frontiers in Oncology, 2021, 11, 805137.	1.3	5
1628	The best prostate biopsy sampling systemâ€"fusion and systematic biopsy: A single center experience. Urologia, 2021, , 039156032110371.	0.3	0
1629	Timing of the Pubertal Growth Spurt and Prostate Cancer. Cancers, 2021, 13, 6238.	1.7	5
1630	Comparison of transperineal and transrectal targeted prostate biopsy using Mahalanobis distance matching within propensity score caliper method: A multicenter study of Turkish Urooncology Association. Prostate, 2022, 82, 425-432.	1.2	8
1631	Classification of Clinically Significant Prostate Cancer on Multi-Parametric MRI: A Validation Study Comparing Deep Learning and Radiomics. Cancers, 2022, 14, 12.	1.7	21
1632	miR-145-5p: A Potential Biomarker in Predicting Gleason Upgrading of Prostate Biopsy Samples Scored 3+3=6. Cancer Management and Research, 2021, Volume 13, 9095-9106.	0.9	5
1633	Effect of Glison index on survival of patients with localized prostate cancer in Samara region. Vestnik Medicinskogo Instituta REAVIZ ReabilitaciÂ¢, VraÄ•I ZdorovÊ¹e, 2022, 12, 90-97.	0.1	1
1634	Single Positive Core Prostate Cancer at Biopsy: Clinicopathological Implications and Risk Factors for Adverse Pathological Outcomes. Clinical Genitourinary Cancer, 2021, , .	0.9	0
1635	Implementing the da Vinci SPÂ® without increasing positive surgical margins: experience and pathological outcomes of a prostate cancer referral center.. Journal of Endourology, 2021, , .	1.1	6
1636	Stratification of prostate cancer patients into lowâ€•and highâ€•grade groups using multiparametric magnetic resonance radiomics with dynamic contrastâ€•enhanced image joint histograms. Prostate, 2022, 82, 330-344.	1.2	4
1637	Prediction of Clinically Significant Cancer Using Radiomics Features of Pre-Biopsy of Multiparametric MRI in Men Suspected of Prostate Cancer. Cancers, 2021, 13, 6199.	1.7	14
1638	Urinary MyProstateScore (MPS) to Rule out Clinically-Significant Cancer in Men with Equivocal (PI-RADS 3) Multiparametric MRI: Addressing an Unmet Clinical Need. Urology, 2022, 164, 184-190.	0.5	8
1639	Second-opinion reads in prostate MRI: added value of subspecialty interpretation and review at multidisciplinary rounds. Abdominal Radiology, 2022, 47, 827-837.	1.0	8
1640	The role of MRI in the detection of local recurrence: Added value of multiparametric approach and Signal Intensity/Time Curve analysis. Archivio Italiano Di Urologia Andrologia, 2022, 94, 25-31.	0.4	1
1641	Social Support Mediates the Relationship between Body Image Distress and Depressive Symptoms in Prostate Cancer Patients. International Journal of Environmental Research and Public Health, 2022, 19, 4825.	1.2	20
1642	Individualised non-contrast MRI-based risk estimation and shared decision-making in men with a suspicion of prostate cancer: protocol for multicentre randomised controlled trial (multi-IMPROD) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50		
1643	Neoadjuvant Hormonal Therapy for Prostate Cancer: Morphologic Features and Predictive Parameters of Therapy Response. Advances in Anatomic Pathology, 2022, 29, 252-258.	2.4	5

#	Article	IF	Citations
1644	Clinical application of single-shot echo-planar diffusion-weighted imaging with compressed SENSE in prostate MRI at 3T: preliminary experience. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2022, 35, 549-556.	1.1	6
1645	Dietary inflammatory index and prostate cancer risk: MCC-Spain study. Prostate Cancer and Prostatic Diseases, 2022, , .	2.0	9
1646	AI Model for Prostate Biopsies Predicts Cancer Survival. Diagnostics, 2022, 12, 1031.	1.3	2
1647	Effect of Clinical Parameters on Risk of Death from Cancer after Radical Prostatectomy in Men with Localized and Locally Advanced Prostate Cancer. Cancers, 2022, 14, 2032.	1.7	1
1648	Infiltrative growth pattern of prostate cancer is associated with lower uptake on PSMA PET and reduced diffusion restriction on mpMRI. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3917-3928.	3.3	10
1649	Early experience in avoiding biopsies for biopsy-naïve men with clinical suspicion of prostate cancer but non-suspicious biparametric magnetic resonance imaging results and prostate-specific antigen density < 0.15Âng/mL^2: A 2-year follow-up study. Acta Radiologica Open, 2022, 11, 205846012210948.	0.3	2
1650	Single-cell proteomics defines the cellular heterogeneity of localized prostate cancer. Cell Reports Medicine, 2022, 3, 100604.	3.3	7
1651	Robot-Assisted Radical Prostatectomy for Potential Cancer Control in Patients with Metastatic Prostate Cancer. Current Oncology, 2022, 29, 2864-2870.	0.9	6
1652	Adenocarcinoma of the Prostate. , 0, , 46-59.		0
1653	Gleason Grading of Prostate Cancer. , 0, , 60-76.		0
1662	Development and Validation of an Artificial Intelligence–Powered Platform for Prostate Cancer Grading and Quantification. JAMA Network Open, 2021, 4, e2132554.	2.8	23
1663	A nomogram for accurately predicting the pathological upgrading of prostate cancer, based on ^{68}Ga–PSMA PET/CT. Prostate, 2022, 82, 1077-1087.	1.2	2
1664	Single center analysis of an advisable control interval for follow-up of patients with PI-RADS category 3 in multiparametric MRI of the prostate. Scientific Reports, 2022, 12, 6746.	1.6	4
1665	Histopathological Outcomes after Radical Prostatectomy for Prostate Cancer Based On a New Grading System. Acta Clinica Croatica, 2018, 57, 50-55.	0.1	0
1667	Improving the detection of aggressive prostate cancer using immunohistochemical staining of protein marker panels.. American Journal of Cancer Research, 2022, 12, 1323-1336.	1.4	0
1668	Paradigm Shift in Prostate Cancer Diagnosis: Pre-Biopsy Prostate Magnetic Resonance Imaging and Targeted Biopsy. Korean Journal of Radiology, 2022, 23, 625.	1.5	6
1669	The role of prostate-specific antigen density and negative multiparametric magnetic resonance imaging in excluding prostate cancer for biopsy-naïve men: clinical outcomes from a high-volume center in China. Asian Journal of Andrology, 2022, 24, 615.	0.8	3
1670	Cribriform prostate cancer: an aggressive pattern where definition and size matter. Diagnostic Histopathology, 2022, , .	0.2	1

#	ARTICLE	IF	CITATIONS
1671	Performance of multi-parametric magnetic resonance imaging through PIRADS scoring system in biopsy naÃ¯ve patients with suspicious prostate cancer. Arab Journal of Urology Arab Association of Urology, 0, , 1-5.	0.7	1
1672	Characterization of a Pyroptosis-Related Signature for Prognosis Prediction and Immune Microenvironment Infiltration in Prostate Cancer. Computational and Mathematical Methods in Medicine, 2022, 2022, 1-51.	0.7	4
1673	The Clinical Impact of Comedonecrosis Within Intraductal Carcinoma of the Prostate. Archives of Pathology and Laboratory Medicine, 2023, 147, 94-99.	1.2	3
1674	Correlation Between Quantitative PSMA PET Parameters and Clinical Risk Factors in Non-Metastatic Primary Prostate Cancer Patients. Frontiers in Oncology, 2022, 12, 879089.	1.3	2
1675	Dynamic evaluation of MRI-targeted, systematic and combined biopsy for prostate cancer diagnosis through 10Âyears of practice in a single institution. World Journal of Urology, 2022, 40, 1661-1668.	1.2	4
1676	A comparative study of transperineal software-assisted magnetic resonance/ultrasound fusion biopsy and transrectal cognitive fusion biopsy of the prostate. BMC Urology, 2022, 22, 72.	0.6	8
1677	[99Tc]Sestamibi bioaccumulation induces apoptosis in prostate cancer cells: an in vitro study. Molecular and Cellular Biochemistry, 2022, 477, 2319-2326.	1.4	2
1678	Inter-Reader Variability Using PI-RADS v2 Versus PI-RADS v2.1: MostÂNew Disagreement Stems from Scores 1 and 2. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2022, 194, 852-861.	0.7	3
1679	Comparative Analysis of PSA Density and an MRI-Based Predictive Model to Improve the Selection of Candidates for Prostate Biopsy. Cancers, 2022, 14, 2374.	1.7	1
1682	Analysis of the cause of missed diagnosis in mpMRI/TRUS fusion-guided targeted prostate biopsy. BMC Urology, 2022, 22, 74.	0.6	2
1683	Management about intravesical histological transformation of prostatic mucinous carcinoma after radical prostatectomy: A case report. World Journal of Clinical Cases, 2022, 10, 4654-4660.	0.3	0
1684	Clinical significance of <scp>IDCâ€P</scp> as predictive factor after intensityâ€modulated radiation therapy. Cancer Science, 2022, 113, 2425-2433.	1.7	7
1685	Prostate biopsy in the era of MRI-targeting: towards a judicious use of additional systematic biopsy. European Radiology, 2022, 32, 7544-7554.	2.3	8
1686	A Novel Risk Score (P-score) Based on a Three-Gene Signature, for Estimating the Risk of Prostate Cancer-Specific Mortality. Research and Reports in Urology, 2022, Volume 14, 203-217.	0.6	1
1688	Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging to Detect Residual Prostate Cancer Following Irreversible Electroporationâ€"A Multicenter Validation Study. European Urology Focus, 2022, 8, 1591-1598.	1.6	6
1689	<i>Inâ€‰situ</i> expression of <scp>ERG</scp> protein in the context of tumor heterogeneity identifies prostate cancer patients with inferior prognosis. Molecular Oncology, 2022, 16, 2810-2822.	2.1	3
1690	ProstatectomÃa Radical LaparoscÃ³pica, Nuestra Experiencia.. , 2018, 6, 25-28.		0
1691	A cross-sectional study on demoralization in prostate cancer patients: the role of masculine self-esteem, depression, and resilience. Supportive Care in Cancer, 2022, 30, 7021-7030.	1.0	15

#	Article	IF	Citations
1692	Current conundrums with cribriform prostate cancer. Histopathology, 2022, 80, 1038-1040.	1.6	5
1693	Prostat Kanserinin Saptanması ve Derecelendirilmesinde Voksel İçi Tutarsız Hareket (IVIM) Parametrelerinin Tanısal Değeri. Sakarya Medical Journal, 0, , .	0.1	0
1694	Risk Estimation of Metastatic Recurrence After Prostatectomy: A Model Using Preoperative Magnetic Resonance Imaging and Targeted Biopsy. European Urology Open Science, 2022, 41, 24-34.	0.2	5
1695	Detection Rate of ^{68}Ga-PSMA PET/CT *vs*. mpMRI Targeted Biopsy for Clinically Significant Prostate Cancer. Anticancer Research, 2022, 42, 3011-3015.	0.5	16
1696	A magnetic resonance imaging-based nomogram for predicting clinically significant prostate cancer at radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 379.e1-379.e8.	0.8	3
1697	The Value of Multimodality PET/CT Imaging in Detecting Prostate Cancer Biochemical Recurrence. Frontiers in Endocrinology, 2022, 13, .	1.5	1
1698	Comparison of Proclarix, PSA Density and MRI-ERSPC Risk Calculator to Select Patients for Prostate Biopsy after mpMRI. Cancers, 2022, 14, 2702.	1.7	2
1699	Prognostic significance of percentage Gleason grade 5 prostatic adenocarcinoma in needle biopsies from patients treated by radical prostatectomy. Pathology, 2022, 54, 694-699.	0.3	1
1700	Prognostic differences among Grade Group 4 subgroups in robotic-assisted radical prostatectomy. BJUI Compass, 0, , .	0.7	2
1701	Prostate Cancer Detection Rate of Manually Operated and Robot-assisted In-bore Magnetic Resonance Imaging Targeted Biopsy. European Urology Open Science, 2022, 41, 88-94.	0.2	3
1702	Changes in Characteristics of Men with Lethal Prostate Cancer During the Past 25 Years: Description of Population-based Deaths. European Urology Open Science, 2022, 41, 81-87.	0.2	0
1703	Prognostic factors in Japanese men with high-Gleason metastatic castration-resistant prostate cancer. Translational Cancer Research, 2022, 11, 2681-2687.	0.4	1
1704	Mucinous adenocarcinoma of the prostate found incidentally in adenomectomy specimen complicated with vesicocutaneous fistulae. Hellenic Urology, 2021, 33, 53.	0.1	0
1705	Transcriptome-wide prediction of prostate cancer gene expression from histopathology images using co-expression-based convolutional neural networks. Bioinformatics, 2022, 38, 3462-3469.	1.8	9
1706	Knowledge, attitudes, and practices of active surveillance in prostate cancer among urologists: a real-life survey from Brazil. BMC Urology, 2022, 22, .	0.6	0
1707	Using deep learning to detect patients at risk for prostate cancer despite benign biopsies. IScience, 2022, 25, 104663.	1.9	5
1708	Preoperative Platelet Count Correlates With Postoperative Perineural Invasion on Specimen in Patients Treated With Radical Prostatectomy. Frontiers in Oncology, 0, 12, .	1.3	2
1709	Development and Validation of Nomograms to Predict Cancer-Specific Survival and Overall Survival in Elderly Patients With Prostate Cancer: A Population-Based Study. Frontiers in Oncology, 0, 12, .	1.3	8

#	ARTICLE	IF	CITATIONS
1711	The Application of Biopsy Density in Transperineal Templated-Guided Biopsy Patients With PI-RADS<3. Frontiers in Oncology, 0, 12, .	1.3	0
1712	Could 68Ga-PSMA PET/CT Evaluation Reduce the Number of Scheduled Prostate Biopsies in Men Enrolled in Active Surveillance Protocols?. Journal of Clinical Medicine, 2022, 11, 3473.	1.0	14
1713	The significance of the extent of tissue embedding for the detection of incidental prostate carcinoma on transurethral prostate resection material: the more, the better?. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 0, , .	1.4	0
1714	Cribriform Patterned Lesions in the Prostate Gland with Emphasis on Differential Diagnosis and Clinical Significance. Cancers, 2022, 14, 3041.	1.7	7
1715	Severe systemic disease of the American Society of Anesthesiologists' (ASA) physical status system classification associated with delayed length of hospital stay in 1329 consecutive patients treated with radical prostatectomy for clinical prostate cancer. Minerva Urology and Nephrology, 2023, 74, .	1.3	1
1716	Predicting biochemical recurrence of prostate cancer with artificial intelligence. Communications Medicine, 2022, 2, .	1.9	8
1717	Impact of cribriform pattern 4 and intraductal prostatic carcinoma on National Comprehensive Cancer Network (NCCN) and Cancer of Prostate Risk Assessment (CAPRA) patient stratification. Modern Pathology, 2022, 35, 1695-1701.	2.9	5
1718	Replication Stress Defines Distinct Molecular Subtypes Across Cancers. Cancer Research Communications, 2022, 2, 503-517.	0.7	12
1719	Podemos usar a expressão de Ki67 para prever a agressividade do câncer de próstata?. Revista Do Colegio Brasileiro De Cirurgioes, 0, 49, .	0.3	0
1720	Can we use Ki67 expression to predict prostate cancer aggressiveness?. Revista Do Colegio Brasileiro De Cirurgioes, 0, 49, .	0.3	5
1721	<scp>WHO</scp> Classification of Tumours fifth edition: evolving issues in the classification, diagnosis, and prognostication of prostate cancer. Histopathology, 2022, 81, 447-458.	1.6	10
1723	Clinical Factors Associated With Pathological Grade Group 1 Patients in D'Amico Intermediate-Risk Group Following Robot-Assisted Radical Prostatectomy: A Retrospective Multicenter Cohort Study in Japan (The MSUG94 Group). Clinical Genitourinary Cancer, 2022, 20, 593-600.	0.9	0
1724	Discovering Gene Signature Shared by Prostate Cancer and Neurodegenerative Diseases Based on the Bioinformatics Approach. Computational and Mathematical Methods in Medicine, 2022, 2022, 1-8.	0.7	2
1725	Significance of pelvic lymph node dissection during radical prostatectomy in high-risk prostate cancer patients receiving neoadjuvant chemohormonal therapy. Scientific Reports, 2022, 12, .	1.6	2
1726	Cribriform Area Suspicion in the Prostates of Patients with Gleason (3+3) Diagnosis in Biopsy Evaluation. Restricted Morphological Appearance may not be Sufficient to Include Patients in the Follow-up Group. Journal of Ankara University Faculty of Medicine, 2022, 75, 274-278.	0.0	0
1728	<scp>TRIM33</scp> drives prostate tumor growth by stabilizing androgen receptor from Skp2â€mediated degradation. EMBO Reports, 2022, 23, .	2.0	9
1729	American Society of Anesthesiologistsâ€™ (ASA) Physical Status System and Risk of Major Clavien-Dindo Complications After Robot-Assisted Radical Prostatectomy at Hospital Discharge: Analysis of 1143 Consecutive Prostate Cancer Patients. Indian Journal of Surgical Oncology, 2022, 13, 848-857.	0.3	2
1730	68Ga-PSMA-11 PET/MRI versus multiparametric MRI in men referred for prostate biopsy: primary tumour localization and interreader agreement. European Journal of Hybrid Imaging, 2022, 6, .	0.6	5

#	Article	IF	Citations
1731	Oncological and urinary outcomes following <scp>LDR</scp> Brachytherapy with median follow up of 11.8 years. BJU International, 0, , .	1.3	0
1732	Predictive Value of Cribriform and Intraductal Carcinoma for the Nomogram-based Selection of Prostate Cancer Patients for Pelvic Lymph Node Dissection. Urology, 2022, 168, 156-164.	0.5	1
1733	Making an art into a science: a mathematical "Likert tool" can change PI-RADS (v2) scores into Likert scores when reporting multiparametric MRI for prostate cancer. Acta Radiologica, 2023, 64, 1245-1254.	0.5	1
1734	Dietary Patterns and Prostate Cancer: CAPLIFE Study. Cancers, 2022, 14, 3475.	1.7	1
1735	Defining Oligometastatic Disease in the New Era of PSMA-PET Imaging for Primary Staging of Prostate Cancer. Cancers, 2022, 14, 3302.	1.7	13
1736	Interlaboratory Gleason grading variation affects treatment: a Dutch historic cohort study in 30 509 patients with prostate cancer. Journal of Clinical Pathology, 2023, 76, 690-697.	1.0	2
1737	Characterization of the Tumor Microenvironment and the Biological Processes with a Role in Prostatic Tumorigenesis. Biomedicines, 2022, 10, 1672.	1.4	5
1738	KIF11: A potential prognostic biomarker for predicting bone metastasis free survival of prostate cancer. Oncology Letters, 2022, 24, .	0.8	4
1739	The Surgical Learning Curve for Biochemical Recurrence After Robot-assisted Radical Prostatectomy. European Urology Oncology, 2023, 6, 414-421.	2.6	13
1740	Detection of Clinically Significant Index Prostate Cancer Using Micro-ultrasound: Correlation With Radical Prostatectomy. Urology, 2022, 169, 150-155.	0.5	1
1741	Long-term Outcomes of Radiation Therapy for Prostate Cancer in Elderly Patients Aged ≥75 Years. Anticancer Research, 2022, 42, 3529-3536.	0.5	2
1742	Review of Toxicities of PARP Inhibitors in Metastatic Castrate Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2023, 21, 183-193.	0.9	6
1743	Treatment patterns and rates of upgrading and upstaging in prostate cancer patients with single GGG1 positive biopsy core. Urologic Oncology: Seminars and Original Investigations, 2022, , .	0.8	1
1744	Trends in disagreement with outside genitourinary pathology diagnoses at an academic center. Pathology Research and Practice, 2022, 236, 153997.	1.0	1
1745	Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer. ESMO Open, 2022, 7, 100518.	2.0	10
1747	Is PSA Still the Best Predictor for Biochemical Recurrence after Radical Prostatectomy in High-Risk Prostate Cancer?. Journal of Investigative Surgery, 2022, 35, 1733-1738.	0.6	1
1748	Any decline in prostate specific antigen levels identifies survivors scheduled for prostate specific membrane antigen directed radioligand therapy. Prostate, 2022, 82, 1406-1412.	1.2	4
1749	A prospective multi-center randomized comparative trial evaluating outcomes of transrectal ultrasound (TRUS)-guided 12-core systematic biopsy, mpMRI-targeted 12-core biopsy, and artificial intelligence ultrasound of prostate (AIUSP) 6-core targeted biopsy for prostate cancer diagnosis. World Journal of Urology, 2023, 41, 653-662.	1.2	9

#	ARTICLE	IF	CITATIONS
1750	The Impact of Gleason Grade 3 as a Predictive Factor for Biochemical Recurrence after Robot-Assisted Radical Prostatectomy: A Retrospective Multicenter Cohort Study in Japan (The MSUG94 Group). Medicina (Lithuania), 2022, 58, 990.	0.8	1
1751	Avoiding Unnecessary Systematic Biopsy in Clinically Significant Prostate Cancer: Comparison Between <scp>MRI</scp> â€Based Radiomics Model and <scp>PIâ€RADS</scp> Category. Journal of Magnetic Resonance Imaging, 0, , .	1.9	4
1752	A CASE REPORT ON PROSTATIC ADENOCARCINOMA WITH MUCINOUS FEATURES. , 2022, , 38-39.		0
1753	Molecular uropathology and cancer genetics for the urologist: key findings for classification and diagnosis. Current Opinion in Urology, 2022, 32, 451-455.	0.9	2
1754	Prostat Adenokarsinomunun tanÄ± ve prognostik sÄ±nÄ±flandÄ±rmasÄ±nda CCR3 ekspresyonunun deÄŸeri. BalÄ±kesir SaÄŸlÄ±k Bilimleri Dergisi, 0, , .	0.0	0
1755	Clinical utility of histopathology data: urological cancers. Journal of Clinical Pathology, 2022, 75, 506-513.	1.0	0
1756	Which men with non-malignant pathology at magnetic resonance imaging-targeted prostate biopsy and persistent PI-RADS 3-5 lesions should repeat biopsy?. Urologic Oncology: Seminars and Original Investigations, 2022, , .	0.8	0
1757	Rupture of liver metastasis in <scp>highâ€volume</scp> metastatic prostate cancer patient on androgen deprivation therapy combined with upfront docetaxel chemotherapy. IJU Case Reports, 0, , .	0.1	0
1758	The association between <scp>PI3K</scp> , <scp>JAK</scp> / <scp>STAT</scp> pathways with the <scp>PDL</scp> â€1 expression in prostate cancer. Andrologia, 0, , .	1.0	0
1759	RE: Grade Migration of Prostate Cancer in the United States During the Last Decade. Journal of the National Cancer Institute, 0, , .	3.0	0
1760	EVALUATION OF Ki-67 IN PROSTATIC CARCINOMA AND ITS CORRELATION WITH GLEASON'S SCORE AND OTHER PROGNOSTIC FACTORS. , 2022, , 23-25.		0
1761	The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organsâ€"Part B: Prostate and Urinary Tract Tumors. European Urology, 2022, 82, 469-482.	0.9	71
1762	Bladder neck-sparing retropubic radical prostatectomy: assessing risk factors for detection of positive surgical margins. Onkourologiya, 2022, 18, 88-101.	0.1	0
1763	Canadian Association of Radiologists Prostate MRI White Paper. Canadian Association of Radiologists Journal, 2022, 73, 626-638.	1.1	1
1764	The lipidomic profile of the tumoral periprostatic adipose tissue reveals alterations in tumor cellâ€™s metabolic crosstalk. BMC Medicine, 2022, 20, .	2.3	6
1765	Diagnostic evaluation and incorporation of PSA density and the prostate imaging and data reporting system (PIRADS) version 2 classification in risk-nomograms for prostate cancer. World Journal of Urology, 0, , .	1.2	3
1766	Proteomic Analysis of Prostate Cancer FFPE Samples Reveals Markers of Disease Progression and Aggressiveness. Cancers, 2022, 14, 3765.	1.7	6
1767	Tissue immunostaining of candidate prognostic proteins in metastatic and non-metastatic prostate cancer. Journal of Cancer Research and Clinical Oncology, 0, , .	1.2	3

#	Article	IF	Citations
1769	Cost-Effectiveness Analysis of Stockholm 3 Testing Compared to PSA as the Primary Blood Test in the Prostate Cancer Diagnostic Pathway: A Decision Tree Approach. Applied Health Economics and Health Policy, 2022, 20, 867-880.	1.0	3
1770	Multiparametric MRI for Staging of Prostate Cancer: A Multicentric Analysis of Predictive Factors to Improve Identification of Extracapsular Extension before Radical Prostatectomy. Cancers, 2022, 14, 3966.	1.7	6
1771	Aberrant protein expression of Appl1, Sortilin and Syndecan-1 during the biological progression of prostate cancer. Pathology, 2023, 55, 40-51.	0.3	12
1772	Serum multi-cytokines screening identifies TRAIL and IL-10 as probable new biomarkers for prostate health index diagnostic utility adjustment in grey zone aggressive prostate cancer detection: A single-center data in China. Frontiers in Immunology, 0, 13, .	2.2	2
1773	The potential of a nomogram combined PI-RADS v2.1 and contrast-enhanced ultrasound (CEUS) to reduce unnecessary biopsies in prostate cancer diagnostics. British Journal of Radiology, 2022, 95, .	1.0	5
1774	Sensitivity of multiparametric MRI and targeted biopsy for detection of adverse pathologies (Cribriform gleason pattern 4 and intraductal carcinoma): Correlation of detected and missed prostate cancer foci with whole mount histopathology. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 452.e1-452.e8.	0.8	4
1775	Prostate Cancer Detection with mpMRI According to PI-RADS v2 Compared with Systematic MRI/TRUS-Fusion Biopsy: A Prospective Study. Tomography, 2022, 8, 2020-2029.	0.8	2
1776	From Cognitive MR-Targeted Fusion Prostate Biopsy to Radical Prostatectomy: Incidence and Predictors of Gleason Grade Group Upgrading in a Chinese Cohort. BioMed Research International, 2022, 2022, 1-5.	0.9	1
1777	Blood Prostate-specific Antigen by Volume of Benign, Gleason Pattern 3 and 4 Prostate Tissue. Urology, 2022, 170, 154-160.	0.5	3
1778	Forecasting of overall and aggressive prostate cancer incident counts at the small area level. Public Health, 2022, 211, 21-28.	1.4	0
1779	Magnetic Resonance Imaging–targeted Prostate Biopsy Compared with Systematic Prostate Biopsy in Biopsy-naïve Patients with Suspected Prostate Cancer. European Urology Open Science, 2022, 44, 125-130.	0.2	1
1780	Histological Evaluations of RADICAL Prostatectomy Specimens. , 2022, , 361-372.		0
1781	Comparison of Computed Diffusion-Weighted Imaging b2000 and Acquired Diffusion-Weighted Imaging b2000 for Detection of Prostate Cancer. Journal of the Korean Society of Radiology, 2022, 83, 1059.	0.1	0
1782	Unusual histomorphological spectrum of urinary bladder cancers and their treatment modalities revisited: Our experience with series of five cases. Journal of Cancer Research and Therapeutics, 2022, .	0.3	2
1783	Synthetic Small Molecules in Prostate Cancer Therapeutics. , 2022, , 985-1004.		0
1784	Grading of prostate cancer: Evolution and changing concepts. Indian Journal of Health Sciences and Biomedical Research KLEU, 2022, 15, 192.	0.1	0
1785	FACTORS PREDICTING A POSSIBLE INCREASE OF GLEASON SCORE AFTER RADICAL PROSTATECTOMY IN PATIENTS WITH WELL-DIFFERENTIATED PROSTATE CANCER. Trakia Journal of Sciences, 2022, 20, 146-151.	0.0	0
1786	Thymic Cancer. Medical Radiology, 2022, , .	0.0	0

#	Article	IF	Citations
1788	An optimized prostate biopsy strategy in patients with a unilateral lesion on prostate magnetic resonance imaging avoids unnecessary biopsies. Therapeutic Advances in Urology, 2022, 14, 175628722211114.	0.9	2
1789	Application of Deep Learning Techniques for Prostate Cancer Grading Using Histopathological Images. Communications in Computer and Information Science, 2022, , 83-94.	0.4	1
1790	Advances in Focal Therapy for Men with Low-Intermediate Risk Prostate Cancer. , 2022, , .		0
1791	Step-by-Step Approach to Robotic-Assisted Radical Prostatectomy. , 2022, , 193-198.		0
1792	Bench to bedside: research influencing clinical practice in prostate pathology. Diagnostic Histopathology, 2022, 28, 488-492.	0.2	0
1793	Prostat biyopsi ve radikal prostatektomide Gleason skor konkordansÄ±nÄ±n deÄŸerlendirilmesi. Cukurova Anestezi Ve Cerrahi Bilimler Dergisi, 2022, 5, 274-279.	0.1	0
1794	Clinical Utility of Prostate Health Index for Diagnosis of Prostate Cancer in Patients with PI-RADS 3 Lesions. Cancers, 2022, 14, 4174.	1.7	4
1795	The Effect of Age on Prostate Cancer Survival. Cancers, 2022, 14, 4149.	1.7	6
1796	Effect of digital-enabled multidisciplinary therapy conferences on efficiency and quality of the decision making in prostate cancer care. BMJ Health and Care Informatics, 2022, 29, e100588.	1.4	2
1797	Investigation into the Optimal Strategy of Radium-223 Therapy for Metastatic Castration-Resistant Prostate Cancer. Radiation, 2022, 2, 273-284.	0.6	3
1798	Magnetic resonance imaging target fusion biopsy vs. transrectal ultrasound-guided biopsy - A comparative study of ISUP score upgrading risk in the ï¬nal radical prostatectomy specimen. Archivio Italiano Di Urologia Andrologia, 2022, 94, 278-284.	0.4	1
1799	Detection of Clinically Significant Prostate Cancer Using Targeted Biopsy with Four Cores Versus Target Saturation Biopsy with Nine Cores in Transperineal Prostate Fusion Biopsy: A Prospective Randomized Trial. European Urology Oncology, 2023, 6, 49-55.	2.6	5
1800	Targeted prostate biopsy: 68Ga-PSMA PET/CT vs. mpMRI in the diagnosis of prostate cancer. Archivio Italiano Di Urologia Andrologia, 2022, 94, 274-277.	0.4	14
1801	Accumulation of copy number alterations and clinical progression across advanced prostate cancer. Genome Medicine, 2022, 14, .	3.6	9
1802	Quality checkpoints in the MRI-directed prostate cancer diagnostic pathway. Nature Reviews Urology, 2023, 20, 9-22.	1.9	17
1803	Efficacy of cabazitaxel in patients with metastatic castrationâ€resistant prostate cancer: A singleâ€center study in Japan. International Journal of Urology, 0, , .	0.5	0
1804	External Validation of Models for Prediction of Side-specific Extracapsular Extension in Prostate Cancer Patients Undergoing Radical Prostatectomy. European Urology Focus, 2023, 9, 309-316.	1.6	8
1805	Comparison of single-shot EPI and multi-shot EPI in prostate DWI at 3.0ÂT. Scientific Reports, 2022, 12, .	1.6	9

#	Article	IF	Citations
1806	Confirmatory transperineal saturation prostate biopsy combined with mpMRI decrease the reclassification rate in men enrolled in Active Surveillance: Our experience in 100 men submitted to eight-years scheduled biopsy. Archivio Italiano Di Urologia Andrologia, 2022, 94, 270-273.	0.4	0
1807	Cellular dissociation grading on biopsies of pulmonary squamous cell carcinoma provides prognostic information across all stages and is congruent with resection specimen grading. Journal of Pathology: Clinical Research, 2022, 8, 567-578.	1.3	0
1808	First Canadian experience with same-day discharge after robot-assisted radical prostatectomy. Canadian Urological Association Journal, 2022, 17, .	0.3	2
1809	Single-fraction prostate-specific membrane antigen positron emission tomography-and multiparametric magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer local recurrences. BJU International, 2023, 131, 101-108.	1.3	2
1810	Magnetic Resonance Imaging-Based Predictive Models for Clinically Significant Prostate Cancer: A Systematic Review. Cancers, 2022, 14, 4747.	1.7	8
1811	Patient-level grading prediction of prostate cancer from mp-MRI via GMINet. Computers in Biology and Medicine, 2022, 150, 106168.	3.9	2
1812	Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification. European Urology, 2023, 83, 301-303.	0.9	7
1813	Novel serum proteomic biomarkers for early diagnosis and aggressive grade identification of prostate cancer. Frontiers in Oncology, 0, 12, .	1.3	3
1814	AZIN1 RNA editing alters protein interactions, leading to nuclear translocation and worse outcomes in prostate cancer. Experimental and Molecular Medicine, 2022, 54, 1713-1726.	3.2	4
1815	Determination of *ERG* (+), *EZH2* , *NKX3.1* , and *SPINK 1* subtypes to evaluate their association with clonal origin and disease progression in multifocal prostate cancer. Cancer Reports, 0, , .	0.6	0
1816	Identification of the Key Genes Involved in the Tumorigenesis and Prognosis of Prostate Cancer. Computational and Mathematical Methods in Medicine, 2022, 2022, 1-17.	0.7	0
1817	Modern paradigms for prostate cancer detection and management. Medical Journal of Australia, 2022, 217, 424-433.	0.8	13
1818	Percentage Gleason pattern 4 and PI-RADS score predict upgrading in biopsy Grade Group 2 prostate cancer patients without cribriform pattern. World Journal of Urology, 2022, 40, 2723-2729.	1.2	3
1819	AI-based prostate analysis system trained without human supervision to predict patient outcome from tissue samples. Journal of Pathology Informatics, 2022, 13, 100137.	0.8	0
1820	Radiomics in PI-RADS 3 Multiparametric MRI for Prostate Cancer Identification: Literature Models Re-Implementation and Proposal of a Clinical–Radiological Model. Journal of Clinical Medicine, 2022, 11, 6304.	1.0	2
1821	Screening for prostate cancer: protocol for updating multiple systematic reviews to inform a Canadian Task Force on Preventive Health Care guideline update. Systematic Reviews, 2022, 11, .	2.5	5
1822	MRI-based analysis of different clinically significant prostate cancer detection rate of prostate imaging reporting and data system score 4 in the peripheral zone. Abdominal Radiology, 0, , .	1.0	0
1823	Cribriform Lesions of the Prostate Gland. Surgical Pathology Clinics, 2022, 15, 591-608.	0.7	2

#	Article	IF	Citations
1824	Identification of senescence-associated long non-coding RNAs to predict prognosis and immune microenvironment in patients with hepatocellular carcinoma. Frontiers in Genetics, 0, 13, .	1.1	3
1825	Single cell analysis of cribriform prostate cancer reveals cell intrinsic and tumor microenvironmental pathways of aggressive disease. Nature Communications, 2022, 13, .	5.8	28
1826	A Clinically Significant Prostate Cancer Predictive Model Using Digital Rectal Examination Prostate Volume Category to Stratify Initial Prostate Cancer Suspicion and Reduce Magnetic Resonance Imaging Demand. Cancers, 2022, 14, 5100.	1.7	10
1827	Validation of the Combination Gleason Score as an Independent Favorable Prognostic Factor in Prostate Cancer Treated with Dose-Escalated Radiotherapy. Practical Radiation Oncology, 2022, , .	1.1	0
1828	Histopathology of Prostate Cancer and its Precursors. Applied Immunohistochemistry and Molecular Morphology, 0, Publish Ahead of Print, .	0.6	3
1829	Dose-Escalated Salvage Radiotherapy for Macroscopic Local Recurrence of Prostate Cancer in the Prostate-Specific Membrane Antigen Positron Emission Tomography Era. Cancers, 2022, 14, 4956.	1.7	2
1830	The highest percentage of Gleason Pattern 4 is a predictor in intermediateâ€‘risk prostate cancer. BJUI Compass, 0, , .	0.7	0
1831	Pre-Treatment Hemoglobin Concentration and Absolute Monocyte Count as Independent Prognostic Factors for Survival in Localized or Locally Advanced Prostate Cancer Patients Undergoing Radiotherapy. Biomedicines, 2022, 10, 2514.	1.4	2
1835	Correlation Between Long-Term Acetylsalicylic Acid Use and Prostate Cancer Screening with PSA. Should We Reduce the PSA Cut-off for Patients in Chronic Therapy? A Multicenter Study. Research and Reports in Urology, 0, Volume 14, 369-377.	0.6	0
1836	Construction and validation of web-based nomograms for detecting and prognosticating in prostate adenocarcinoma with bone metastasis. Scientific Reports, 2022, 12, .	1.6	1
1837	Use of the ISUP e-learning module improves interrater reliability in prostate cancer grading. Journal of Clinical Pathology, 2024, 77, 22-26.	1.0	1
1838	Quantitative multiparametric MRI as a promising tool for the assessment of early response to neoadjuvant chemotherapy in bladder cancer. European Journal of Radiology, 2022, 157, 110587.	1.2	6
1839	Comparison of PSA density and lesion volume strategies for selecting men with equivocal PI-RADS 3 lesions on bpMRI for biopsies. Abdominal Radiology, 0, , .	1.0	1
1840	Data on the detection of clinically significant prostate cancer by magnetic resonance imaging (MRI)-guided targeted and systematic biopsy. Data in Brief, 2022, 45, 108683.	0.5	0
1841	Association between the presence of bacteria in prostate tissue and histopathology in biopsies from men not complaining of lower urinary tract symptoms. Fukushima Journal of Medical Sciences, 2022, 68, 161-167.	0.1	1
1842	French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Diagnosis and management of localised disease. Progres En Urologie, 2022, 32, 1275-1372.	0.3	15
1843	A high serum dehydroepiandrosterone concentration is a predictor of candidates for active surveillance in men with serum prostate-specific antigenâ€‰<â€‰10Â ng/mL. BMC Cancer, 2022, 22, .	1.1	0
1844	Heterogeneity of contemporary grade group 4 prostate cancer in radical prostatectomy specimens. World Journal of Urology, 0, , .	1.2	0

#	Article	IF	Citations
1845	Imaging-based representation and stratification of intra-tumor heterogeneity via tree-edit distance. Scientific Reports, 2022, 12, .	1.6	3
1846	Clinical Predictors of Grade Group Upgrading for Radical Prostatectomy Specimens Compared to Those of Preoperative Needle Biopsy Specimens. Diagnostics, 2022, 12, 2760.	1.3	0
1847	The Changing Landscape of Systemic Therapy in the Treatment of Synchronous Metastatic Hormone-sensitive Prostate Cancer. Clinical Genitourinary Cancer, 2023, 21, 415.e1-415.e8.	0.9	0
1848	Combination of PI-RADS score and PSAD can improve the diagnostic accuracy of prostate cancer and reduce unnecessary prostate biopsies. Frontiers in Oncology, 0, 12, .	1.3	3
1849	A Comparative Study of Multiparametric MRI Sequences in Measuring Prostate Cancer Index Lesion Volume. Journal of the Belgian Society of Radiology, 2022, 106, 105.	0.1	1
1850	Role of the Prostate Imaging Quality PI-QUAL Score for Prostate Magnetic Resonance Image Quality in Pathological Upstaging After Radical Prostatectomy: A Multicentre European Study. European Urology Open Science, 2023, 47, 94-101.	0.2	16
1851	Automatic diagnosis and grading of Prostate Cancer with weakly supervised learning on whole slide images. Computers in Biology and Medicine, 2023, 152, 106340.	3.9	9
1852	Topography of Prostate Cancer Recurrence: A Single-centre Analysis of Salvage Radical Prostatectomy Specimens and Implications for Focal Salvage Treatments. European Urology Open Science, 2023, 47, 110-118.	0.2	3
1853	Prostatakarzinom: Histopathologie. Springer Reference Medizin, 2022, , 1-23.	0.0	0
1854	Treatment of rectal cancer after previous prostate cancer: A single institution experience. Oncology Letters, 2022, 25, .	0.8	0
1855	American Society of Anesthesiologists (ASA) physical status system predicts the risk of postoperative Clavienâ€"Dindo complications greater than one at 90Âdays after robot-assisted radical prostatectomy: final results of a tertiary referral center. Journal of Robotic Surgery, 0, , .	1.0	2
1856	Correlation of Intravoxel Incoherent Motion and Diffusion Kurtosis <scp>MR</scp> Imaging Models With Reactive Stromal Grade in Prostate Cancer. Journal of Magnetic Resonance Imaging, 0, , .	1.9	1
1857	Health-related quality of life in patients newly diagnosed with prostate cancer: CAPLIFE study. Quality of Life Research, 0, , .	1.5	1
1858	Multi-Stage Classification-Based Deep Learning for Gleason System Grading Using Histopathological Images. Cancers, 2022, 14, 5897.	1.7	3
1859	MRI-Derived Apparent Diffusion Coefficient of Peri-Prostatic Adipose Tissue Is a Potential Determinant of Prostate Cancer Aggressiveness in Preoperative Setting: A Preliminary Report. International Journal of Environmental Research and Public Health, 2022, 19, 15996.	1.2	1
1860	The value of artificial intelligence for detection and grading of prostate cancer in human prostatectomy specimens: a validation study. Patient Safety in Surgery, 2022, 16, .	1.1	3
1861	Development of a novel nomogram for predicting clinically significant prostate cancer with the prostate health index and multiparametric MRI. Frontiers in Oncology, 0, 12, .	1.3	3
1862	Pelvic Lymphadenectomy May Not Improve Biochemical Recurrence-Free Survival in Patients with Prostate Cancer Treated with Robot-Assisted Radical Prostatectomy in Japan (The MSUG94 Group). Cancers, 2022, 14, 5803.	1.7	3

#	Article	IF	Citations
1863	Development of a Prediction Model for Positive Surgical Margin in Robot-Assisted Laparoscopic Radical Prostatectomy. Current Oncology, 2022, 29, 9560-9571.	0.9	3
1864	Optimizing multiparametric magnetic resonance imaging-targeted biopsy and prostate cancer grading accuracy. World Journal of Urology, 2023, 41, 77-84.	1.2	2
1865	Risk and predictors of adverse pathology after radical prostatectomy in patients diagnosed with IUSP 1â€"2 prostate cancer at MRI-targeted biopsy: a multicenter analysis. World Journal of Urology, 2023, 41, 427-434.	1.2	1
1866	Initial Quality of Life and Toxicity Analysis of a Randomized Phase 3 Study of Moderately Hypofractionated Radiation Therapy With or Without Androgen Suppression for Intermediate-Risk Adenocarcinoma of the Prostate: PCG GU003. Advances in Radiation Oncology, 2023, 8, 101142.	0.6	1
1867	Spatial biology of cancer evolution. Nature Reviews Genetics, 2023, 24, 295-313.	7.7	42
1868	The use of ⁶⁸ Gaâ€PSMA PET/CT to stratify patients with PIâ€RADS 3 lesions according to clinically significant prostate cancer risk. Prostate, 0, , .	1.2	2
1869	Choice of imputation method for missing metastatic status affected estimates of metastatic prostate cancer incidence. Journal of Clinical Epidemiology, 2023, 155, 22-30.	2.4	2
1870	Vitamin D and genetic ancestry are associated with apoptosis rates in benign and malignant prostatic epithelium. Prostate, 2023, 83, 352-363.	1.2	0
1871	The cribriform morphology impairs Gleason 7 prostate cancer lesion detection on multiparametric magnetic resonance imaging. Prostate, 2023, 83, 331-339.	1.2	2
1872	Clinical outcomes of intraductal carcinoma or cribriform in radical prostatectomy specimens of men opting for active surveillance: data from the PRIASâ€"JAPAN study. International Journal of Clinical Oncology, 2023, 28, 299-305.	1.0	6
1873	Reply to M. Baboudjian et al. Journal of Clinical Oncology, 0, , .	0.8	0
1874	Prostate magnetic resonance imagingâ€targeted biopsy global grade correlates better than highest grade with prostatectomy grade. Prostate, 2023, 83, 323-330.	1.2	2
1875	Salvage irreversible electroporation for radioâ€recurrent prostate cancer â€" the prospective <scp>FIRE</scp> trial. BJU International, 2023, 131, 23-31.	1.3	7
1876	Beyond Multiparametric MRI and towards Radiomics to Detect Prostate Cancer: A Machine Learning Model to Predict Clinically Significant Lesions. Cancers, 2022, 14, 6156.	1.7	4
1877	Dual attention guided multiscale neural network trained with curriculum learning for noninvasive prediction of Gleason Grade Group from MRI. Medical Physics, 2023, 50, 2279-2289.	1.6	3
1878	An AI-assisted tool for efficient prostate cancer diagnosis in low-grade and low-volume cases. Patterns, 2022, 3, 100642.	3.1	1
1880	When to order genomic tests: development and external validation of a model to predict high-risk prostate cancer at the genotypic level. World Journal of Urology, 0, , .	1.2	0
1881	Prognostic Impact and Clinical Implications of Unfavorable Upgrading in Low-Risk Prostate Cancer after Robot-Assisted Radical Prostatectomy: Results of a Single Tertiary Referral Center. Cancers, 2022, 14, 6055.	1.7	0

#	Article	IF	Citations
1882	External Validation of the Rotterdam Prostate Cancer Risk Calculator and Comparison with Stockholm3 for Prostate Cancer Diagnosis in a Swedish Population-based Screening Cohort. European Urology Focus, 2023, 9, 455-462.	1.6	4
1883	3D-Reconstructed Contact Surface Area and Tumour Volume on Magnetic Resonance Imaging Improve the Prediction of Extraprostatic Extension of Prostate Cancer. Journal of Digital Imaging, 2023, 36, 486-496.	1.6	3
1884	High-resolution 3D T2-weighted SPACE sequence with compressed sensing for the prostate gland: diagnostic performance in comparison with conventional T2-weighted images. Abdominal Radiology, 0, , .	1.0	0
1885	Magnetic resonance imaging-guided ultrasound ablation for prostate cancer â€" A contemporary review of performance. Frontiers in Oncology, 0, 12, .	1.3	3
1886	PI-RADSAI: introducing a new human-in-the-loop AI model for prostate cancer diagnosis based on MRI. British Journal of Cancer, 2023, 128, 1019-1029.	2.9	6
1887	Nomograms Combining PHI and PI-RADS in Detecting Prostate Cancer: A Multicenter Prospective Study. Journal of Clinical Medicine, 2023, 12, 339.	1.0	1
1888	Assessment of the Impact of Pentafecta Parameters Affecting the Quality of Life of Patients Undergoing Laparoscopic Radical Prostatectomy. International Journal of Environmental Research and Public Health, 2023, 20, 944.	1.2	2
1889	High-throughput precision MRI assessment with integrated stack-ensemble deep learning can enhance the preoperative prediction of prostate cancer Gleason grade. British Journal of Cancer, 2023, 128, 1267-1277.	2.9	4
1890	Stimulated Raman Scattering Microscopy Enables Gleason Scoring of Prostate Core Needle Biopsy by a Convolutional Neural Network. Cancer Research, 2023, 83, 641-651.	0.4	29
1891	Improved diffusion-weighted imaging of the prostate: Comparison of readout-segmented and zoomed single-shot imaging. Magnetic Resonance Imaging, 2023, , .	1.0	0
1892	Role of inflammatory factors in prediction of Gleason score and its upgrading in localized prostate cancer patients after radical prostatectomy. Frontiers in Oncology, 0, 12, .	1.3	1
1893	Clinical performance of magnetic resonance imaging <scp>and</scp> biomarkers for prostate cancer diagnosis in men at high genetic risk. BJU International, 2023, 131, 745-754.	1.3	3
1894	Polymorphisms in the gene encoding CYP1A2 influence prostate cancer risk and progression. Oncology Letters, 2023, 25, .	0.8	1
1895	An update on computational pathology tools for genitourinary pathology practice: A review paper from the Genitourinary Pathology Society (GUPS). Journal of Pathology Informatics, 2023, 14, 100177.	0.8	2
1896	Retzius-sparing robot-assisted radical prostatectomy in a medium size oncological center holds adequate oncological and functional outcomes. Journal of Robotic Surgery, 0, , .	1.0	3
1897	Evaluation of automatic discrimination between benign and malignant prostate tissue in the era of high precision digital pathology. BMC Bioinformatics, 2023, 24, .	1.2	6
1898	Impact of prebiopsy MRI on prostate cancer staging: Results from the Norwegian Prostate Cancer Registry. BJUI Compass, 0, , .	0.7	2
1899	Prostate Pathology: What is New in the 2022 WHO Classification of Urinary and Male Genital Tumors?. Pathologica, 0, , 1-16.	1.3	2

#	Article	IF	Citations
1900	Median 4‑year outcomes of salvage irreversible electroporation for localized radio‑recurrent prostate cancer. BJU International, 2023, 131, 14-22.	1.3	8
1901	Efficacy and safety of the new biopsy strategy combining 6-core systematic and 3-core MRI-targeted biopsy in the detection of prostate cancer: Study protocol for a randomized controlled trial. Frontiers in Surgery, 0, 9, .	0.6	0
1902	Analytical exploratory tool for healthcare professionals to monitor cancer patients' progress. Frontiers in Oncology, 0, 12, .	1.3	5
1903	Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutations. Nature Reviews Urology, 2023, 20, 205-216.	1.9	10
1904	Comparison of Diffusion Kurtosis Imaging and Standard Mono-Exponential Apparent Diffusion Coefficient in Diagnosis of Significant Prostate Cancer—A Correlation with Gleason Score Assessed on Whole-Mount Histopathology Specimens. Diagnostics, 2023, 13, 173.	1.3	2
1905	bpMRI and mpMRI for detecting prostate cancer: A retrospective cohort study. Frontiers in Surgery, 0, 9, .	0.6	0
1906	The CAPRA&PDE4D5/7/9 Prognostic Model Is Significantly Associated with Adverse Post-Surgical Pathology Outcomes. Cancers, 2023, 15, 262.	1.7	1
1907	Prostate Cancer: Pathophysiology, Pathology and Therapy. Cancers, 2023, 15, 281.	1.7	1
1908	Comparison Between Amide Proton Transfer Magnetic Resonance Imaging Using 3-Dimensional Acquisition and Diffusion-Weighted Imaging for Characterization of Prostate Cancer: A Preliminary Study. Journal of Computer Assisted Tomography, 2023, 47, 178-185.	0.5	1
1909	A Critical Analysis of the Magnetic Resonance Imaging Lesion Diameter Threshold for Adverse Pathology Features. Prague Medical Report, 2023, 124, 40-51.	0.4	1
1910	Nanobodies: a new potential for prostate cancer treatment. Journal of Cancer Research and Clinical Oncology, 2023, 149, 6703-6710.	1.2	2
1911	Cone Beam Computed Tomography Radiomics for Prostate Cancer: Favourable vs. Unfavourable Prognosis Prediction. Applied Sciences (Switzerland), 2023, 13, 1378.	1.3	1
1912	Diagnostic and cost‑effectiveness of axial skeleton MRI in staging high‑risk prostate cancer. BJUI Compass, 0, , .	0.7	0
1913	Monoparametric high-resolution diffusion weighted MRI as a possible first step in an MRI-directed diagnostic pathway for men with suspicion of prostate cancer. Frontiers in Oncology, 0, 13, .	1.3	1
1914	Interobserver reproducibility of cribriform cancer in prostate needle biopsies and validation of International Society of Urological Pathology criteria. Histopathology, 2023, 82, 837-845.	1.6	2
1915	Combining clinical parameters and multiparametric magnetic resonance imaging to stratify biopsy-naïve men for an optimum diagnostic strategy with prostate-specific antigen 4 ng ml⁻¹ to 10 ng ml⁻¹. Asian Journal of Andrology, 2023, 25, 492-498.	0.8	1
1916	Raman spectroscopy system for real‑time diagnosis of clinically significant prostate cancer tissue. Journal of Biophotonics, 0, , .	1.1	0
1917	Inflammation and Prostate Cancer: Pathological Analysis from Pros-IT CNR 2. Cancers, 2023, 15, 630.	1.7	1

#	Article	IF	Citations
1918	Foggia Prostate Cancer Risk Calculator 2.0: A Novel Risk Calculator including MRI and Bladder Outlet Obstruction Parameters to Reduce Unnecessary Biopsies. International Journal of Molecular Sciences, 2023, 24, 2449.	1.8	0
1919	Cribriform pattern and intraductal carcinoma of the prostate can have a clinicopathological impact, regardless of their percentage and/or number of cores. Human Pathology, 2023, 135, 99-107.	1.1	6
1920	Ejaculation Frequency and Prostate Cancer: CAPLIFE Study. World Journal of Men?s Health, 2023, 41, 724.	1.7	2
1921	Incidence and Predicting Factors of Histopathological Features at Robot-Assisted Radical Prostatectomy in the mpMRI Era: Results of a Single Tertiary Referral Center. Medicina (Lithuania), 2023, 59, 625.	0.8	5
1922	A glycosylation signature for predicting the progression and immunotherapeutic response of prostate cancer. Journal of Gene Medicine, 2023, 25, .	1.4	2
1923	Federated Learning with Research Prototypes: Application to Multi-Center MRI-based Detection of Prostate Cancer with Diverse Histopathology. Academic Radiology, 2023, 30, 644-657.	1.3	2
1924	Associations Between Intraductal Prostate Cancer and Metastases Following Radical Prostatectomy in Men With Prostate Cancer in the Veterans Affairs Database. Clinical Genitourinary Cancer, 2023, 21, 452-458.	0.9	2
1925	Study protocol for a prospective, multi-centered randomized controlled trial comparing pelvic fascia-sparing radical prostatectomy with conventional robotic-assisted prostatectomy: The PARTIAL trial. Contemporary Clinical Trials, 2023, 128, 107168.	0.8	2
1926	Test-retest repeatability of ADC in prostate using the multi b-Value VERDICT acquisition. European Journal of Radiology, 2023, 162, 110782.	1.2	0
1927	The 17-Gene Genomic Prostate Score Assay Is Prognostic for Biochemical Failure in Men With Localized Prostate Cancer After Radiation Therapy at a Community Cancer Center. Advances in Radiation Oncology, 2023, 8, 101193.	0.6	0
1929	Lymphatic Dissemination in Prostate Cancer: Features of the Transcriptomic Profile and Prognostic Models. International Journal of Molecular Sciences, 2023, 24, 2418.	1.8	4
1930	Dual-Tracer PET-MRI-Derived Imaging Biomarkers for Prediction of Clinically Significant Prostate Cancer. Current Oncology, 2023, 30, 1683-1691.	0.9	0
1931	A nomogram model for determining optimal patients for local therapy in metastatic prostate cancer: a SEER database-based study. BMC Urology, 2023, 23, .	0.6	1
1932	T1 Mapping of the Prostate Using Single-Shot T1FLASH. Investigative Radiology, 2023, 58, 380-387.	3.5	4
1933	Patient‐specific voxel‐level dose prescription for prostate cancer radiotherapy considering tumor cell density and grade distribution. Medical Physics, 2023, 50, 3746-3761.	1.6	2
1934	Detection of intraductal carcinoma in prostate cancer patients with small tumor volume. Prostate, 2023, 83, 580-589.	1.2	1
1935	Effectiveness and Accuracy of <scp>MRI</scp> â€Ultrasound Fusion Targeted Biopsy Based on <scp>PIâ€RADS</scp> v2.1 Category in Transition/Peripheral Zone of the Prostate. Journal of Magnetic Resonance Imaging, 0, , .	1.9	1
1936	Efficient 3D light-sheet imaging of very large-scale optically cleared human brain and prostate tissue samples. Communications Biology, 2023, 6, .	2.0	5

#	ARTICLE	IF	CITATIONS
1937	Does including histological outcomes in a multiparametric MRI report improve prostate biopsy decision making?. British Journal of Radiology, 2023, 96, .	1.0	0
1938	Determination of Whether Apex or Non-Apex Prostate Cancer Is the Best Candidate for the Use of Prostate-Specific Antigen Density to Predict Pathological Grade Group Upgrading and Upstaging after Radical Prostatectomy. Journal of Clinical Medicine, 2023, 12, 1659.	1.0	0
1939	Correlation between ADC, ADC ratio, and Gleason Grade group in prostate cancer patients undergoing radical prostatectomy: Retrospective multicenter study with different MRI scanners. Frontiers in Oncology, 0, 13, .	1.3	3
1940	Treatment of localized prostate cancer in elderly patients: the role of partial cryoablation. International Urology and Nephrology, 2023, 55, 1125-1132.	0.6	1
1941	The role of [18F]-DCFPyL PET/MRI radiomics for pathological grade group prediction in prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50, 2167-2176.	3.3	6
1942	A Neural Network Model Combining [-2]proPSA, freePSA, Total PSA, Cathepsin D, and Thrombospondin-1 Showed Increased Accuracy in the Identification of Clinically Significant Prostate Cancer. Cancers, 2023, 15, 1355.	1.7	3
1943	Prostate Cancer Morphologies: Cribriform Pattern and Intraductal Carcinoma Relations to Adverse Pathological and Clinical Outcomesâ€"Systematic Review and Meta-Analysis. Cancers, 2023, 15, 1372.	1.7	6
1944	Tumour grading: communication is the key. Journal of Clinical Pathology, 2023, 76, 291-292.	1.0	2
1945	The devil is in the details: a small-lesion sensitive weakly supervised learning framework for prostate cancer detection and grading. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2023, 482, 525-538.	1.4	3
1946	Deepâ€'Learning Models for Detection and Localization of Visible Clinically Significant Prostate Cancer on Multiâ€'Parametric <scp>MRI</scp>. Journal of Magnetic Resonance Imaging, 2023, 58, 1067-1081.	1.9	8
1947	A comprehensive comparison between mpMRI of the prostate, MR-US fusion biopsy and whole mount histopathology. World Journal of Urology, 0, , .	1.2	0
1948	Multiplex protein analysis and ensemble machine learning methods of fine needle aspirates from prostate cancer patients reveal potential diagnostic signatures associated with tumour grade. Cytopathology, 2023, 34, 286-294.	0.4	2
1949	Learning Curve of Transperineal MRI/US Fusion Prostate Biopsy: 4-Year Experience. Life, 2023, 13, 638.	1.1	1
1950	Direct Comparison of Two Different Definitions with Biochemical Recurrence after Low-Dose-Rate Brachytherapy for Prostate Cancer. Current Oncology, 2023, 30, 2792-2800.	0.9	0
1951	Impact of Stain Normalization on Pathologist Assessment of Prostate Cancer: A Comparative Study. Cancers, 2023, 15, 1503.	1.7	5
1952	Differences in Quality of Life between German and Dutch Patients with Prostate Cancer Treated with Robot-assisted Radical Prostatectomy: Implications for International Multicenter Randomized Controlled Trials. European Urology Focus, 2023, , .	1.6	1
1953	Label Distribution Learning for Automatic Cancer Grading of Histopathological Images of Prostate Cancer. Cancers, 2023, 15, 1535.	1.7	4
1954	MEDICINAL BIOMAGNETISMO IN THE TREATMENT OF PROSTATE CANCER. Health and Society, 2023, 3, 438-464.	0.0	3

#	ARTICLE	IF	CITATIONS
1955	Impact of changing PI-RADS cutoff on prostate cancer detection by MRI cognitive fusion biopsy in biopsy-naïve patients. Journal of the Egyptian National Cancer Institute, 2023, 35, .	0.6	0
1957	Anti-Cancer Stem-Cell-Targeted Therapies in Prostate Cancer. Cancers, 2023, 15, 1621.	1.7	8
1958	Long-Term Exposure to Nitrate and Trihalomethanes in Drinking Water and Prostate Cancer: A Multicase–Control Study in Spain (MCC-Spain). Environmental Health Perspectives, 2023, 131, .	2.8	8
1960	The role of multiparametric magnetic resonance in active surveillance of a low‐risk prostate cancer cohort from clinical practice. Prostate, 2023, 83, 765-772.	1.2	1
1961	Effects of Concentrated Long-Chain Omega-3 Polyunsaturated Fatty Acid Supplementation on Quality of Life after Radical Prostatectomy: A Phase II Randomized Placebo-Controlled Trial (RCT-EPA). Nutrients, 2023, 15, 1369.	1.7	2
1962	Convolutional Neural Network Quantification of Gleason Pattern 4 and Association With Biochemical Recurrence in Intermediate-Grade Prostate Tumors. Modern Pathology, 2023, 36, 100157.	2.9	1
1963	Evaluation of Patients for Radiotherapy for Prostate Adenocarcinoma. , 0, , .		0
1964	Diagnostic Value of Synthetic MRI for Prostate Cancer Grade. Medical Diagnosis, 2023, 13, 56-63.	0.0	0
1965	Status of 18F-PSMA-1007-PET/CT compared with multiparametric MRI in preoperative evaluation of prostate cancer. World Journal of Urology, 2023, 41, 1017-1024.	1.2	1
1966	Role of [68Ga]Ga-PSMA-11 PET radiomics to predict post-surgical ISUP grade in primary prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50, 2548-2560.	3.3	5
1967	Importance of long non-coding RNAs in the pathogenesis, diagnosis, and treatment of prostate cancer. Frontiers in Oncology, 0, 13, .	1.3	5
1968	Perineal nerve block versus periprostatic block for patients undergoing transperineal prostate biopsy (APROPOS): a prospective, multicentre, randomised controlled study. EClinicalMedicine, 2023, 58, 101919.	3.2	2
1969	Prediction of upgrade to clinically significant prostate cancer in patients under active surveillance: Performance of a fully automated AI‐algorithm for lesion detection and classification. Prostate, 2023, 83, 871-878.	1.2	5
1970	The risk of prostate cancer on incidental finding of an avid prostate uptake on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography/computed tomography for non-prostate cancer-related pathology: A single centre retrospective study. Asian Journal of Urology, 2024, 11, 33-41.	0.5	0
1971	New transperineal ultrasound-guided biopsy for men in whom PSA is increasing after Miles' operation. Insights Into Imaging, 2023, 14, .	1.6	1
1972	Validation of the prognostic value of a three‐gene signature and clinical parameters‐based risk score in prostate cancer patients. Prostate, 2023, 83, 1133-1140.	1.2	2
1973	Machine learning-based radiomics model to predict benign and malignant PI-RADS v2.1 category 3 lesions: a retrospective multi-center study. BMC Medical Imaging, 2023, 23, .	1.4	5
1974	A novel lysosome-related gene signature coupled with gleason score for prognosis prediction in prostate cancer. Frontiers in Genetics, 0, 14, .	1.1	1

#	ARTICLE	IF	CITATIONS
1975	Radiogenomics Reveals Correlation between Quantitative Texture Radiomic Features of Biparametric MRI and Hypoxia-Related Gene Expression in Men with Localised Prostate Cancer. Journal of Clinical Medicine, 2023, 12, 2605.	1.0	1
1976	Multi-Institutional Clinical Outcomes of Biopsy Gleason Grade Group 5 Prostate Cancers Treated With Contemporary High-Dose Radiation and Long-Term Androgen Deprivation Therapy. Clinical Oncology, 2023, , .	0.6	0
1977	Controlling nutritional status score in predicting International Society of Urological Pathology score upgrading and biochemical recurrence after radical prostatectomy. Asia-Pacific Journal of Clinical Oncology, 0, , .	0.7	1
1978	Novel sampling scheme with reduced cores in men with multiparametric MRI-visible lesions undergoing prostate biopsy. Abdominal Radiology, 0, , .	1.0	0
1981	Renaming Grade Group 1 Prostate â€œCancerâ€•From a Pathology Perspective: A Call for Multidisciplinary Discussion. Advances in Anatomic Pathology, 2023, 30, 293-300.	2.4	2
1982	High adherence to Western dietary pattern and prostate cancer risk: findings from the <scp>EPICâ€Spain</scp> cohort. BJU International, 2023, 132, 272-282.	1.3	1
1983	Relationship between Proclarix and the Aggressiveness of Prostate Cancer. Molecular Diagnosis and Therapy, 2023, 27, 487-498.	1.6	1
1984	Screening for prostate cancer: evidence, ongoing trials, policies and knowledge gaps. , 2023, 2, e000039.		5
1985	Role of targeted biopsy, perilesional biopsy, and random biopsy in prostate cancer diagnosis by mpMRI/transrectal ultrasonography fusion biopsy. World Journal of Urology, 2023, 41, 3239-3247.	1.2	2
2043	Desorption electrospray ionization mass spectrometry imaging (DESI-MSI) in disease diagnosis: an overview. Analytical Methods, 2023, 15, 3768-3784.	1.3	5
2049	AI inÂProstate MRI Analysis: A Short, Subjective Review ofÂPotential, Status, Urgent Challenges, andÂFuture Directions. Lecture Notes in Networks and Systems, 2023, , 76-84.	0.5	0
2050	Prostatakarzinom: Histopathologie. Springer Reference Medizin, 2023, , 1547-1569.	0.0	0
2070	The diagnostic accuracy of radiolabeled PSMA-ligand PET for tumour staging in newly diagnosed prostate cancer patients compared to histopathology: a systematic review and meta-analysis. European Journal of Nuclear Medicine and Molecular Imaging, 0, , .	3.3	0
2096	Circulating Tumor Cells in Men Treated for Prostate Cancer. Current Cancer Research, 2023, , 565-574.	0.2	0
2103	Role of phospholipase A2 in prostate cancer. , 2023, , 39-54.		0
2121	Decoupled Conditional Contrastive Learning withÂVariable Metadata forÂProstate Lesion Detection. Lecture Notes in Computer Science, 2023, , 95-105.	1.0	0
2122	Diagnosis and Clinical Staging. , 2023, , 187-208.		0
2123	Pathology and Staging. , 2023, , 209-227.		0

#	ARTICLE	IF	CITATIONS
2205	LANDMARKS AND MODERN APPROACHES IN PROSTATE CANCER DIAGNOSIS. , 0, , .		0
2230	Understanding Prostate Cancer Care Process Using Process Mining: A Case Study. Communications in Computer and Information Science, 2024, , 118-130.	0.4	0
2239	Histopathological and Molecular Markers in the Assessment of Prostate Cancer Aggressivity. , 2024, , 179-206.		0